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Abstract 
 
Amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy with lower 
extremity predominance (SMA-LED) represent two distinctive types of motor 
neuron disease, the first of which ALS manifests usually as an adult-onset, rapidly 
progressive, terminal neurodegenerative disorder. Conversely, SMA-LED a 
childhood-onset disease is mainly characterised by lower limb wasting and 
intermittently compounded by intellectual disability. Firstly, this thesis represents 
investigations in the roles of both Fused in Sarcoma (FUS) and TAR-DNA binding 
protein (TDP-43), two mutated proteins in ALS. Secondly, this thesis explores the 
implications of SMA-LED mutations in the cytoplasmic dynein heavy chain 
(DYNC1H1) to investigate disease pathogenesis.     
 
Mutations found in RNA binding proteins FUS and TDP-43 are pathogenic in the 
adult-onset form of motor neuron disease ALS. These proteins are known to 
interact with DNA and it is suggested in the literature that FUS in particular has a 
protective role to repair DNA after lesions. FUS was shown to localise to sub-
nuclear regions of UVA induced oxidative damage as well as nucleoli foci after 
induction of DNA single strand breaks through RNA polymerase II inhibition in 
mitotic cells and neurons. This re-localisation was inhibited by both caffeine and 
dipyridamole indicating FUS recruitment via phophodiesterases (PDEs). TDP-43 
was found to vacate regions of oxidative damage and showed neuronal specific 
re-localisation to nucleoli in response to polymerase II inhibition that was not 
observed in mitotic cells.  
 
These data for the first time show that both FUS and TDP-43 re-localise after 
DNA damage events. FUS is shown to respond to transcriptional stress perhaps 
to protect nascent RNA, whereas the expulsion of TDP-43 may indicate a role in 
transcription coupled excision repair or heterochromatin remodelling.  
 
The SMA-LED autosomal dominant DYNC1H1 mutation p.R399G causes lower 
limb weakness and muscle atrophy as well as cognitive impairment but the 
pathogenesis remains unknown. p.R399G mutant fibroblasts exhibit a 
fragmented Golgi apparatus phenotype rescuable by HDAC6 inhibition in 
conjunction with a reduced localisation of the dynein complex to the Golgi 
membranes. Furthermore, western blot and immunoprecipitation assays showed 
decreased acetylation in mutant fibroblasts as well as an increased interaction 
between dynein and golgin160 in p.R399G mutants. These data for the first time 
show that mutations in dynein can modulate acetylation of microtubules and 
caffect dynein recruitment to the Golgi apparatus. This suggests a novel 
mechanism in which perturbed dynein-mediated regulation of microtubule 
acetylation and dynein-Golgi interaction underpin SMA-LED. 
 
Finally, the Dync1h1 mutant Arl SMA-LED mouse model recapitulates 
phenotypes of the human disease and presents with motor phenotypes. 
However, this mouse model is yet to be fully characterised and the extent of any 
aberrant brain development is unknown. Analysis of the model indicated 
defective cortical organisation in addition to defective cell migration seen in Arl/+ 
fibroblasts. Furthermore, collapse of the third ventricle and condensation of the 
corpus callosum was also observed in this model.  
 
These data show that the Arl p.Trp1206Arg mutation in the tail domain of 
Dync1h1 results in defective cellular migration as well as gross morphological 
brain deficits that mirror malformation of cortical development (MCD) in patients 
with SMA-LED. This is likely related to microtubule instability, Golgi abnormalities 
or impaired force production of dynein leading to suppressed cell migration and 
neuronal arborisation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1- Introduction 
 
1 
 
1.0 Motor neuron disease 
 
Motor neuron disease is a broad classification for a group of neurological 
diseases in which the deterioration of motor neurons results in an impairment of 
muscle innervation. The disease itself can manifest as either an adult onset or 
childhood onset condition in which both upper and lower motor neurons can be 
affected (see Figure 1.1). This predominantly results in muscle atrophy 
confounded by a multitude of other clinical presentations. Primarily, this thesis 
will focus on amyotrophic lateral sclerosis (ALS), an adult onset motor neuron 
disease and spinal muscular atrophy with lower extremity pre-dominance (SMA-
LED) a type of congenital motor neuron disease. 
 
1.1 Amyotrophic lateral sclerosis (ALS) 
 
1.2 An introduction to ALS 
 
Amyotrophic lateral sclerosis (OMIM#105400) is a progressive disease of the 
nervous system in which upper and lower motor neurons degenerate and become 
denervated (see Table 1.1). The word amyotrophic comes from the Greek word 
‘amyotrophia’ which means ‘no muscle nourishment’. The word ‘lateral’ indicates 
the part of the spinal cord that becomes damaged and ‘sclerosis’ is the Greek 
word for ‘hard’ reflecting the scarring of the tissue (Morris 2015).The disease is 
also referred to as Lou Gehrig’s disease in the United States after the famous 
baseball player who suffered with the condition until 1941 (Morris 2015). 
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This neurological disease can be characterised by a rapid onset and fast 
progression of neurodegeneration typically occurring between 50 – 75 years of 
age (Laferriere & Polymenidou 2015). These severe progressing features of the 
disease include muscle atrophy, paralysis, and eventually respiratory failure 
leading to death (see Table 1.1). This occurs usually within five years of the onset 
of the disease and has an incidence of around 2 in every 100,000 people 
(Laferriere & Polymenidou 2015).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1- The anatomy of the corticospinal tract. Upper motor 
neurons originate in the primary motor cortex; in contrast lower motor 
neurons typically originate from the pons or lower lumbrosacral 
regions. 
Figure 1.1 
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1.3 Adult onset motor neuron diseases and neuropathies 
 
Table 1.1- Adult onset motor neuron diseases and neuropathies 
 
 
Motor neuron 
disease 
 
 
Disease characteristics and  
clinical features  
 
References 
 
ALS 
 
ALS – 
Frontotemporal 
dementia (FTD) 
 
Upper and lower motor neuron involvement resulting 
in deterioration of the spinal cord, brainstem and 
motor cortex, affects 2 in every 100,000.  
 
Upper motor neuron characteristics 
 Hyperreflexia 
 Spasticity 
 Inability to communicate and detect sensory 
stimuli (dysphasia and agnosia) 
 
Lower motor neuron characteristics 
 Muscle weakness 
 Muscle cramps 
 Impaired or lack of reflexes 
 Muscle hypotonia and flaccid paralysis 
 
FTD symptoms 
 Change in personality 
 Apathy 
 Disinhibition 
 Hallucinations  
 
 
(Morris 2015; 
Lattante et al. 
2015) 
 
Charcot-Marie-
Tooth disease 
(CMT) 
 
(Hereditary and 
sensory 
neuropathy) 
 
 
 
CMT is the most common hereditary neuromuscular 
neuropathy (40 in every 100,000). 
 
 Lower motor and sensory nerves affected. 
 Pre-dominance of distal limb wasting. 
 Muscle weakness and sensory loss. 
(Pareyson & 
Marchesi 
2009) 
Distal 
hereditary 
motor 
neuropathy 
(dHMN) 
 
(Spinal CMT) 
 
 
A neuropathy which resembles Charcot-Marie-Tooth 
(CMT) disease, but lacks sensory involvement.   
 
 
 
 
(Luigetti et al. 
2016; Devic 
et al. 2012) 
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Table 1.1- cont.  
 
 
Motor neuron 
disease 
 
 
Disease characteristics and  
clinical features  
 
References 
 
 
Monomelic 
amyotrophy 
(MMA) 
 
(Hirayama 
disease) 
 
 
 
Predominantly affects young men with no 
involvement of sensory neuron deterioration. The 
disease is non-progressive although it can lead to 
morbidity. 
 
 Onset of limb weakness and thinning 
restricted to either a single upper or lower 
limb. 
 Lower motor neuron deterioration only. 
 Typically worsens progressively over a 2-4 
year period. 
 
 
(Nalini et al. 
2004; Vibha 
et al. 2015) 
 
 
 
Multifocal 
motor 
neuropathy 
(MMN) 
 
 
 
 
A neuropathy characterised by nerve conduction 
block through an immune response. 
 
 Lower motor neuron deterioration. 
 Distal limb progressive weakness. 
 Common involvement of upper extremities. 
 Muscle weakness without wasting. 
 No sensory involvement. 
 
(Vlam et al. 
2015; Muley 
& Parry 
2012) 
 
 
Primary lateral 
sclerosis 
(PLS) 
 
 
 
 
A rare neurological disorder usually seen in the sixth 
decade of life with a slower rate of progression 
compared to ALS. 
 
 Degeneration of upper motor neurons with no 
lower motor neuron involvement. 
 Spastic paresis. 
 Usually develops in the lower extremities. 
 Progresses with pseudobulbar features. 
 
(Agosta et al. 
2014) 
 
Progressive 
muscular 
atrophy 
(PMA) 
 
 
 
 
Progressive muscular atrophy (or lower motor neuron 
disease) with sporadic onset in adulthood. 
 
 Lower motor neuron deterioration only. 
 Progressive muscle weakness. 
 Loss of anterior horn cells. 
 Similar to the progression of ALS although 
life expectancy can be longer. 
(Bogucki et 
al. 2016; 
Visser et al. 
2008) 
Table 1.1 –  Adult onset motor neuron diseases and neuropathies with associated 
motor neuron involvement and clinical features. 
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1.3.1 Motor neuron degeneration and associated clinical symptoms  
 
The clinical presentation of ALS results from deterioration of either upper or lower 
motor neurons or both (see Figure 1.1). Upper motor neurons (UMN) originate in 
the primary motor cortex and span from the sylvian fissure to the cingulate gyrus. 
These neurons project a minimum of 12cm from cortical layer 5 in a caudal 
direction towards lower motor neurons (LMN). Lower motor neurons are 
organised in a columnar fashion spanning from the pons to the lumbrosacral 
region of the spinal cord over a distance of 55 cm and consist of mainly alpha 
motor neurons (Ravits 2014). Table 1.1 highlights the clinical symptoms 
associated with the loss of motor neurons from either pathway. Limb ALS refers 
to degeneration of neurons driving leg and arm function whereas bulbar ALS 
refers to primary degeneration of neurons controlling swallowing and speech. 
 
ALS motor phenotypes can be categorised into five main observations, the first 
is the random and localised onset of the disease. The symptoms may first appear 
in the tongue or facial muscles, for example, (bulbar ALS) or in the limbs in a 
unilateral fashion (limb ALS). This highlights the appearance of a random focal 
onset characteristic of the disease (Ravits 2014). Secondly, the spread of the 
disease appears to occur in a contact-dependent proximal nature. This arises 
from the fact that the area where the motor symptoms arise tends to worsen over 
a course of time. Additionally, the deterioration of the motor neurons progresses 
into neighbouring regions, from one side of the body to the other (Ravits 2014). 
This suggests neuroanatomical spread of the disease from one region to another. 
Thirdly, whilst the initial symptoms are focal in either a UMN or LMN region or 
both, the deterioration is maximal in all of the affected areas where the disease 
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first begins. This suggests that the disease is triggered within a network 
encompassing both UMN’s and LMN’s (Ravits 2014). 
 
The next important and fourth observation is that once the disease is progressing 
in a contiguous manner, the progression of the disease at the UMN and LMN 
levels seem disharmonious (Ravits 2014). For example, if the onset of disease 
occurs in one arm at a LMN level, the progression of the disease can spread to 
the other arm.  In an instance when the disease begins at the UMN level for 
example the progression can spread from an arm to the leg on the same side of 
the body (Ravits 2014). Overall, this observation suggests the segregation and 
independent spread of motor neuron deterioration at UMN and LMN levels.  
 
Lastly, although the degeneration of motor neurons and the muscles they 
innervate seem to progress at the anatomical level, the disease progression is 
likely related to specific disease kinetics. Studies of rate of disease progression 
have mainly focussed upon functional deficiencies rather than regional disease 
progression. The molecular underpinnings of diffusion of motor neuron loss and 
how this differs at both the UMN and LMN levels are still to be determined (Ravits 
2014).  
 
1.3.2 ALS and frontotemporal dementia (FTD)  
 
Clinically reported incidences of psychiatric disturbance or dementia in 
association with clinical presentations of ALS were recognised in the early 20th 
century (Bak & Hodges 2001). Increased recognition of behavioural abnormalities 
in ALS patients began to gather pace in the 1990’s (Van Langenhove et al. 2012). 
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FTD is a disease in which specific atrophy of the anterior and frontal lobes of the 
brain is accompanied with typical dementia. The prevalence of FTD is around 10 
per 100,000 and clinically presents around 45 to 65 years of age (Sieben et al. 
2012). It represents the second most common type of dementia second to 
Alzheimer’s disease.  
 
Currently it is estimated that ALS criteria are met in around 15% of FTD patients 
and similarly around 15% of ALS patients can present with dementia-like 
symptoms that  agree with the FTD definition (Ringholz et al. 2005; Wheaton et 
al. 2007). Both ALS and FTD are recognised as an interrelated broad 
neuropathological disorder which are linked both genetically and pathologically 
(Ling et al. 2013). 
 
1.4 Treatment for ALS 
  
The only current available drug for ALS is rilluzole which is a treatment which only 
modestly improves life span of patients. Riluzole was approved by the FDA in 
1995 for the treatment for ALS and remains to date the only treatment available. 
This drug has been found to have a multitude of varying effects in terms of 
neuronal survival across a dose range of 1-1000 M. The greatest clinical efficacy 
of intracellular riluzole concentrations are observed at 5M. At this concentration 
riluzole is expected to depress neuronal hyper-excitability by decreasing the firing 
frequency of neurons through reducing Na+ influx. The effects of riluzole has been 
comprehensively reviewed by Bellingham  (Bellingham 2011).  
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1.5 The molecular genetics of ALS  
 
The first description of ALS came in the 19th century in which Aran (1848), 
Cruveilhier (1852), and Charcot and Joffroy (1869) had all played a part. At this 
time the disease was thought to be non-heritable and it wasn’t until 1955 when 
Kurland and Mulder suggested that the disease could have heritable elements 
(Kurland & Mulder 1955; Visser et al. 2008).  
 
ALS today is recognised to be 10% familial ALS (fALS) and 90% deemed 
sporadic ALS (sALS) (Marangi & Traynor 2015). Of the 10% that is heritable 
around two thirds of the genes implicated have been discovered with the final 
third yet to be identified (see Figure 1.2). The so-called sporadic contribution to 
the disease is thought to be at least 23% attributable to genetics according to 
genome-wide studies (Keller et al. 2014). Table 1.2 outlines the major genes 
implicated in both fALS and sALS (also see ‘ALSoD’ database for a 
comprehensive list).   
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Figure 1.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2- A schematic representation of the proportion of ALS 
associated genes with mutations in both familial and sporadic ALS.  
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Table 1.2- Main mutated genes in ALS  
 
 
 
 
 
 
 
 
 
 
Gene 
 
 
Protein 
 
Function 
 
fALS 
 
sALS 
 
MOI 
SOD1 SOD Antioxidant fALS1 Yes AD/AR 
Alsin ALS2 TRAF, ESCRT f+jALS2 No AR 
SETX Senetaxin Replication f+jALS4 No AR 
SPG11 Spatacsin Unclear f+jALS5 No AR 
FUS/TLS FUS RBP f+jALS6 Yes AD/AR 
VAPB VAMP ERGP, TRAF fALS8 No AD 
ANG Angiogenin 
RBP, 
angiogenesis 
fALS9 Yes AD 
TARDBP TDP-43 RBP fALS10 Yes AD 
FIG4 FIG4 PRD,ERGP,TRAF fALS11 Yes AD 
OPTN Optineurin PRD,ERGP,TRAF fALS12 Yes AD/AR 
VCP VCP PRD fALS14 No AD 
UBQLN2 Ubiquilin-2 PRD f+jALS15 Yes XR 
SigMAR1 Sigma rec.1 ERGP f+jALS16 No AR 
PFN1 Profilin 
Actin 
polymerisation 
fALS18 Yes AD 
ERBB4 ERBB4 TRAF fALS19 No AD 
C9orf72 Unknown TRAF fALS Yes AD 
CHMP2B Unknown 
PRD, 
TRAF,ESCRT 
fALS Yes AD 
DAO D-AA oxidase AA oxidation fALS No AD 
DCTN1 Dynactin TRAF fALS Yes AD 
SQSTM1 P62 PRD fALS Yes AD 
hnRNPA1 hnRNPA1 RBP fALS Yes NP 
Erlin2 Erlin ER lipid rafts jALS Yes No 
UNC13A UNC13 
Regulates 
transmitters 
No Yes No 
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Table 1.2 Cont. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NEFH Neurofilament TRAF No Yes AD 
PRPH Peripherin TRAF No Yes No 
TAF15 TBP factor 15 RBP No Yes AD 
GRN Progranulin 
Cell growth 
regulator 
No Yes No 
EWSR1 EWSR1 RBP No Yes No 
ATXN2 Ataxin-2 Repeat expansion No Yes AD 
DJ1 DJ-1 Antioxidant Yes No AR 
TUBA4a Tubulin Cytoskeleton Yes No AD 
 
Gene 
 
 
Protein 
 
Function 
 
fALS 
 
sALS 
 
MOI 
Table 1.2- Main mutated proteins found in ALS adapted from Finsterer and 
Burgunder, Hanagasi et al., and Smith (Finsterer & Burgunder 2014; Hanagasi 
et al. 2016; B. N. Smith et al. 2014). Abbreviations are as follows: TRAF: 
trafficking, ESCRT: endosomal sorting complexes required for transport, AA: 
amino acid, PRD: protein degradation, ERGP: ER-Golgi pathway, jALS: 
juvenile ALS, FTLD: fronto-temporal lobe degeneration, RBP: RNA binding 
protein, AD: autosomal dominant, AR: autosomal recessive, XR: x-linked 
recessive.  
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1.5.1 Cu Zn Super-oxide dismutase 1 (SOD1) 
 
Linkage analysis provided the first common genetic factor contributing to fALS 
and alluded to the potential underlying pathogenesis of the disease. In 1993 
dominant missense mutations were identified in the SOD1 gene in fALS patients 
(Rosen et al. 1993). This gene codes for an enzyme which binds Cu and Zn and 
catalyses the reaction of O2- (a toxic anion) to O2 and H2O2, this toxic H2O2 species 
is then neutralised by the catalase enzyme (Rosen et al. 1993; Kirkman & Gaetani 
2007). 
 
Overall data from population studies have revealed that mutations in SOD1 
account for about 1% of all sporadic cases of ALS and 12% of familial cases (Chiò 
et al. 2008). It is also important to note that over 100 mutations have been 
reported in SOD1 and are presumed to contribute to the disease pathogenesis 
however, many of these mutations are lacking validation as causative through 
either statistics or mouse models (Andersen 2006).  
 
The majority of SOD1 mutations exhibit a high penetrance with an autosomal 
dominant mode of inheritance (Marangi & Traynor 2015). Despite this a D90A 
mutation has been identified in a Scandinavian population which exhibits 
recessive inheritance (Andersen et al. 1996). Only a small number of mutations 
can be shown to correlate with phenotypic presentations from a prognostic point 
of view. The A4V mutation is the most common in North America and represents 
a particularly lethal form of ALS in which patients die within a year of the onset of 
the disease (Cudkowicz et al. 1997). 
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1.5.2 Structure and function of SOD1 
 
SOD1 is an enzyme found in the intermembrane space of mitochondria as well 
as both the nuclear and cytoplasmic compartments of eukaryortic cells. The 
protein consists of 153 residues (32-kDa) which homodimerise to form the 
functional enzyme (Valentine et al. 2005). Each subunit of SOD1 contains a 
copper and zinc binding region. The structure of the monomer is highly conserved 
between species and are structured centrally around a -barrel. Each monomer 
contains two large loops which are structured regions of the protein termed the 
‘electrostatic’ and ‘zinc’ loops that encompass the metal binding region of the 
protein (Valentine et al. 2005). 
 
The function of SOD1 as previously alluded to is to convert superoxide ions to 
both oxygen and hydrogen peroxide with the interaction of both zinc and copper 
catalysing this conversion (Bunton-Stasyshyn et al. 2014; Zelko et al. 2002). The 
superoxide reactive oxygen species (ROS) at high levels are toxic and can affect 
many cellular processes (see oxidative stress) as well as cause DNA damage 
(Carrì et al. 2015). ROS are generated through oxygen metabolism and thus can 
be increased through high levels of cellular metabolism which is particularly 
elevated in motor neurons due to their size and function (Briese et al. 2005). 
Interestingly, in yeast only around 1% of SOD1 is needed to carry out this anti-
oxidative role. This has led to other proposed functions of SOD1 including RNA 
metabolism, signalling, and as an endoplasmic reticulum (ER) stress sensor 
(Bunton-Stasyshyn et al. 2014).
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1.5.3 TAR DNA-binding protein (TARDBP) 
 
A major breakthrough in understanding the genetics and potential pathogenic 
mechanisms in ALS came from the discovery of TDP-43 (coded by TARDBP) 
positive cellular inclusions in 2006 (discussed in ALS pathology). This finding was 
swiftly followed by the discovery of mutations in TARDBP in 2008 in families with 
autosomal dominant ALS and FTD (Sreedharan et al. 2008; Chiò et al. 2010). 
TDP-43 is a protein which is involved in the processing of transcripts by binding 
to nascent pre-RNA molecules (see below) (Ratti & Buratti 2016).  
 
Mutations found in TARDBP contribute to around 4% of fALS cases and a smaller 
number of sALS cases of around 1% (Chio et al. 2012; Marangi & Traynor 2015). 
Mutations in TARDBP are found worldwide with some regional variation, the 
A382T mutation is particularly prevalent in Sardinia perhaps due to a founder 
effect (Chiò et al. 2011).  Overall there are 47 missense mutations and one 
truncating mutation that have currently been reported (Lattante et al. 2013). 
 
1.5.4 Structure and function of TDP-43 
 
TDP-43 encoded by the TARDBP gene is a 43 kDa protein comprised of 414 
amino acids located on chromosome 1p36.2 (see Figure 1.3). This protein is 
ubiquitously expressed, highly conserved, and localises predominantly in the 
nucleus (Banks et al. 2008). Originally in 1995, it was first identified as a 
transcription factor responsible for regulating transcripts associated with human 
immunodeficiency virus type 1 (HIV-1) (Ou et al. 1995). Later in 2001, it was 
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shown to be a pre-messenger RNA (mRNA) splicing protein in relation to the 
cystic fibrosis transmembrane conductance regulator gene (CTFR) (Buratti et al. 
2001). Additionally, it has been found to regulate the splicing of hundreds of other 
genes such as SMN which is later discussed (Lagier-Tourenne et al. 2010). 
 
The TARDBP gene structurally consists of a total of six exons, the first of which 
is non-coding, with the remaining 5 exons responsible for encoding the protein. 
These regions show a high level of conservation of the amino sequence in many 
different species (Sreedharan et al. 2008). TDP-43 is part of the heterogeneous 
nuclear ribonucleoprotein family (hnRNP) (Krecic & Swanson 1999). It has an N-
terminal domain which contains a nuclear localisation signal and a C-terminal 
domain consisting of a glycine rich region of the protein responsible for 
interactions with other proteins (Lukavsky et al. 2013). In between these regions 
exist the RRM1 and RRM2 domains responsible for binding RNA and DNA shown 
in Figure 1.3 (Warraich et al. 2010). Interestingly, the most homology was found 
across species in these regions suggesting that the binding of RNA and DNA 
between species is a highly specific process (Ayala et al. 2005). These RRM 
domains contain RNP1 and RNP2 regions which are required for the binding of 
TDP-43 to UG repeats specifically (Kuo et al. 2009). Additionally, TDP-43 
contains both a nuclear localisation signal (NLS) and a nuclear export signal 
(NES) allowing it to be motile between the cytoplasmic and nuclear compartments 
(Warraich et al. 2010). 
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Figure 1.3 
 
 
 
 
Figure 1.3- The functional regions of TDP-43. Importantly the glycine rich domain is a mutation ‘hot-spot’ in cases of familial 
ALS and is particularly important for protein-protein interactions. The nuclear localisation signal (NLS) and the nuclear export 
signal (NES) are the regions responsible for shuttling the protein between the nucleus and the cytoplasm. Figure adapted 
from (Lagier-Tourenne et al. 2010). 
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1.5.5 TDP-43 dependent transcription and its autoregulation 
 
The functional roles of TDP-43 are diverse, as previously alluded to, TDP-43 has 
an important role in transcription. It has been found to bind regulatory DNA 
elements in both HIV-1 and a spermatogenesis-related gene in mice (SP-10) to 
negatively repress the production of transcripts (Ou et al. 1995; Acharya et al. 
2006). Conversely, TDP-43 has also been found to localise to areas of 
transcriptionally active DNA (euchromatin) through immunofluorescence and in 
situ transcription assay techniques in mammalian neurons (Casafont et al. 2009). 
TDP-43 has many other direct targets highlighted by Ratti and Buratti with likely 
many more that will become apparent (Ratti & Buratti 2016). In addition to the 
ability of TDP-43 to target transcripts of other proteins, TDP-43 can also target its 
own. This type of TARDBP autoregulation enables the tight control of TDP-43 
expression thus ensuring that the concentrations of the protein remain in a 
physiological range (Ayala et al. 2011). A recent study has shown that the 
depletion of TDP-43 results in altered expression across 273 proteins in SH-
SY5Y cells, most of which were found to be involved in RNA processing (Štalekar 
et al. 2015).  
 
1.5.6 TDP-43 and splicing of pre-mRNA  
 
Another key role that TDP-43 plays in the processing of mRNA transcripts is 
splicing.  This is a crucial process which removes introns (not in every case) from 
pre-RNA transcripts to facilitate the correct expression of genes. Short 
sequences that exist at intron-exon junctions enable a splicing code to be 
recognised by the spliceosome (Singh & Cooper 2012). This is a protein complex 
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comprised of small ribonucleoproteins (snRNPs) which interact with the introns 
whilst an orchestration of over 100 proteins facilitate the removal of the intron and 
joining of the exons (Singh & Cooper 2012). TDP-43 has been found to bind to 
many introns of pre-mRNAs and the knockdown of TDP-43 has been shown to 
cause splicing alterations in the striatum of mice as well as in the SH-SY5Y 
neuroblastoma cell line (Tollervey et al. 2011; Polymenidou et al. 2011). 
Additionally, Tollervey indicates that many of the TDP-43 RNA binding targets 
are in fact non-coding RNA (ncRNA) which is becoming further implicated in 
neurological disease (Szafranski et al. 2015).  
 
1.5.7 TDP-43 and micro RNA (miRNA) biogenesis 
 
MiRNAs are short non-coding RNA molecules of around 20 nucleotides in length 
and play a vital role in the regulation of gene expression (Chekulaeva & Filipowicz 
2009). These short sequences are generated from double stranded RNA 
containing a loop (pri-miRNAs) which are then processed by the Drosha complex 
(creating pre-miRNAs) in the nucleus and then the Dicer complex in the 
cytoplasm. This maturation then allows them to interact with the 3’ untranslated 
region of their targets to prevent their translation (Kawahara & Mieda-Sato 2012). 
TDP-43 has been shown to be a component of the Drosha complex promoting its 
interaction with certain pri-miRNAs. In addition to this TDP-43 has also been 
shown to complex with Dicer to facilitate the processing of these specific pri-
miRNAs (Kawahara & Mieda-Sato 2012). The altered expression of miRNAs has 
been identified in ALS, skeletal muscle from patients have been found to contain 
elevated levels of miR-23a (targets PGC1-, miR-29b and miR-455 which have 
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been suggested to affect gene expression in mitochondria (Kye & Gonçalves 
2014). 
 
1.5.8Transport of mRNA granules via TDP-43 
 
Granules refer to aggregates found in the cytoplasm comprised of RNA and RBP. 
These granules can contain multiple mRNA molecules as well as a diverse 
selection of RNA binding proteins and are trafficked in the cytoplasm (R. Smith 
et al. 2014). In neurons these granules can be trafficked in order to supply key 
transcripts to both dendrites and axons to be locally translated in these distal 
regions (R. Smith et al. 2014). TDP-43 was found to be associated with the 3’ 
UTR’s of many transcripts in human brain suggesting a role for transport or 
stability of mRNA (Tollervey et al. 2011). Further investigation has shown that 
TDP-43 is a main component of mRNA-RNP (mRNP) containing granules and is 
transported in an anterograde direction in neurons. The exact role that TDP-43 
plays in this instance, however, is still unclear (Alami et al. 2014).  
 
1.5.9 TDP-43 and the stress granule response  
 
Stress granules are structures found in the cytoplasm comprised of mRNAs, the 
40s subunit of ribosomes, and a myriad of more than thirty other proteins. As the 
name suggests they form under instances of environmental stressors such as 
hyperosmolarity or heat shock (Dewey et al. 2012). The stress granules are 
generated when the initiation step of translation is interrupted. TDP-43 has been 
found to be a main component of stress granules in many instances. The caveat 
here however, is that the localisation of TDP-43 to stress granules is dependent 
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upon the stressor as well as the cell (Dewey et al. 2012).  Although the exact 
mechanisms of TDP-43 stress granule biology are unknown the RRM1 domain 
(residues 267-324) is thought to play a vital role in its localisation to stress 
granules (Dewey et al. 2011).  
 
1.5.10 TDP-43 mouse models 
 
There have been many murine models of TDP-43 that have attempted to model 
ALS with a spectrum of varied phenotypes (see Table 1.3). Mouse models of 
TDP-43 (like many other mouse models) and the generation of ALS phenotypes 
are dependent upon the promotor used for the expression of the transgene. The 
level of TDP-43 expression is likely to affect potential motor phenotypes. Many of 
the TDP-43 mouse models exhibit axonal phenotypes but only moderate loss of 
motor neurons is observed (McGoldrick et al. 2013). To analyse the phenotypic 
repercussions of the loss of function of TDP-43, knock-out mice have been 
developed. However, total loss of TDP-43 results in embryonic lethality indicating 
that it plays a crucial role in development (Sephton et al. 2010). Mice with one 
functional allele of the TARDBP gene do not show any reduction of protein level 
likely due to TDP-43 autoregulation (McGoldrick et al. 2013).  
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Table 1.3- Mouse models of TDP-43 
 
Promotor Protein 
Protein 
expression 
(fold) 
Survival  
(weeks) 
Motor 
phenotype 
LMN 
degen.  
UMN 
degen. 
Cortex 
degen.. 
Axonal 
degen. 
Gliosis 
path. 
TDP-43 
path. 
CTFs Reference 
Hb9:Cre 
MN 
depletion 
0 40 Yes 
60% 
loss 
nd nd nd Yes nd nd 
(Wu et al. 
2012) 
mPrp A315T 3 22 Yes 
20% 
loss 
Yes nd Yes Yes Yes Yes 
(Wegorzewska 
et al. 2009; 
Guo et al. 
2012) 
MPrp WT 1.9 Not aff.  No - - - - - - - 
(Xu et al. 
2010) 
mPrp WT 2.5 4-8 Yes No nd nd Yes Yes Yes Yes 
(Xu et al. 
2010) 
mPrp M337V 1.9 Not aff. No - - - - - - - 
(Wegorzewska 
et al. 2009) 
mPrp M337V 2.5 4 Yes nd nd nd Yes Yes Yes Yes 
(Y.-F. Xu et al. 
2011) 
mPrp WT 3-4 nd No nd  nd nd nd Yes nd nd 
(Stallings et al. 
2010) 
mPrp A315T 4 37.5 Yes nd nd nd nd Yes Yes Yes 
(Stallings et al. 
2010) 
Thy 1.2 WT Males:3.6 nd Yes No nd nd Yes Yes No No  
(Shan et al. 
2010) 
Thy 1.2 WT Females:1.3 nd Yes No nd nd nd nd No No 
(Shan et al. 
2010) 
Thy 1.2 WT 1.9 nd Yes nd nd nd nd nd nd nd 
(Wils et al. 
2010) 
Thy 1.2 WT 3.8 27 Yes 
10% 
loss 
15% 
loss 
nd nd Yes Yes nd 
(Wils et al. 
2010) 
Thy 1.2 
WT 
 
5.1 4 Yes 
25% 
loss 
30% 
loss 
nd nd Yes Yes Yes 
(Wils et al. 
2010) 
CaMKII WT 2 71 Yes nd nd Yes nd Yes Yes Yes 
(Tsai et al. 
2010) 
CaMKII WT 0.8 (4 WKs) nd Yes nd Yes Yes nd Yes nd nd 
(Igaz et al. 
2011) 
CaMKII NLS 7.9 (4 WKs) 26 Yes nd Yes Yes Yes Yes Yes nd 
(Igaz et al. 
2011) 
CaMKII WT 3 nd nd nd nd Yes nd Yes Yes nd 
(Cannon et al. 
2012) 
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Table 1.3 cont 
 
 
 
TDP-43 
(BAC) 
WT 3 nd Yes nd nd nd No Yes nd nd (Swarup et 
al. 2011) 
TDP-43 
(BAC) 
A315T 3 nd Yes nd nd nd No Yes Yes Yes  (Swarup et 
al. 2011) 
TDP-43 
(BAC) 
G348C 3 nd nd nd nd nd No Yes Yes Yes (Swarup et 
al. 2011) 
Table 1.3-  The above table outlines all known published TDP-43 mouse 
models and their respective lifetimes as well as observed phenotypes. 
Table adapted from (McGoldrick et al. 2013). 
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1.5.11 Fused in sarcoma (FUS)/Translocated in liposarcoma (TLS) 
 
After mutations in TDP-43 were identified, ALS associated mutations in a gene 
known as Fused in sarcoma were identified in 2009 (Vance et al. 2009; 
Kwiatkowski et al. 2009). This gene encodes FUS which shares much functional 
homology with TDP-43 as it is similarly a RNA binding protein. Like TDP-43 many 
of the mutations reside in the RNA binding domain of the protein (Marangi & 
Traynor 2015). Mutations in FUS therefore, reinforced theories supporting 
aberrant RNA metabolism (see ALS pathology) although only accounting for 
around 4% of the cases of fALS and around 1% of sALS (Renton et al. 2014; 
Marangi & Traynor 2015).  The phenotype often associated with FUS mutations 
relates to typical ALS symptoms (see table 1.1) but often presents at a juvenile 
stage with some patients exhibiting FTD (Marangi & Traynor 2015).  
 
1.5.12 Structure and function of FUS  
 
FUS is a 75 kDa protein comprising of 526 amino acids which are encoded by a 
total of 15 exons (Lagier-Tourenne et al. 2010). The protein can be divided into 
two main regions, firstly, the N-terminal (or ‘prion-like’) domain contains a high 
number of glutamine, glycine, serine and tyrosine residues known as a QGSY 
region spanning amino acids 1-165 (see Figure 1.4). Furthermore, the N-terminal 
segment of the protein contains a glycine rich region (amino acids 166-267) in 
which many of the ALS associated mutations are found (Lagier-Tourenne et al. 
2010). Secondly, the C-terminal half of the protein comprises of a RRM (RNA 
recognition motif) domain (amino acids 285-371) as well as two RGG (Arg-Gly-
Gly) regions that span from amino acids 371-422 and 453-501. In between these 
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regions (amino acids 422-453) exists a Cys2-Cys2 zinc-finger domain (ZNF) 
(Shang & Huang 2016). The C-terminal region of the protein is highly conserved 
and contains the nuclear localisation signal (NLS) in the most distal region of the 
protein which is also a hot-spot for ALS associated mutations (Shang & Huang 
2016).  
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Figure 1.4  
 
 
 
 
 
  
 
Figure 1.4-  The illustration above depicts the structure of the FUS protein. The L segment 
of the protein represents the nuclear localisation signal for the protein. This region is a 
‘hot-spot’ for ALS mutations and some of the common mutations observed in this region 
are depicted above. Figure adapted from (Lagier-Tourenne et al. 2010). 
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1.5.13 FUS dependent transcription and autoregulation 
 
Originally FUS/TLS (hereafter FUS) was identified in instances of genomic 
translocation of its N terminal domain to fusion genes in both liposarcoma tumors 
and myeloid leukemia (Crozat et al. 1993; Ichikawa et al. 1994).  This was found 
to increase the transcription of the associated chimeric genes in both cases (Ratti 
& Buratti 2016). Recently in 2014, the QGSY region of FUS has been found to be 
particularly important for binding with chromatin (Yang et al. 2014). Furthermore, 
it has been proposed that the interaction between FUS and chromatin occurs 
through a mediation with RNA polymerase II, although its interaction with this 
enzyme is not thought to be through the QGSY region (Yang et al. 2014). This 
data supports previous findings of FUS mediated transcription of manganese 
superoxide dismutase (MnSOD) in which FUS knockdown led to inhibition of 
MnSOD transcription (Dhar et al. 2013). 
 
As with TDP-43, transcriptionally regulating the expression of other genes and its 
own protein levels, FUS can also regulate its own expression through binding of 
its own pre-mRNA (Zhou et al. 2013). This type of autoregulation mechanistically 
differs from the self-regulation of TDP-43 as it is driven by non-sense mediated 
decay of the transcript. FUS targets transcripts that have been subjected to exon 
7 skipping through a splicing event and FUS knockdown prevents this repression 
(Zhou et al. 2013).  
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1.5.14 RNA binding properties of FUS  
 
To elucidate if FUS specifically interact with RNA motifs, various studies have 
employed techniques to confirm that this is the case. Cross linking 
immunoprecipitation (CLIP) and in vitro selection assays have been used to show 
that FUS can bind to RNA containing a GUGGU motif (using mouse and brain 
tissue) (Lerga et al. 2001; Polymenidou et al. 2011). Interestingly it must be noted 
that other studies using similar techniques do not identify specific FUS-RNA 
binding sequences (Colombrita et al. 2012). Additionally, there have been reports 
of FUS binding to RNA exhibiting ternary structure, and also binding RNA in the 
absence of previously reported motifs (Takahama et al. 2013; Wang et al. 2015). 
Overall this evidence suggests that the interaction of FUS to RNA can be both 
specific and general not excluding higher order RNA structures.  
 
1.5.15 FUS regulated splicing of pre-mRNA  
 
The role of FUS in the splicing of pre-mRNA in accordance with the current 
literature can be segregated into direct and indirect mechanisms of splicing. The 
direct mechanism of FUS mediated splicing is closely related to transcription as 
FUS regulates the interaction between RNA pol II and U1 small nuclear 
ribonucleoprotein (U1 snRNP) which is a splicing factor and one of the initial 
factors to bind RNA during the assembly of the spliceosome (Yu & Reed 2015; 
Wahl et al. 2009). A comprehensive review of the make-up of the spliceosome is 
covered by Wahl et al. (2009). Secondly, FUS can interact with the survival motor 
neuron gene (SMN), deficiency in which is deemed pathogenic in spinal muscular 
atrophy. SMN is one of many important factors making up the SMN complex 
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which is involved in snRNP biogenesis (Battle et al. 2006). Despite FUS clearly 
integrating into the processes involving the splicing of pre-mRNA, the specific 
splicing targets are not clear due to mixed reports (Ratti & Buratti 2016). 
 
1.5.16 The role of FUS in mRNA stability 
 
As FUS can interact with the 3’ UTR sequences of certain transcripts it is plausible 
that this may influence the degradation and over stability of these associated 
transcripts.  A study by Colombrita et al. (2012) analysed the stability of certain 
transcripts after FUS depletion in motor neuron like cells in mice (Colombrita et 
al. 2012). The knockdown of FUS did not affect the stability of the mRNA in this 
case, another study indicated that FUS reduction can result in reduced AMPA 
receptor expression through reducing transcript stability of a GluA 1 subunit in 
cortical neurons (Udagawa et al. 2015). This indicates that FUS bound mRNA is 
likely altering inherent transcript stability, but could be transcript dependent and 
requires further investigation.   
 
1.5.17 FUS regulation of miRNA processing  
 
Similar to TDP-43, FUS has been associated with the Drosha complex. The ability 
of FUS to interact with nascent pre-mRNA molecules drives translocation of the 
Drosha complex to areas of active transcription enabling the processing of 
miRNA (Gregory et al. 2004; Morlando et al. 2012). FUS has been shown to 
regulate the biogenesis of a subset of miRNAs through knockdown experiments. 
The reduction of FUS primarily resulted in the reduction of miRNA (but not in all 
cases) expression including miRNAs important in neuronal function (miR-9, miR-
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125b, and miR-132) (Morlando et al. 2012).  Interestingly, the overexpression of 
FUS has been found to increase the production of two specific miRNAs (miR200a 
and miR141) which interact with the 3’ untranslated region of the FUS transcript. 
This is another example of FUS expression regulation separable from interacting 
with its own mRNA in order to control the physiological concentrations of FUS 
(Dini Modigliani et al. 2014).  
 
1.5.18 Long non-coding RNA (lncRNAs) and nuclear paraspeckles 
 
Long non-coding RNA molecules are defined as any non-coding RNA molecule 
over 200 nucleotides in length and on a molecular level identical to mRNA  
(Szafranski et al. 2015). They have many emerging roles some of which include 
regulation of gene expression as well as regulation of neuronal function (Wu et 
al. 2013). One important role for lncRNAs is promotion of nuclear paraspeckle 
formation (otherwise known as nuclear bodies). Nuclear paraspeckles are 
nuclear sub structures that store edited RNA as well as RNPs to be released 
under stress conditions (Prasanth et al. 2005). FUS has been shown to be a 
component of these paraspeckles and knockdown of FUS has been shown to 
prevent paraspeckle formation in human cell lines (Shelkovnikova et al. 2014). 
Furthermore, FUS interacts with a lncRNA known as NEAT1 which induces 
paraspeckle formation and has been found to be upregulated in motor neurons 
in ALS (Nishimoto et al. 2013). 
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1.5.19 FUS associated mRNA transport  
 
The first evidence that FUS was involved in mRNA transport was in 2005 when 
investigations revealed FUS localisation to dendritic spines in hippocampal 
neurons. FUS was shown to co-localise with other RBPs as well as with NMDA 
receptors. Furthermore, FUS-depleted hippocampal neurons exhibited reduced 
spine density as well as abnormal morphologies (Belly et al. 2005; Fujii et al. 
2005). Additionally, FUS has been found to localise with ribonucleoprotein 
complexes in distal cellular regions promoting local translation of a subset of 
mRNAs (Yasuda et al. 2013). The co-localisation of FUS with actin rich spines as 
well as neurofilament associated FUS localisation, suggests a dependency of 
FUS localisation on specific cytoskeletal elements (Belly et al. 2005; Muresan & 
Ladescu Muresan 2016). This evidence taken together suggests a role for FUS 
in synaptic metabolism and neuronal morphology.  
 
1.5.20 Response to DNA damage 
 
The first discovery that FUS was involved in DNA damage repair mechanisms 
was in 1995 when a protein known as POMp75 (FUS) promoted double strand 
break repair through homologous recombination (Baechtold et al. 1999). A year 
later in 2000 a study of B-lymphocytes and embryonic fibroblasts from neonatal 
mice indicated that the Fus protein was imperative for development. Additionally, 
the authors found that 67% of Fus knockout fibroblasts exhibited aneuploidy 
(Hicks et al. 2000).  Further observations in Fus depleted fibroblasts included 
centromeric fusion as well as chromosomal breakage (Hicks et al. 2000). These 
studies indicated the importance of FUS in maintaining genomic stability.  
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Later in 2008 a study using DNA-chromatography was implemented to identify 
DNA binding proteins such as FUS, that were targets for ataxia-telangiectasia 
mutated (ATM) and ATM- and Rad3 related (ATR) (Gardiner et al. 2008). These 
proteins are kinases that belong to the phosphoinositide 3-kinase-like kinase 
(PIKK) family and are important in maintenance of genome stability (Gardiner et 
al. 2008). Interestingly, an overlap between FUS, ncRNAs, and DNA damage 
was also discovered in 2008. DNA damage was shown to promote FUS 
dependent inhibition of the Cyclin D1 gene through inhibiting histone 
acetyltransferases induced by a conformational change in FUS when it bound 
certain ncRNAs (Wang et al. 2008).  
 
More recently, research has shown that the localisation of FUS to DNA damage 
is dependent on poly ADP ribose polymerase 1 (PARP1). The recruitment of both 
endogenous and GFP- FUS to sites of UVA induced DNA damage was impaired 
in PARP1 null cells (Rulten et al. 2013). This finding was confirmed by Mastrocola 
et al (2013) and showed that FUS depletion affected homologous recombination 
(HR) and non-homologous end joining (NHEJ) (Mastrocola et al. 2013). The 
extent of the role that FUS plays in DNA damage events is still to be determined.  
 
 
1.5.21 FUS mouse models 
 
Compared to TDP-43 there are few FUS transgenic models (published) that aim 
to recapitulate the ALS motor phenotype (see Table 1.4). Firstly, there are 
transgenic mice which overexpress human FUS (tagged with HA) using a prion 
promotor. Secondly, there are transgenic models which express human FUS (V5 
tagged) that have been generated using somatic viral techniques. Thirdly, a 
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mutant model expressing a R521C variant, and lastly, a 14 model in which the 
FUS protein is truncated and the nuclear localisation signal is no longer present 
(McGoldrick et al. 2013). FUS knockout mice are not viable similar to that of TDP-
43 knockout mice and die within 16 hours (Hicks et al. 2000). The D520G mouse 
model (unpublished) which is subject to investigation in chapter 3 was generated 
through N-ethyl-N-nitrosourea (ENU) mutagenesis at Harwell laboratories. This 
model has no known motor phenotypes and has a normal life span. 
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Table 1.4- FUS mouse models 
 
 
 
 
 
 
  
 
 
 
 
 
Promotor Protein 
Protein 
expression 
(fold) 
Survival  
(weeks) 
Motor 
phenotype 
LMN 
degen.  
UMN 
degen. 
Cortex 
degen.. 
Axonal 
degen. 
Gliosis 
path. 
FUS 
path. 
CTFs Reference 
mPrp WT 1.4 Not aff. - - - - - - - - 
(Mitchell et al. 
2013) 
mPrp WT 1.7 12 Yes 
60% 
loss 
nd nd nd Yes Yes nd 
(Mitchell et al. 
2013) 
SBT-
rAAV 
WT nd nd nd nd nd nd nd nd Yes nd 
(Verbeeck et 
al. 2012) 
SBT-
rAAV 
R521C nd nd nd nd nd nd nd nd Yes nd 
(Verbeeck et 
al. 2012) 
SBT-
rAAV 
14 nd nd nd nd nd nd nd nd Yes nd 
(Verbeeck et 
al. 2012) 
Table 1.4 -  FUS mouse models that have been published with the aim of 
recapitulating the ALS motor phenotype in mice. These models include transgenic, 
mutant, and truncated expression of the protein. 
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1.5.22 Hexanucleotide repeat expansion in C9orf72  
 
A recent discovery in 2011 has provided perhaps one of the most important 
genetic signatures to date in the ALS field. This relates to a repeat expansion 
discovered at C9orf72 (chromosome 9 open reading frame 72) which has been 
strongly implicated in the cause of chromosome 9p21-linked ALS and FTD 
(Renton et al. 2011; DeJesus-Hernandez et al. 2011). This newly discovered 
expansion is found at an astounding percentage in both fALS and familial FTD 
(40% and 25%), respectively. This finding may help to explain the connection 
between these two seemingly different disorders (Majounie et al. 2012). In 
addition to this in ALS cases with European ancestry, the C9orf72 expansion 
accounts for 7% of sALS cases (Renton et al. 2014).  
 
1.5.23 Structure and function of C9ORF72 
 
The C9orf72 gene consists of 11 exons interconnected with introns illustrated in 
Figure 1.5. The expansion consists of a GGGGCC (G4C2) sequence that exists 
in intron 1 which is between exons 1a and 1b (both non-coding). The exons 
become differentially spliced in order to produce 3 variants. The ‘long’ isoform 
(isoform a) is generated from variants 2 and 3 and the ‘short’ isoform (isoform b) 
does not include the final 6 exons (Todd & Petrucelli 2016). In healthy individuals 
the repeat length of the G4C2 sequence is commonly between 5 and 10 but is 
mostly (in nearly all cases) below 23 (Gitler & Tsuiji 2016).  
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Figure 1.5 
 
  
  
  
Figure 1.5 – The translation of the C9ORF72 isoforms are driven from 3 variant transcripts generated, variants 2 and 3 produce 
isoform a and variant 1 produces isoform b. The hexanucleotide repeat is marked by the red triangle in intron 1. The exons that 
are non-coding are coloured in green and coding exons are coloured blue. The amino acid lengths of each protein are annotated 
below each isoform produced. Figure adapted from Todd et al. 2016 (Todd & Petrucelli 2016).   
37 
 
Currently there is limited information on the function and structure of the protein 
translated from the C9orf72 gene. Despite this some studies have reported the 
protein to have similar homology to that of the Differentially Expressed in Normal 
and Neoplasia (DENN) family of proteins. This family of proteins are Guanine 
nucleotide exchange factors (GEFs) which control the activity of Rab GTPase 
enzyme activity through enabling GDP-GTP exchange (Levine et al. 2013; Gitler 
& Tsuiji 2016; Bhuin & Roy 2014). Rab GTPase enzymes can regulate membrane 
trafficking at the Golgi and the trans-Golgi-network (TGN) (McDonold & Fromme 
2014). C9ORF72 has been specifically found to co-localise with many Rab’s 
including Rab7 and Rab5 in primary cortical neurons (Farg et al. 2014).  
 
In addition to this, some evidence has suggested that the C9ORF72 protein has 
an important role in motor neurons. Zebrafish have an orthologue to the protein 
which exhibits 76% homology (Ciura et al. 2013). Experiments blocking the 
translation of this protein through antisense oligonucleotides resulted in perturbed 
neuronal arborisation and stunted axons in motor neurons (Ciura et al. 2013). 
However, it is important to mention that off-target effects of the oligonucleotides 
cannot be ruled out. Crucially, mammalian expression of C9orf72 has been 
reported in neurons of mice with strong expression in the gray matter of the spinal 
cord and weaker expression detected in the cortex (Koppers et al. 2015). 
Importantly, there are also reports outlining the expression patterns of C9orf72 in 
human neocortex and spinal cord (Stewart et al. 2012).  
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The cellular localisation of C9ORF72 will at this current juncture somewhat be 
dictated by the availability and quality of the commercially available antibodies. 
The protein has been found to exhibit a diffuse nuclear localisation as well as 
display punctate cytoplasmic aggregates in SH-SY5Y and Neuro2a cell lines as 
well as primary cortical neurons. The cytoplasmic pattern of staining could 
support the role of C9ORF72 in membrane trafficking (Farg et al. 2014).  
Knockdown of C9ORF72 using siRNA led to impaired endocytic trafficking and 
the formation of autophagosomes (Farg et al. 2014).  
 
Recently, a study using isoform specific antibodies found contrasting evidence to 
that of Farg et al. Antibodies against both the long and short isoforms of the 
C9ORF72 protein did not produce punctate staining in spinal motor neurons in 
either control or ALS patients (C9orf72 associated or otherwise) (Xiao et al. 
2015). The long isoform antibody did produce a punctate staining pattern in 
Purkinje cells but with no co-localisation to endosomes. The short isoform 
antibody contrastingly outlined the nucleus in all cells and was depleted from the 
nucleus in ALS cases, but instead stained the plasma membrane (Xiao et al. 
2015). 
 
Strikingly, C9ORF72 interacts with hnRNP-A1/A2/B1 which all have ALS 
associated mutations and could elucidate to a common mechanistic link in terms 
of disease pathogenicity (Farg et al. 2014). Overall, these data suggest that the 
C9orf72 gene encodes a protein important for intracellular trafficking in both 
nuclear and cytoplasmic compartments perhaps associated with RNA binding 
proteins.  
 
39 
 
2.0 ALS pathology 
 
2.1 Protein aggregation  
 
Protein aggregation is a pathological feature of many neurodegenerative 
diseases including ALS, FTD, Alzheimer’s disease and Huntington’s disease. 
Although this is the case the underlying related mechanisms of aggregation are 
not well understood. In ALS, protein inclusions and aggregates are found in motor 
neurons as well as other brain regions such as the hippocampus (Blokhuis et al. 
2013). The aggregates that are primarily found in ALS motor neurons are 
ubiquitinated and are termed skein-like or Lewy body-like inclusions. These exist 
as randomly arranged filaments associated with fine granules. Ubiquitin-negative 
inclusions termed Bunina bodies appear as tubular aggregates surround electron 
dense material (Blokhuis et al. 2013). 
 
The aggregates in ALS neurons can be co-localised with many proteins in which 
mutations in are also deemed pathogenic in ALS (see Table 1.5). This is a striking 
pathogenic feature of the disease perhaps due to interrelated functions of ALS 
associated proteins. Recent investigations have indicated that some misfolded 
proteins in ALS (Such as TDP-43, FUS, and SOD1) have prion protein like 
properties. Misfolded prion proteins underlie prion disease which is a group of 
neurodegenerative diseases in which transmissible proteins misfold and create 
amyloid -sheets which promote further misfolding by acting as a template.  
Although no other neurodegenerative diseases are transmissible, the spreading 
of the pathology (see motor neuron degeneration and associated clinical 
symptoms) and age-related onset is similar to that of ALS (Smethurst et al. 2015).  
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The presence of protein aggregates likely result in loss of function of aggregating 
proteins, impaired transcription and translation, perturbed transport and disrupted 
cytoskeletal integrity in motor neurons.  
 
2.2 Defective RNA metabolism 
 
Many ALS causing mutations reside in proteins important for multiple steps in the 
metabolism of RNA most notably FUS and TDP-43. Physiologically, FUS and 
TDP-43 localise predominantly to the nucleus where they perform multiple roles 
in RNA biogenesis. Mutations in both TDP-43 and FUS result in thier 
mislocalisation from the nucleus into the cytoplasm. This perhaps hints at a loss 
of function mechanism of toxicity, but accumulation of FUS and TDP-43 
aggregates in the cytoplasm may lead to a toxic gain-of-function (Rossi et al. 
2016). The exact mechanisms of how mutations in these RNA binding proteins 
cause death of motor neurons is still unclear. A summary of the effects of ALS 
mutations in both TDP-43 and FUS driven RNA metabolism are outlined in 
Figures 1.6 and 1.7. 
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Table 1.5- The immunoreactivity of protein aggregates in ALS 
 
 
 
 
 
 
 
 
 
 
 Ub p62 SOD1 TDP-43 FUS OPTN UBQLN2 ATXN2 C9ORF72 
sALS + + - + +- + + + - 
ALS SOD1 + + + - - +- + NR + 
ALS VCP NR NR NR + NR NR NR NR NR 
ALS VAPB NR NR NR NR NR NR NR NR NR 
ALS TDP-43 + + - + + + + NR - 
ALS FUS + + - + - + +- + + - 
ALS OPTN + + - + NR +- NR NR NR 
ALS UBQLN2 + + - + + + + NR NR 
ALS ATXN2 + + -  NR NR NR + NR 
ALS 
C9ORF72 
+ + - + NR + + NR - 
Table 1.5 – The immunoreactivity of protein aggregations in ALS is outlined in the above table. Non-responsive 
(NR), positive (+), negative (-), and conflicting evidence (+-) is annotated in each case. Adapted from Blokhuis 
2013 (Blokhuis et al. 2013). 
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Figure 1.6 
 
 
 
 
  
 
 
Figure 1.6 – The above diagram outlines the known roles for TDP-43 in RNA metabolism. The 
associated genes and proteins that have been validated experimentally are also included. 
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 Figure 1.7– The above diagram outlines the known roles for FUS in RNA metabolism. The associated 
genes and proteins that have been experimentally validated are also included. 
Figure 1.7 
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2.3 TDP-43 mutations and aberrant axonal transport 
 
Axonal transport deficits have been reported in many neurodegenerative 
diseases including Alzheimer’s disease, multiple sclerosis and ALS. 
Investigations into the transport of TDP-43 granules in axons has been 
extensively reported. Using Drosophila as a model, TDP-43 ALS mutations 
A315T and M337V have been shown to impair anterograde and retrograde 
transport in motor neurons (Alami et al. 2014; Baldwin et al. 2016). This could be 
a compounding pathology and promote TDP-43 associated aggregation in the 
cytoplasm in motor neurons. Similarly, using similar Drosophila models a FUS 
ALS mutation P525L exhibited defective anterograde transport of vesicles in 
motor neurons, but not mitochondria. Interestingly, recent data from a C9orf72 
expansion Drosophila model has indicated severe anterograde transport deficits 
caused by the hexanucleotide expansion (Baldwin et al. 2016). This indicates that 
disrupting multiple processes through different ALS related mutations can cause 
axonal transport discrepancies.  
 
2.4 Gliosis and excitotoxicity of motor neurons 
 
Glial cells are the predominant population of immune cells in the central nervous 
system. They interact with both T-cells and astrocytes in modifying the 
inflammatory response. Additionally, glial cells accomplish this modification by 
releasing cytokines that can promote or depress the inflammatory response. In 
patients with ALS, migration of microglia to areas of injury (known as microgliosis) 
occurs and is increased in the cortex, brainstem, corticospinal tract, and the 
ventral horn of the spinal cord.  Aberrant glial function was first reported in ALS a 
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glutamate transporter EAAT2/GLT1 was found to be depleted in the spinal cord 
and motor cortex of sALS and fALS patients. This was also found in a mutant 
SOD1 mouse model G85R and further studies have shown that deletion of mutant 
SOD1 from both astrocytes and microglia improve motor neuron survival (Philips 
& Rothstein 2014; Bruijn et al. 1997). This indicates that some immune cells of 
the central nervous system contribute to motor neuron deterioration. 
 
Even though glutamate is well known for presynaptic release from neurons, 
astrocytes release glutamate extracellularly and this concentration of glutamate 
is tightly regulated. Inhibition of glutamate uptake is toxic to cortical and spinal 
motor neurons shown in vitro (Rothstein et al. 1993). Therefore, the dysfunction 
of the EAAT2 transporter could play a crucial role in motor neuron death. This 
glutamate toxicity could be exacerbated by over excitability of neurons causing 
an increase of glutamate release from the presynaptic neuron. This could be 
primarily driven by mechanisms such as ER stress or changes in calcium influx 
in pre-synaptic neurons but the evidence for this induction of excitotoxicity is not 
well reported. However, data from the SOD1-G93A mouse model derived from 
synaptosomes suggested that the efflux of glutamate was increased in mutant 
mice compared to wild-type mice (Milanese et al. 2011). Although the 
mechanisms are not clear, mutant SOD1 likely plays a regulatory role in 
glutamate homeostasis.   
 
2.5 Oxidative stress and its potential detriment in ALS 
 
Oxidative stress refers to the generation of noxious free radical species known 
as reactive oxygen species (ROS). The generation of these free radicals could 
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be induced by environmental factors and biomarkers of oxidative stress have 
been found commonly in sALS patients (D’Amico et al. 2013). Oxidative stress 
may have an important role in non-SOD1 ALS as mutations in valosin-containing 
protein (VCP) have also shown susceptibility to ROS in SH-SY5Y cells (Hirano 
et al. 2015). Despite this, no single pro-ROS mechanism or factor has been found 
in ALS to date. However, there may be a pathogenic link between oxidative stress 
and protein aggregation. The SOD1 protein has been found to aggregate when 
oxidized which again could be another compounding factor in mutant SOD1 ALS 
(Guareschi et al. 2012).  
 
2.6 Mitochondrial damage in ALS 
 
Mitochondria are the main production site for both adenosine triphosphate (ATP) 
and consequently, ROS, and can be themselves damaged by toxic free radicals. 
Perturbed activity of the mitochondrial respiratory complex in ALS has been found 
in post-mortem spinal cord and brain tissue from ALS patients as well as in a 
SOD1 transgenic mouse model (Cozzolino & Carri 2012). It has been suggested 
that mitochondrial damage is a consequence of SOD1 aggregation and 
furthermore provides another possible pathological relationship (Carrì et al. 
2015). The fALS associated protein VCP is crucial for mitochondrial function as 
VCP mutations result in abnormal mitochondrial function and reduced ATP 
production (Bartolome et al. 2013).  Mutations in both TDP-43 and FUS have also 
been suggested to cause aberrant mitochondrial functions but the ways in which 
defective RNA metabolism may be detrimental to mitochondria are unclear (Carrì 
et al. 2015). The instability of mitochondrial DNA has also been implied in through 
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ALS associated mutations in a protein of unknown function encoded by 
CHCHD10 resulting in mitochondrial DNA breakage (Bannwarth et al. 2014).  
 
2.7 DNA damage and neurodegeneration  
 
Macromolecules in biology are all susceptible to corruption, but DNA lesions are 
particularly detrimental to cells. DNA is the blueprint from which proteins are 
produced and cannot be resynthesized in a straightforward manner. These 
aberrations can lead to disruption of cellular mechanisms inducing cell death, 
senescence, or uncontrolled replication leading to cancer. Motor neurons have to 
last for a lifetime and so have to be able to cope with prolonged DNA damage. 
Many neurodegenerative diseases are caused by defects in DNA damage repair 
proteins although many of these diseases are congenital, DNA damage could 
also underlie age associated deterioration of neurons (Madabhushi et al. 2014). 
Neurons are postmitotic cells and rely on repair mechanisms which are 
summarised below.  
 
2.7.1 Nucleotide excision repair (NER) 
 
This is the repair process in which the aberrations in the DNA helix are detected 
rather than modifications of bases. These aberrations are diverse and can 
prevent the continuation of transcription and result in apoptosis. There are over 
30 proteins which orchestrate to complete the NER process which can be 
segregated into two categories. The first is known as global genome NER (GG-
NER) and is a process which is global. The second is transcription coupled NER 
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(TC-NER) which only targets the DNA strand transcribed in genes which are 
active (Madabhushi et al. 2014).  
 
2.7.2 Base excision repair (BER) 
 
BER is a process similar to that of the NER process but has evolved to specifically 
detect modified bases and excising them via the cleavage of a N-glycosidic bond. 
The BER pathway targets a large range of damage induced modifications which 
are subsequently converted into a small number of intermediates via DNA 
glycosylases of which there are at least 15 found in humans. These produced 
intermediates are then the primary substrates for the BER machinery including 
XRCC1, APE1, and pol (Madabhushi et al. 2014)

2.7.3 Single strand break repair (SSBR) 
 
Although ROS can lead to modifications of existing bases, damage can also lead 
to the induction of a single strand break (SSB). These type of lesions can also 
arise from the BER pathway or from topoisomerase I aborted reactions. In this 
type of repair pathway, the outcome generates DNA ends which are conducive 
to ligation. As the lesions produced can vary this requires a large number of 
processes that will produce compatible DNA ends, similarly SSBR uses 
molecular machinery found in the BER pathway. 
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2.7.4 Double strand break repair (DSBR) 
 
Single strand breaks that occur in proximal regions of DNA can lead to double 
strand breaks of the double helix. This can also occur when translation machinery 
collides with a single strand break leading to abortive reactions. This type of 
lesions can be induced by environmental factors such as ionising radiation or 
other noxious drugs used in chemotherapy. For these reasons, double strand 
breaks are not as common as single strand breaks and can result in chromosome 
rearrangements which can lead to cell death or sometimes uncontrolled cell 
division. In neurons these types of lesions are repaired through non-homologous 
end joining (Madabhushi et al. 2014). This type of damage is recognised by 
KU70/80 which attaches itself to the broken DNA ends before recruiting other 
DNA repair machinery such as ARTEMIS and APLF to access the damage site 
(Madabhushi et al. 2014). This interaction prepares the strands to be ligated 
before the XRCC4/LIG4 complex completes the ligation.  It is important to note 
that even though this process is integral for the resistance to DSB in neurons this 
repair pathway has not been extensively investigated in the mature brain 
(Madabhushi et al. 2014).  
 
 
3.0 Childhood-onset motor neuron diseases 
 
 
3.1 Spinal muscular atrophy (SMA) 
 
Spinal muscular atrophy (OMIM#253300) is the largest genetic contributor to 
mortality in infants and is characterised by the loss of anterior horn lower motor 
neurons. The clinical features of the disease vary in severity through type I SMA 
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(where the disease is most lethal) to type III in which patients exhibit altered 
mobility (see Table 1.6).  The molecular genetics of SMA are underpinned by the 
loss of telomeric survival motor neuron 1 (SMN1). This gene encodes SMN which 
is found in both the nucleus and the cytoplasm. SMN complexes with gemin 
proteins to form an assemblyosome which is key for the production of snRNPs 
(Arbab et al. 2014). This indicates that RNA metabolism may be defective in this 
disease although the available data is limited (Tisdale & Pellizzoni 2015). 
 
The deficiency of SMN1 is compensated for by SMN2 which encodes a truncated 
form of the SMN protein which is quickly degraded. This only partially 
compensates for its functionality and the copy number associated with SMN2 can 
dictate the severity of the disease. SMA mouse models have exhibited varying 
vulnerability of neurons, for example, neurons that innervate muscles proximal to 
lumbar level L1 seem to deteriorate quicker than neurons that innervate distal 
muscles from L5 (Tisdale & Pellizzoni 2015). The complete knock-out of SMN1 
is embryonically lethal and it is not known why mutations in SMN1 are so 
detrimental to motor neurons (Arbab et al. 2014).  
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Table 1.6-Childhood onset motor neuron diseases 
 
Motor neuron 
disease 
 
 
Disease characteristics and  
clinical features  
 
References 
 
Hereditary 
spastic 
paraplegia 
 
(HSP) 
 
 
  
A subset of childhood neurodegenerative disorders 
affecting the spinal cord clinically characterised 
through progressive spasticity with a prevalence of 2-
10:100,000. 
 
Pure HSP 
 
 Progressive spasticity and weakness. 
 Mild sensory abnormalities. 
 Urinary dysfunction. 
 
Complicated HSP (additional complications) 
 
 Cerebellar ataxia. 
 Epilespy. 
 Cognitive deficits. 
 Deafness. 
 
 
(Lindig et al. 
2015) 
Brown-
Vialetto-Van 
Laere 
syndrome 
 
(BVVL) 
 
 
 
 
 
 
A progressive and sensory neuropathy with an early 
childhood onset of disease caused by mutations in 
the riboflavin transporter type 2. 
 
 Early onset hearing loss. 
 Sensory hearing loss. 
 Upper limb weakness. 
 Optic atrophy. 
 Bulbar weakness.  
 Respiratory failure. 
 
 
(Menezes et 
al. 2016) 
 
Spinal 
muscular 
atrophy. 
 
 
(SMA) 
 
 
 
Neurodegenerative disorder affecting lower alpha 
motor neurons with onset spanning between 
childhood and early adulthood with an incidence of 
1:10,000. 
 
Type I  
 Cessation of fetal movements in mothers. 
 Severe weakness at birth. 
 Respiratory failure within 2 years. 
Type II 
 Inability to stand but can sit unaided. 
 Prognosis between 5-25 years depending on 
respiratory muscle involvement. 
Type III 
 Varied ability to walk. 
 Life expectancy normal. 
 
 
(Arbab et al. 
2014; 
Scheffer 
2004) 
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Table 1.6 cont. 
 
 
Motor neuron 
disease 
 
 
Disease characteristics and  
clinical features  
 
References 
 
Spinal 
muscular 
atrophy with 
lower extremity 
pre-
dominance. 
 
(SMA-LED) 
 
 
  
Characterised by congenital or childhood onset of 
disease which is autosomal dominant and non-
progressive with broad clinical features.  
 
 Lower limb weakness and atrophy 
 Waddling gait. 
 Reduced ability to climb stairs. 
 Incidences of ADHD. 
 Epilepsy. 
 Some incidences of severe mental 
retardation. 
 
 
 
(Harms et 
al. 2012; 
Schiavo et 
al. 2013) 
  
 
 
 
 
 
 
 
 
3.3 Spinal muscular atrophy with lower extremity pre-dominance (SMA-
LED) 
 
SMA-LED (OMIM#158600) may have been clinically reported as early as 1917 
by Timme who describes a family with a form of muscular dystrophy in which the 
onset of disease was noted at 3-4 years of age. Years later a follow-up on this 
family was conducted by Young in 1972 and indicated that the disease seemed 
to resemble an early childhood onset autosomal dominant spinal muscular 
atrophy (Timme 1917). Many years later Harms et al. (2010) reported a family of 
North American heritage in which 10 individuals exhibited onset of a mild or non-
Table 1.6-  Childhood motor neuron diseases with 
associated disease characteristics and clinical 
features. 
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progressive SMA with early age onset (Harms et al. 2010). These individuals 
presented with a lower extremity predominance and Harms coined the disease 
SMA-LED which marked the modern age of investigation into the disease.   
 
3.2 Clinical characteristics of SMA-LED  
 
The clinical presentation of SMA-LED can be very diverse and affect a range of 
mobility and cognitive related abilities (see Table 1.5). A study by Harms et al. in 
2012 in which SMA-LED was confirmed in a 3 generation family described typical 
SMA-LED symptoms. Affected individuals all were described as having an 
abnormal gait with atrophy of lower limbs which did not progress into later life 
(see figure 1.8). This was coupled by reduced tendon reflexes in the knees and 
a disparity in strength between flexion and tension of the knees. Investigations 
into nerve conduction indicated that sensory nerve conduction was normal but 
motor neuron conduction was poor, this finding was coupled by chronic 
denervation (Harms et al. 2012). The cognitive deficits experienced by patients 
with SMA-LED can range from mild learning difficulties to severe mental 
retardation.  
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Figure 1.8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8- The above picture illustrates the severity of lower 
limb wasting in SMA-LED, picture adapted from Oates et al. 
2013 (Oates et al. 2013). 
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3.4 Molecular genetics of SMA-LED 
 
SMA-LED is a congenital autosomal dominant heritable disease which is 
characterised by lower limb atrophy of the muscles combined with motor deficits. 
Human mutations identified through linkage analysis were first identified on 
chromosome 14 (14q32) which was found to encode for DYNC1H1 a subunit 
component of the motor complex dynein (See dynein structure and function) 
(Harms et al. 2010; Harms et al. 2012; Vissers et al. 2010). Additionally, in 2013 
linkage analysis identified mutations at another locus (9q22.3) which encodes 
BICD2 a protein which interacts directly with dynein (see Figure 2.1) (Neveling et 
al. 2013). These pathogenic mutations show complete penetrance and both 
result in very similar disease phenotypes typical of SMA-LED. 
 
3.5 Molecular motors 
 
Molecular motors are stunning examples of harmonious biological machinery in 
which protein complexes orchestrate to exert force on a cellular scale. There are 
three main types of molecular motors found in cells, firstly, there are dyneins 
which interact with microtubule tracks to produce motion in a retrograde direction. 
Secondly, there are kinesins which also interact with microtubules but travel in 
the opposite anterograde direction towards the cell periphery. Lastly, there are 
myosins which interact directly with actin filaments to influence contraction and 
torsion forces within cells. All of these motors hydrolyse ATP in order to produce 
conformational changes in subunits of the motor to evoke a stepping motion along 
its respective substrate. There is a large diversity observed in these molecular 
motors as various subunits can be utilised in their function. Furthermore, when 
56 
 
accounting for their post-translational modifications and respective binding 
partners, these motors are equipped to serve the highly diverse requirements of 
cellular dynamism.  
 
3.5.1 Dynein families 
 
There are two distinct families of dynein termed axonemal dynein and 
cytoplasmic dynein. Axonemal dynein is a molecular motor which is abundant in 
cilia and flagella protrusions associated with some cell types. The primary core 
structural component in these protrusions is known as the axoneme. This 
consists of nine pairs of microtubules that interact with axonemal dynein (Kuhns 
et al. 2013). The second family is known as cytoplasmic dynein which binds to 
cytoskeletal microtubules in eukaryotic cells to primarily provide retrograde 
transportation of cargoes such as endosomes or mitochondria. Two subdivisions 
of cytoplasmic dynein exist: Cytoplasmic dynein 1 and cytoplasmic dynein 2. 
Cytoplasmic dynein 1 (hereafter dynein) is the SMA-LED disease relevant 
complex that will be referred to in the subsequent sections. 
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3.5.2 The structure and function of the Dynein complex 
 
Dynein is a large motor complex (~1.5MDa) comprised of multiple subunits which 
cohesively function to primarily transport cellular cargo towards the minus-end of 
microtubules (retrograde direction). The DYNC1H1 homodimer (dimerization 
region 302-1142) is the core of the complex and binds with the intermediate 
chains (DYNC1I1 and DYNC1I2) and light intermediate chains (DYNC1LI1 and 
DYNC1LI2). Additionally, light chains (DYNCLT1, DYNCLT2, DYNLL1, 
DYNCLL2, DYNLRB1 or DYNLRB2) interact with the complex through the 
intermediate chains (see Figure 1.9 A)  (Chowdhury et al. 2015). The holoenzyme 
complex utilises ATP in the nervous system to provide transport over large 
distances especially in the case of motor neurons.  
 
Cytoplasmic dynein heavy chain 1 encoded by DYNC1H1 (hereafter DHC) can 
be subdivided into the tail domain and the motor domain (see Figure 1.9 B). The 
motor domain includes six AAA ATPase domains (1868-4221 amino acids) which 
are responsible for ATP hydrolysis and the microtubule binding domain (MTBD). 
ATP hydrolysis is hypothesised to drive conformational changes in the linker and 
the tail domain of dynein to generate a ‘power stroke’ for dynein motility (Carter 
2013). 
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Figure 1.9 A 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9 A-  The above figure depicts a schematic of cytoplasmic 
dynein. The DHC (violet) is the core of the complex to which all the other 
subunits attach. The ATPase domains (orange) are a ring structure 
which hydrolyses ATP to ADP. The stalk domain of the complex 
includes the microtubule binding domain (yellow) responsible for the 
attachment of the complex to microtubules. This figure was adapted 
from (Schiavo et al. 2013). 
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Figure 1.9 B 
 
 
 
 
 
 
 
 
  
Figure 1.9 B-  The above schematic depicts the organisation of the DYNC1H1 subunit 
of cytoplasmic dynein segregated into the tail and the motor domain. The intermediate 
(green) and light intermediate chain binding region (blue) reside in the homodimerisation 
domain which are located in the tail domain of the protein. The motor domain 
encompasses all AAA domains including the stalk domain. The light yellow highlighted 
box indicates the microtubule binding domain portion of the stalk domain. 
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3.5.3 The ATPase activity of Dynein 
 
When there is absence of binding of a nucleotide at the AAA1 domain the dynein 
complex remains tightly associated with the microtubules, but interaction with 
ATP results in rapid dissociation between the MTBD and the microtubules. After 
ATP has been hydrolysed to ADP and an inorganic phosphate, the motor domain 
interacts with a new binding site on the microtubule. This interaction is thought to 
gradually become stronger straightening the linker representing the ‘power 
stroke’ and the inorganic phosphate is released from the AAA1 domain. Lastly, 
ADP dissociates from the AAA1 domain before the cycle restarts (Roberts et al. 
2013). The AAA2-4 domains of the DHC are thought to also contain nucleotide 
binding pockets whereas the AAA5 and AAA6 domains do not have hydrolysing 
activities and their precise role is yet to be elucidated (Roberts et al. 2013).   
 
The tail domain of dynein is towards the N-terminal region of the DYNC1H1 
homodimer and regulates interaction between other adaptor proteins and 
cargoes (Schiavo et al. 2013). The association of adaptor proteins modulate the 
processivity of dynein along microtubules.  
 
3.5.4 The dynein adaptor dynactin  
 
Mammalian dynein on its own is non-processive and therefore, requires 
association with other proteins to facilitate movement of the complex, dynactin is 
the primary facilitator of dynein functionality. Dynactin is a large protein complex 
(~1.0MD) consisting of over 20 subunits that relate to 11 separate proteins (see 
Figure 2.0). The dynactin complex is constructed around a core filament of actin 
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related protein (ARP1). This protein has close structural similarities with actin and 
has both a pointed and a barbed end, both of which are capped by protein 
complexes.  
 
This filamentous structure interacts with a p150Glued (DCTN1) ‘shoulder’ which 
contains a dynein binding region and is the largest subunit of dynactin (Urnavicius 
et al. 2015). Additionally, the shoulder can consist of p135 which is a truncated 
isoform of p150Glued and is deficient of a Cap-Gly domain which is a microtubule 
binding region (Mckenney et al. 2014).  
 
Dynactin consists of two ARP1 protofilaments that intertwine, the lower of the two 
filaments also contains -actin (see Figure 2.0). The pointed end of the complex 
consists of p25, p27 and p62 whereas the barbed end is comprised of 
CapZ(Urnavicius et al. 2015) The interaction between dynactin and dynein is 
stabilised by Bicaudal-D2 (BICD2). Dynactin is regarded as vital for all the 
functional roles that dynein is associated with and specifically is important for the 
attachment of cargo and to act as a processivity factor (Cianfrocco & Leschziner 
2014).  
 
 
 
 
 
 
 
 
62 
 
Figure 2.0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.5.5 Dynein-dynactin-microtubule structural organisation  
 
Recent investigations through cryo-EM imaging has enabled visualisation of the 
interaction between dynein, dynactin, and microtubules at a resolution of 6.5 
angstroms. Data from Chowdhury et al (2015) has indicated structural insights 
into the dynein complex. The dynein heavy chain appears to have a structural 
‘kink’ which has not been previously observed (see Figure 2.1). It is positioned 
between the tail domain and the motor domain and has been suggested to act as 
a shock absorber or hinge during the cyclical ATP driven motion of dynein. 
Secondly, the authors show that a portion of the intermediate chain of dynein 
Figure 2.0 – The structural composition of dynactin is depicted above. The 
dark purple ‘shoulder’ region consists of p150Glued/p135, p50 and p24. This 
interacts with the top protofilament (coloured beige) which is wrapped 
around the bottom filament (coloured red). Subunits A-I consist of ARP1 
whereas subunit H represents -actin. The pointed end of the complex 
consists of ARP11 (yellow), p62 (orange), and p25/p27 (brown) which caps 
the pointed end of the complex. The barbed end of the complex is capped 
by CapZgreen). Figure adapted from Urnavicius et al (Urnavicius et al. 
2015).  
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extends behind the complex and does not interact with the heavy chain. This 
flexible domain of the intermediate chain interacts with the LC7 (DYNLRB2) dimer 
(see figure 2.1), this information refines the structural complexity of the tail 
domain of dynein (Chowdhury et al. 2015). 
 
3.5.6 The dynein adaptor BICD2 
 
The BICD protein was originally identified in Drosophila in which mutations 
caused defective mRNA transport during development leading to physical 
abnormalities. The BICD homologues in mammals are BICD1 and BICD2 and 
are comprised of three colied coil (cc) domains responsible for maintaining a 
homodimer of the protein (Rossor et al. 2015). BICD2 is a member of the golgin 
family which are proteins characterised by coiled coil domains that reside on the 
cis and trans regions of the Golgi. The N-terminal region (cc1 and cc2) of the 
protein is responsible for dynein and dynactin interactions (see figure 2.1) and 
can interact with the p50 dynactin subunit as well as the dynein intermediate 
chain (hereafter, DIC)  (Neveling et al. 2013; Matanis et al. 2002; Hoogenraad 
et al. 2001). The third cc3 domain is crucial for interacting with cargo-associated 
proteins such as Rab6 which is located on Golgi derived vesicles (Matanis et al. 
2002). It is through these interactions that BICD2 is likely important for 
regulating cargo interactions with molecular motors such as dynein. McKenney 
et al. has importantly shown that when BICD2 is removed from the dynein-
dynactin complex, dynactin will dissociate away from dynein and the motor is no 
longer processive (McKenney et al. 2014). 
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Figure 2.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 2.1- The interaction between dynein, dynactin, BICD2, and 
microtubules. The dynein complex interacts with the p150Glued subunit of 
dynactin (purple) via a coiled-coiled domain obscured by the ARP1 
filaments of dynactin (beige and red). BICD2 interacts with the complex via 
the intermediate chain of dynein and sits between both the dynein and 
dynactin complexes. The kink in the heavy chain of dynein can be pictured 
in this diagram close to the LIC binding region and is proposed to facilitate 
dynein motility. The above diagram was adapted from Chowdhury et al. 
(2015) (Chowdhury et al. 2015).   
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3.5.7 Other co-factors of cytoplasmic dynein 
 
Even though both dynactin and BICD2 represent the primary adaptors of dynein 
there are other dynein co-factors that have evolved to regulate the activity of the 
motor complex. The first of which is LIS1 which interacts with the AAA1 domain 
of the DHC. Mutations in LIS1 are associated with the disease lissencephaly in 
which malformation of the cortex and disruption of neuronal migration in the 
cortex occur during development. Even though the exact influence that LIS1 has 
on dynein is far from complete, recent evidence from yeast studies have 
suggested that it can block the mechanochemical cycle of dynein. This suggests 
that LIS1 can sterically inhibit dynein and promote a constant microtubule-bound 
state (Toropova et al. 2014). Data from the LIS1 homolog NUDF in fungi has also 
shown that LIS1 is closely associated with the plus-end microtubule tips. In 
summary, this indicates that LIS1 stalls cytoplasmic dynein and associates with 
the motor complex at the tips of microtubules (Han et al. 2001). 
 
Other proteins known as Nudel/NudE have been found to interact with LIS1 in 
vitro and became linked with dynein regulation (Sasaki et al. 2000). Mutations in 
Nudel/NudE are related to abnormally developed brains and microcephaly 
(Bradshaw et al. 2013). Aside from their interactions with LIS1 these proteins also 
bind dynein directly through interaction with the dynein intermediate chain 
(Cianfrocco et al. 2015). It has been suggested that the role of Nudel/NudE is to 
directly tether LIS1 to dynein indicating a purely mechanistic contribution to the 
dynein complex (Cianfrocco et al. 2015).  A summary of dynein co-factors can be 
seen in Table 1.7.  
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 Table 1.7- Co-factors of cytoplasmic dynein 
Co-factor 
Subunit 
binding 
Role Reference 
Dynactin DIC Processivity 
(Holzbaur & 
Tokito 1996) 
BICD2 DIC 
Processivity/Dynein-
dynactin complex 
integrity/cargo binding 
(Hoogenraad et 
al. 2001) 
LIS1 DHC 
Mechanochemical 
clutch 
(Huang et al. 
2012) 
Nudel/NudE DIC LIS1 tether 
(Cianfrocco et al. 
2015) 
Spindly nd Kinetochore recruitment 
(M. A. 
Cianfrocco & 
Leschziner 
2014) 
Hook DHC/p25 
Endocytosis/cargo 
binding 
(Minton 2014) 
Rab11-FIPS LIC 
Endosomal membrane 
association 
(Horgan et al. 
2010) 
 
 
 
Table 1.7- The above table summarises dynein co-factors which modulate 
dynein-centric processes or dynein motility. 
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3.5.8 Dynein, axonal transport and microtubules 
 
Cytoplasmic dynein 1 is crucial in the transport of cargos along microtubule tracks 
from the cell periphery. This retrograde stream of cargo is especially important in 
large polarised cells such as motor neurons in which the trafficking occurs 
between distal neuronal synaptic terminals and the cell soma.  
 
Whilst the regulation of dynein and its specific cargoes can be modulated via 
various co-factors and adaptors, the activity of dynein is totally dependent on 
microtubules. Firstly, the posttranslational modifications of tubulin, the primary 
subunit of microtubules have been strongly implied in the interaction between 
dynein and their microtubule tracks. Increasing acetylation of tubulin at lysine 40 
has been shown to increase retrograde transport through the recruitment of the 
dynein motor (Dompierre et al. 2007). Secondly, intracellular location of 
microtubules is vital as dynein can only act in cellular compartments in which 
microtubules are intact. The permutations of these mechanisms will be 
thoroughly discussed in chapter 6.  
 
3.5.9Endocytic vesicle transport 
 
Aside from transportation of cargo over large distances, dynein is also involved 
in shorter forms of transport between the cell soma membrane and the 
cytoplasmic compartment. Endosomal transport is a vital cellular process in which 
epidermal growth factor (EGF) receptors and G-protein coupled receptors 
(GPCRs) for example bind their respective ligands and become internalised 
before being transported to the peri-nuclear region (Sorkin & von Zastrow 2009). 
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This processes are integral for maintaining physiological concentrations and 
localisation of proteins. Endosomes in mammals are transported by dynein to 
perinuclear regions for degradation or to be recycled back to the cell membrane 
via kinesin motors (Soldati & Schliwa 2006). The disruption of the endocytic 
pathway has been suggested to play a role in neurodegenerative diseases such 
as Parkinson’s Disease (Schreij et al. 2015). 
 
3.6 Transport independent roles of dynein 
 
3.6.1 Dynein at the Golgi apparatus  
 
The Golgi apparatus is a highly dynamic organelle responsible for the post 
translational modifications of proteins. It is an organelle that is important for axon 
homeostasis and neuronal migration. Structurally, the Golgi apparatus (hereafter 
Golgi) is comprised of multiple stacks of interconnected cisternae, this forms a 
continuous membrane ‘ribbon’ which is closely localised to the centrosome 
(Klumperman 2011). The size of the Golgi is dictated by cell type as well as 
secretory pathway requirements (Yadav & Linstedt 2011).  
 
The Golgi can be subdivided into three distinct segments known as cis, medial or 
trans Golgi where the cis side of the Golgi faces the nucleus and the trans side 
faces the cell membrane (see Figure 2.2). Each subdivision has its own subset 
of proteins that are associated with that particular region of the Golgi although 
some proteins reside in multiple segments (Yadav & Linstedt 2011). Table 1.8 
outlines key proteins and their associated Golgi localisation including optineurin 
mutations in which cause ALS. In neurons small segments of Golgi membrane 
69 
 
reside in dendrites and distal regions of axons known as Golgi outposts that are 
crucial for local translation of proteins (Quassollo et al. 2015).  
Cytoplasmic dynein is localised to the Golgi and DHC knockout mice exhibit 
fragmented Golgi in early embryonic cells (Harada et al. 1998). Furthermore, 
targeted knockdown of either the DHC, DIC, or dynein light chain (hereafter, DLC) 
resulted in perturbed Golgi structure (Palmer et al. 2009). A mouse model of 
SMA-LED which is discussed later (Loa mice) also shows a deficiency in Golgi 
reformation after washout of microtubule depolymerising agent nocodazole 
(Hafezparast 2008).This clearly indicates that cytoplasmic dynein has an 
important functional role at the Golgi apparatus. 
 
Recent evidence from Yadav et al. has identified golgin 160 as a binding partner 
for dynein at the Golgi membranes (Yadav et al. 2012). The DIC subunit interacts 
with golgin 160 via Arf1 and is important for Golgi positioning. Golgi positioning 
is crucial in neurons as secretory pathways need to face the direction of 
polarisation in neurons in order to deliver proteins to distal compartments such 
as synapses. However, this only provides a very basic insight into the function of 
dynein at the Golgi apparatus. Golgi membrane trafficking is not well understood 
and the holistic role that dynein plays in this respect is likely to be complex.  
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Table 1.8-  Key Golgi proteins 
 
Protein Localisation 
Lava lamp Golgi 
Golgin 160 cis Golgi 
GMAP210 cis Golgi 
Golgin 245 trans Golgi 
Dynein Golgi 
Dynactin Centrosome 
Huntingtin trans Golgi 
BICD2 trans Golgi 
Golgin 97 trans Golgi 
Golgin 84 trans Golgi 
Myosin VI Golgi 
Optineurin Golgi 
Hook 3 Centrosome 
Clasp 1/2 Golgi 
GM130 cis Golgi 
Spectrin Endomembranes 
Giantin cis/medial 
 
Figure 2.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Table 1.8 and Figure 2.2 – A list of key proteins and their 
respective Golgi localisations. The term Golgi refers to the entire 
organelle and endomrembranes refer to membranes from the 
endocytic pathway. Table adapted from (Yadav & Linstedt 2011). 
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3.6.2 Cortical and nuclear dynein 
 
Microtubule organising centres (MTOCs) such as the centrosome are important 
for generation of microtubules and for imposing intracellular forces through 
molecular motors such as dynein. These forces control cell polarities as well as 
dictate aspects of cell division (Laan et al. 2012). The positioning of MTOCs are 
controlled by the interaction between microtubules and the cell cortex.  Studies 
in yeast have identified that dynein is captured by a cortical anchor Mcp5 which 
subsequently activates dynein motility in order to position the mitotic spindle 
(Lammers & Markus 2015). The capture of dynein to the cell cortex involves 
dynein at the tips of microtubules in an ‘off’ state, recently Num1 was identified 
as the molecular ‘on’ switch that removes LIS1 motor inhibition (Lammers & 
Markus 2015). This indicates that dynein is an important cellular anchor between 
microtubules and the cell cortex. Furthermore, dynein has been reported to be 
found on nuclear pores along with dynactin and BICD2. This is thought be a 
mechanism to facilitate nuclear migration in dividing cells between G2 of the cell 
cycle and mitosis (Hu et al. 2013). In summary, these functions of dynein indicate 
that it has a crucial role to play in cell division.  
 
3.7 SMA-LED DYNC1H1 mutations 
 
3.7.1 R399G mutation 
 
The p.Arg399Gly mutation was identified in a homozygous patient that had 
presented with floppiness and joint contractures at birth (the source of 
homozygous human fibroblasts in this study were obtained from a skin biopsy 
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from this patient). This patient also presented with thinning of the lower limbs 
(typical of SMA-LED) as well as learning and speech difficulties with attention 
deficit hyperactivity disorder (ADHD) at the age of 9.5 with malformations of 
cortical development (MCD). The father and mother were both heterozygous for 
the variant and the father presented with lower limb weakness in the fourth 
decade with no data available for cognitive ability (Scoto et al. 2015). In this study 
the heterozygous fibroblasts were obtained from a skin biopsy from the father.  
 The R399G mutation resides in the tail domain of dynein specifically in the 
homodimerisation domain of the DHC and is outside of the region in which the 
DIC interacts with the DHC subunit (see Figure 2.3). A comprehensive list of all 
known SMA-LED mutations in the DHC is shown in Table 1.9. 
 
Ethical approval of the use of human fibroblasts from the MRC Centre for 
Muscular Diseases was obtained in an ethical committee on the 22nd December 
2010. Please see the National Research Ethics Service document for full details 
(REC reference 09/H071661).  
 
3.8 SMA-LED mouse models 
 
3.8.1 Loa mouse model  
 
The Loa (legs at odd angles) mouse model was developed at the MRC 
Mammalian Genetics Unit in Harwell in 1984. The original female mouse was 
generated by ENU mutagenesis of male C3H mice and was noticed for having a 
reptilian locomotion as well as holding her legs at unusual angles when 
suspended from the tail. This is an indicative phenotype that corresponds to a 
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motor system deficit. The mouse was subsequently bred with the 101 strain and 
the heterozygous mice were found to exhibit a slowly progressive locomotor 
phenotype (similar to that observed in SMA-LED) with grip strength deficiencies 
compared with wild-type littermates.  The point mutation induced by the ENU led 
to a p.Phe580Tyr substitution in the DIC binding region of the Dync1h1 gene (see 
Figure 2.3) in which homozygotes die shortly after birth (~24 hours).  
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Table 1.9- DYNC1H1 mutations in SMA-LED 
 
 
 
 
Protein variation Location MCD 
p.Ser3360Gly Stalk No 
p.Glu3048Lys AAA4 Yes 
p.Glu2616Lys AAA3 No 
p.Arg1603Thr Tail domain No 
p.Gln1194Arg DHC HD Yes 
p.Tyr970Cys DHC HD Yes 
p.Trp673Cys 
DLIC BR 
 DIC BR 
 DHC HD 
No 
p.Lys671Glu 
DLIC BR 
 DIC BR 
DHC HD 
No 
p.Val612Met 
DIC BR 
DHC HD 
No 
p.Glu603Val 
DIC BR 
DHC HD 
No 
p.Arg598Cys 
DIC BR 
 DHC HD 
No 
p.Arg598Leu 
DIC BR 
 DHC HD 
No 
p.Ile584Leu 
DIC BR 
 DHC HD 
No 
p.Met581Leu 
DIC BR 
 DHC HD 
No 
p.Arg399Gly DHC HD Yes 
p.Asp338Asn DHC HD No 
p.His306Arg DHC HD No 
p.Arg264Gly Tail domain Yes 
p.Asn199Ser Tail domain No 
Table 1.9- Table outlining all SMA-LED causing DYNC1H1 mutations 
outlining subunit binding regions (BR) and the homodimerisation domain 
(HD). Information regarding functional regions of the DHC protein was cross-
referenced using Uniprot and Scoto et al. (2015). The table also outlines if 
the mutation causes malformation of cortical development (MCD). Table 
adapted from (Strickland et al. 2015; Scoto et al. 2015). 
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Figure 2.3
Figure 2.3- Schematic diagram with amino acid annotations of the DHC depicting the 
location of the R399G mutation as well as the locations of the Loa, Cra, Swl, and Arl mouse 
model mutations. The homodimerisation domain (HD), tail domain and motor domain all have 
amino acid annotations corresponding to the human protein. 
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Subsequently, research on the effect of this mutation on the dynein complex 
showed that the DIC binding affinity to the DHC is increased and subsequently 
LC binding (alternatively named Tctex-1) to the DIC (Garrett et al. 2014). This in 
turn causes a compromised binding of the p150Glued subunit of dynactin (Deng et 
al. 2010). Consistent with these findings further research has shown aberrant 
trafficking of endosomes through impaired velocity and run lengths in 
homozygous Loa mice (Garrett et al. 2014).  
 
3.8.2 Cra1 mouse model 
 
In 2001 when the genomic region of the Loa mouse was presented at a 
conference Dr. Andreas Russ realised that the region and mutation was near 
identical to another mouse model, Cramping 1. This was a mouse model 
generated by a German ENU mutagenesis project and was found to have a 
p.Tyr1055Cys mutation over 400 amino acids away (see Figure 2.3) from the Loa 
mutation in the homodimerisation (HD) domain (Hrabé de Angelis et al. 2000).  
Similar to the Loa model the Cra1 model exhibits an unusual twisting and hind-
limb grasping phenotype when tail-suspended, and the homozygous mice die 
shortly after birth (~24 hours). At 16 months old significant loss of spinal motor 
neurons is observed in heterozygous mice a phenotype which is mirrored by the 
heterozygous Loa mice (Hafezparast 2008).  
 
 
3.8.3 Swl mouse model 
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The Sprawling (Swl) model was similarly developed at Harwell although this 
model was generated through irradiation rather than ENU. The Swl mouse was 
generated much earlier than other models in 1967, but it was only in 2007 that 
the mouse was genetically characterised. A deletion of 9-bp (1040-3) was 
detected giving rise to a G-I-V-T to A amino acid change at position 1040 (see 
Figure 2.3) (Chen et al. 2007).  The Swl mice show an abnormal clenching 
phenotype similar to that of the Loa and Cra1 models and also show a reduction 
in hind-limb grip strength. These mice additionally have sensory deficiencies and 
exhibit dorsal root ganglion degeneration during development (Chen et al. 2007).  
 
3.8.4 Arl mouse model  
 
The Arl model coined ‘Abnormal rear leg’ was generated via an ENU mutagenesis 
project in Toronto at the Centre for Modelling Human Disease (CMHD). 
Characteristic of other Dync1h1 mutations the Arl model exhibits a similar 
clenching of the hind limbs reflective of the previously discussed models.  The 
autosomal dominant p.T3616C mutation leads to a more severe phenotype than 
the Loa mice resulting in a p.Trp1206Arg change in the protein sequence. 
Noticeably, the breeding of this model line is notoriously difficult to maintain 
through sporadic loss of new-born pups possibly due to parental behaviours or 
feeding difficulties. This is supported by a noticeable reduction in size in 
comparison to wild-type litter mates up to 2 weeks of age seen in heterozygous 
mice as homozygous mice are non-viable. A slow progressive motor phenotype 
exhibited by the Arl mice is supported by loss of muscle force in 1-year-old mice 
(data unpublished) although further experiments are required to characterise the 
severity of the Arl mutation.  
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3.9 Research aims and objectives 
 
The basis of my research is concentrated on revealing the cellular and molecular 
basis underlying neurodegeneration in adult onset amyotrophic lateral sclerosis 
(ALS) and in the congenital disease spinal muscular atrophy with lower extremity 
predominance (SMA-LED).  
 
Mutations in RNA binding proteins FUS and TDP-43 are pathogenic in motor 
neuron disease but the disease mechanisms of motor neuron degeneration are 
unknown. Although previous literature has suggested a role for FUS in DNA 
damage repair little information currently exists about the specific role it plays at 
DNA lesions. Additionally, as TDP-43 shares many functional similarities with 
FUS there has been no published research analysing the potential role that TDP-
43 could also play in DNA repair. To investigate this, I have investigated what 
response both FUS and TDP-43 have to DNA damage, if mutations in FUS can 
perturb this response and what mechanisms may underlie the recruitment of FUS 
to DNA lesions. 
 
Mutations in dynein cytoplasmic 1, heavy chain 1 (DYNC1H1) are associated 
with SMA-LED, an autosomal dominant congenital motor neuron disease. The 
holistic role that the retrograde dynein motor plays in cells is incomplete and the 
implications of mutations in its largest subunit are not clear. In order to analyse 
the repercussion of human DYNC1H1 mutations I studied human patient 
fibroblasts harbouring a p.R399G mutation. This work was firstly to elucidate if 
this mutation could impair the subunit composition of the complex. Secondly, to 
explore the potential impact this mutation could have on the Golgi apparatus as 
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dynein mutations are known to impair Golgi reformation after artificial 
fragmentation. Thirdly I set out to unveil potential underlying mechanisms that 
could relate dynein mutations and perturbed Golgi structure. 
 
The Arl mouse model (see SMA-LED mouse models) is known to recapitulate the 
slow motor neuron disease progression of SMA-LED, but this model is yet to be 
fully characterised. One symptomatic feature sometimes seen in SMA-LED is 
malformations of cortical development (MCD). I set out to understand if this 
dynein mutation resulted in any malformation of cortical organisation in the brains 
of Arl mice. Additionally, I went on to investigate if any changes in cortical 
development were related to cell migration deficits caused by the Arl mutation by 
analysing mouse embryonic fibroblasts from this model. 
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Chapter 2- Materials and methods 
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4.0 Genotyping  
 
4.1 DNA preparation  
 
Approximately 0.1 cm2 of tissue was obtained either from the ear or tail using a 
sterilised ear punch or scissors, respectively (unless stated otherwise). The tissue 
was subjected to a digest using 200 l of lysis buffer containing 2 l of proteinase 
K (20 mg/ml) at 55 oC overnight. The following day the digested tissue was 
subjected to centrifugation at 16 RCF for 5 minutes before diluted in double 
distilled water (1:50). To ensure homogeneity, diluted DNA samples were 
vortexed and unless otherwise stated l of this diluted DNA was used in all PCR 
reactions.  
 
4.2 Arl genotyping  
 
A 10l PCR reaction was conducted comprised of Qiagen Hot Start Taq (Qiagen, 
203203) comprising of dNTPs (200 M), MgCl2 (4 mM), Qiagen Hot Start 
polymerase (2.5 units of activity), forward primer (0.1 M), reverse primer 
(0.1M), double distilled H20, and DNA (0.1g). The primer sequences used are 
as follows: Forward primer sequence 5’-
CACTCCAGATGCACAGTGCTCTCCAACCAC -3’; Reverse primer sequence 5’- 
CCCACTCACCCTCGATGTTGTCAATGTAAACCC -3’.  
 
The PCR parameters are outlined as: DNA denaturation (initial) 15 minutes at 95 
oC, denaturation for 30 seconds at 94 oC, primer annealing for 30 seconds at 63 
oC, extension for 1 minute at 72 oC, these steps were repeated 34 times before a 
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final extension for 10 minute at 72 oC. The subsequent PCR product was then 
digested with Ava I restriction enzyme (5 units per reaction). This will result in 
distinct signature bands as the Arl mutation creates a site that the Ava I enzyme 
can recognise (C’YCGR’G) this PCR protocol was designed by Amelia Philpott. 
The PCR product was subsequently run on a 3% agarose gel for 35 minutes in 
order to achieve adequate separation (Figure 2.4). Heterozygous mice will 
produce 3 bands (270bp, 235bp, and 35bp), homozygous mice would produce 2 
bands (although these mice are not viable) of 235bp and 35bp, and wild-type 
mice will produce a single band (270bp) as shown in the figure below. The 270bp 
fragment represents the uncut product and the 235bp fragment and the 35bp 
fragments are the product of Ava I restriction (note the 35bp product will run off 
the gel during the separation of the 270bp and 235bp product).  
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Figure 2.4 
 
 
 
 
 
 
 
Primer sequences 5’ - 3’ 
F- CACTCCAGATGCACAGTGCTCTCCAACCAC 
R- CTCACCCTCGATGTTGTCAATGTAAACCC 
 
GTTTGTGTTGGTAGAGAAACTGACAGGCCACTCCAGATGCACAGTGCTCTCC
AACCACAACAGTCGTGAGGTAGACGGTTATAGAAGGCAGGTGCTTTGATCTG
TGTGTCCTTCTGTCCCAGGAGTCCTGCTTGTTGTCGAGAGGTTGGCAGTGAT
TTCTCCTATTGTTATAGGAAAAAAACCAATTTATCCTTTTATCTTTCAAAGCTCT
ACCGCAATGGTCAGCGTCTGCTGGAAAAACAAAGGTTCCAGTTCCCGCCTTC
TcGGGTTTACATTGACAACATCGAGGGTGAGTGGGGGGCCTTCAATGACAT
CATGCGGCGGAAGGACTCTGCCATTCAGCAACAGGTGGCAAACCTGCAAAT
GAAGATCGTACAGGAGGACAGAGCTGTGGAAAGCCGGACCACGGATCTGTT
GACAGACTGGGAGAAGACCAAACCTGTCACAGTGAGTGTCACTTAACCCTGC
CAGCCAGCAGCACATCATGGCTTCTTTCTGACAGACTTGGGAGGCCACTCCG
CGGCATAGCTTTTCAGATATGTCTGCCCTCCAGTAACTACAAGGCCGCATGG
TAGCCAGTCATTTAGGCTAAGGCAGAAGGGTTGCTTGGGTATGTGAGTGTGA
GGCAGCATGGCAAGATGCCACCAAAATAACAGTGAGGAGCTGGGAGCAGAG
CAGTAGGGACC 
 
 
Figure 2.4- (a) The figure depicted above indicates an agarose 3% gel 
representative of PCR products after AvaI restriction in Arl mice in comparison 
to wild-type mice. (b) Additionally, the figure illustrates the primers employed 
and the subsequent sequence that is amplified during the PCR reaction. The 
reverse primer shows a mismatch shown in red this should be a ‘G’ but the 
mutation ‘C’ creates the Ava I site (highlighted in blue) in conjunction with the 
mutation. The Arl mutation is a 3616T>C substitution (larger font) resulting in 
a change from tryptophan to arginine.  
 
A 
B 
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4.3 TDP-43 F210I genotyping  
 
A 10 l PCR reaction comprised of Microzone (2MM-1) Taq (5 l), forward primer 
(0.1 M), reverse primer (0.1 M), MgCl2 (2.75 mM), double distilled H20, and 
DNA (1 g) per reaction was employed. This method of identification relies on 
two separate reactions per DNA sample. The PCR parameters used are as 
follows: DNA denaturation (initial) 5 minutes at 95 oC, denaturation for 30 seconds 
at 95 oC, primer annealing for 30 seconds at 63.5 oC, extension for 1 min at 72 
oC, these steps were repeated 34 times before a final extension for 10 min at 72 
oC. 
 
One reaction uses two outer primers that produce a band of 225bp in addition a 
primer specific to the wild-type sequence was included producing a 143bp band 
in both the wild-type and the heterozygous mice (Figure 2.5). Similarly, the 
second reaction comprised of the same outer primers but the inner primer is 
specific to the F210I mutation (Figures 2.5, 2.6 and 2.7). The outer primers simply 
provide a control to asses if the PCR reaction has worked whereas the allele 
specific primer denotes the genotype.  
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Figure 2.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5- The above figure illustrates the band pattern 
produced by the products of the F210I genotyping in each 
of the cases for both reactions 1 & 2 for each of the 
genotypes. The PCR product was run on a 2% agarose 
gel for 20 minutes depicted at the top of the figure, along 
with the positive (+ve) and negative (-ve) controls. 
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Figure 2.6 
 
 
Primer Type Primer sequence 
Wild-type allele specific 
primer 
TACCACTTCTCCATACTGACAGAATAA 
Mutant allele specific primer TACCACTTCTCCATACTGACAGAATAT 
Outer forward primer GTGTTTACCATCTCCTGTTCTCTCTT 
Outer reverse primer GACAAATGACCAACAAATATACCTTATC 
 
 
 
GTCTTGTCAGTATACACCTTTAATTTCCATCTGGGGTGCGGGTGTGTGTACAGG
CCAGGCAGTAGTACACAGTTAGCCTCATCTTTAGAAACAAAAACACCCAAGACG
GGAAGGCACTTAAGTATGCATTGATGTGTTTACCATCTCCTGTTCTCTCTTGACC
AGCAAAGCCCAGACGAGCCTTTGAGAAGCAGAAAGGTGTTTGTTGGACGTTGT
ACAGAGGACATGACTGCTGAAGAGCTTCAGCAGATTTTCTGTCAGTATGGAGA
AGTGGTAGATGTCTTCATTCCCAAACCATTCAGAGCTTTTGCCTTCGTCACCTTT
GCAGATGATAAGGTATATTTGTTGGTCATTTGTCCCAGGGCTGGGAATGGATCT
GGTTTAGTGCTACTGTATGTGCCCAGCATGGTACACCAGGGGCTGCACTCAGT
CTCCAACACTGAAAATGATAAGT 
 
Figure 2.6- The above figure shows the sequence that is amplified 
surrounding the F210I mutation (A>T). The colour coded primers in the table 
correspond to the nucleotides they complement in the above sequence. The 
‘A’ in larger font denotes the mutation whilst the nucleotide ‘T’ highlighted in 
purple corresponds to the introduced mismatch. 
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Figure 2.7 
Figure 2.7- The above schematic diagram illustrates the methodology of 
genotyping TDP-43F210I mice  using three separate primers to generate PCR 
products. The red lettering denotes the mutation; the green lettering denotes 
the wild-type sequence. 
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4.4 Fus D520G genotyping 
 
 
A 10 l PCR reaction comprised of Microzone (2MM-1) Taq (5 l), forward primer 
(0.1 M), reverse primer (0.1 M), MgCl2 (2.75 mM), double distilled H20, and 
DNA (1 g) per reaction was employed. The reaction conditions for the PCR are 
as follows: denaturation (initial) 5 minutes at 95 oC; denaturation for 30 seconds 
at 95oC; primer annealing for 30 seconds at 64.1oC; extension for 1 minute at 72 
oC; 34 cycles; final extension for 10 minutes at 72 oC.  The subsequent PCR 
product is then digested with Alw I producing three separate segments of DNA 
as two restriction sites are present in the wild-type sequence. The D520G 
mutation removes one of the restriction sites producing only 2 bands (Figures 2.8 
and 2.9). 
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Figure 2.8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primer Type Primer sequence 
Forward TTTTGGCCCTGGCAAGAT 
Reverse TAGTCTGACACACACACACAC 
AGAATTGAAGATGATAACATGACTTTTTTTCTAGGGGGAAACTATGGAGATGAT
CGACGTGGCAGAGGAGGATATGACCGGGGCGGCTACCGGGGCCGAGGAGG
GGACCGTGGGGGCTTCAGAGGGGGCCGGGGTGGTGGGGACAGAGGCGGTT
TTGGCCCTGGCAAGATGGACTCCAGGTGAGTAAGTCAAAACAAAAGTCAAGA
AAATTGGTCAGAGATCATGAGGAAATCAGGTTTCCCTGGGAAAGTCAGCTTAG
CTGGTTACATTTTTGGGAAGGAAGAAGAAAAGTTCAGAACCCAGTCTTTGAGG
CTGTTTTGCTTTAAAGTCATTTGTTGGGTAGCAGAGACTTGAAGGGTGTGCAT
GGGTAGGGTAGTTCAGTAACACGTAATCTAACATAACTTTTTCTTTCAGGGGC
GAGCACAGACAGGATCGCAGGGAGAGGCCATATTAGCCTGGCTCCTGAAGTT
CTGGAACTCTTCCTGTACCCAGTGTTACCCTTGTTATTTTGTAAACTTACAATT
CAGGATCGCTCATGGATATTTTTTTTTGGGGGGGGTGGGGCGGTTGTGTGTG
TATGTGTGTGTGTGTGTGTCAGACTACCCTAATTGTAACCATATCTCTGGTTCC
CATTAAAAAACATCATTTTAGTTAAATTCTGTTTCCCCCAGTTTACTTTCTGAAG
AATGGGTCCATGTTATTAATGTGGGGCAGTATTAT 
 
Figure 2.8- The above illustrates the agarose gel run for both wild-
type and FUS D520G sequences after a 1.5-hour digestion at 37 
oC with the AlwI restriction enzyme. Additionally, the sequence 
amplified is encompassed by the forward (yellow) and reverse 
(blue) primers shown above. 
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Figure 2.9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.5 DYNC1H1 R399G genotyping  
 
DNA was obtained from collecting human fibroblasts from a T25 tissue culture 
flask before lysing the cells using the same protocol employed for DNA extraction 
when using tissue biopsies.  
 
A 10 l PCR reaction comprised of Microzone (2MM-1) Taq (5 l), forward primer 
(0.1 M), reverse primer (0.1 M), MgCl2 (2.75 mM), double distilled H20, and 
DNA (1 g) per reaction was employed. The reaction conditions for the PCR were 
as follows: denaturation (initial) 5 minutes at 95 oC; denaturation for 30 seconds 
at 95 oC; primer annealing for 30 seconds at 64.1 oC; extension for 1 minute at 
72 oC; 34 cycles; final extension for 10 min at 72 oC. Two reactions are set up in 
parallel for each cell sample. The first reaction (reaction 1) comprised of two outer 
primers (which will anneal to both wild-type and mutant sequences) and one inner 
Figure 2.9- The above figure illustrates the locations of the 
restriction sites that the Alw I restriction enzyme can recognise in 
the PCR products for both wild-type and mutant D520G 
sequences. 
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reverse primer specific to the wild-type sequence. Reaction 2 had the same outer 
primers but the inner reverse primer had specificity to the mutant sequence. 
When the allele specific primer can adequately anneal to the corresponding 
sequence a product of 188bp is produced which out-competes the outer primers 
during the PCR reaction (normally producing a product of 515bp). Conversely, if 
the inner allele specific primer cannot anneal to the template the outer primers 
will successfully amplify the 515bp product (Figure 3.0). 
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Figure 3.0 
 
Primer Type Primer sequence 
Wild-type allele specific primer GCAACATGCATCAATTTCCT 
Mutant allele specific primer GCAACATGCATCAATTTCCC 
Outer forward primer GATTTGCTGTCTGCCACGGA 
Outer reverse primer AGGACCCTGACGATAACAGC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GTCTAAAACAGGCTTTGGAAACTGTGAATGACTACAATCCTCTGATGAAAGATTT
CCCTCTGAATGATTTGCTGTCTGCCACGGAGCTGGACAAAATAAGACAGGCGC
TTGTTGCCATTTTCACACATTTGAGAAAGATCCGAAACACAAAATATCCTATTCA
GAGGGCACTGCGTTTGGTGGAGGCAATTTCAAGAGACTTGAGTTCTCAATTACT
CAAAGTATTGGGCACTAGGAAATTGATGCATGTTGCTTATGAAGAATTTGAAAAA
GTAAGTTTGAATATATAAGACAACCAACCTCAAGACATTGAGATGAAAATATGTC
TTAATAATAAGCCTCACTTTTGAAATTATATCCTAGGTTATGGTAGCATGCTTTGA
AGTTTTTCAGACTTGGGATGATGAGTATGAGAAACTTCAGGTATTGTTGAGAGA
CATCGTCAAAAGAAAAAGGGAAGAAAATCTGAAGATGGTGTGGCGTATCAACCC
TGCCCACAGGAAGCTGCAGGCCCGCCTTGACCAGATGAGAAAATTTAGACGCC
AGCATGAACAGCTAAGAGCTGTTATCGTCAGGGTCCTGAGGCCACAG 
Figure 3.0- The above figure illustrates the substitution at position 1195 
from an A to a G (base highlighted in red). The yellow portion of the 
sequence denotes an intron whereas the black font represents coding 
sequences (all primers here were designed against coding sequences). 
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5.0 Cell culture and tissue dissection  
 
5.1 Dissection and culture of murine embryonic fibroblasts  
 
A female pregnant mouse was sacrificed through cervical dislocation at 13 days 
post-coitum. The mouse was then position using pins on a cork dissection board 
in order to access the ventral side of the mouse. Sterile autoclaved and ethanol 
(80%) washed dissection tools were used to open the abdomen of the mouse 
and carefully remove the embryos. Subsequently the embryos were placed in a 
10 cm diameter sterile petri dish in DPBS (Thermofisher,14040133) 
supplemented with penicillin and streptomycin (Sigma, P4333) at 4 oC on ice. 
 
Each embryo was removed from its respective amniotic sac and placed in a black 
dissection dish under a dissection microscope. The amniotic sac from each 
embryo was kept aside in a 1.5 ml tube on ice for genotyping purposes. For each 
embryo the head was then removed using a sterile scalpel as well as any 
remaining red coloured tissue. Subsequently, this dissected tissue was then 
washed with DPBS supplemented with P/S before dicing the body tissue with a 
razor blade in 100 l of DPBS until homogenous. The tissue was transferred into 
a 15 ml falcon tube before allowing the tissue to settle in the bottom of the tube 
through gravity in a laminar flow cabinet. The DPBS was carefully aspirated 
before adding 0.05% Trypsin (Gibco, 25200056) supplemented with DNase 
(Sigma, D5025) at an activity of 100 u/ml and incubating in a water bath at 37 oC 
for 15 minutes inverting the tube every 5 minutes. The tube was removed from 
the water bath and any undigested pieces of tissue were allowed to sink to the 
bottom of the tube. The supernatant was then carful removed and added to 2 ml 
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of MEF media in a universal tube before centrifuging the cells for 5 minutes at 
390 g. The resultant cell pellet was then resuspended in 5 ml of MEF media 
before transferring the suspension to a T25 tissue culture flask for subsequent 
culturing of fibroblasts.  
 
 
5.2 Dissection and culture of cerebral cortex neurons 
 
A female CD1 mouse was sacrificed at 18 dpc by cervical dislocation. 
Subsequently, embryos were removed from the abdomen followed by quick 
removal of the heads. When required tail tissue was removed in order to genotype 
the mice. Carefully, the brains were removed from the cranial cavity and placed 
in HBSS -/- (Invitrogen, 10594243) containing 1% P/S. Using a dissection 
microscope and forceps the meninges covering the cortical surface of the brain 
were carefully removed and the hemispheres were then separated. Both 
hemispheres were then moved into fresh HBSS -/- (without Ca2+or Mg2+) in order 
to avoid debris accumulation.  One at a time, both hemispheres were sliced as 
finely as permitted by anchoring the hemisphere with forceps whist slicing 
sections using a scalpel producing around 5 slices per hemisphere. These slices 
were then placed flat and then using 18-gauge hypodermic needles the cortical 
tract was targeted and carefully the cortical tissue was removed away from the 
rest of the brain for each slice concurrently. After the slices were obtained each 
was sliced into cubes, collected and placed into 10 ml of HBSS -/- in a 15 ml tube. 
The cortical tissue was then washed once in HBSS -/- before being exposed to 
pre-warmed HBSS-/- containing 0.04 % trypsin for 15 minutes (inverting the tube 
every 5 minutes) at 37 oC. Subsequently 5 ml of DNAase solution (0.2 mg/ml) 
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was added and then aspirated after which 1 ml of triturating solution was added 
to the re-suspend the cortical tissue. Pasteur pipettes were then fire polished by 
flaming the opening of each pipette using a blue flamed Bunsen burner to obtain 
three sizes of opening each getting gradually smaller. Starting with the pipette 
with the largest opening the pipette was attached to a pipet aid and the cortical 
tissue was pipetted up and down 15 times. This procedure was then repeated for 
the other two pipettes with smaller openings at which point all of the cortical tissue 
had dissociated and the solution had become cloudy. Neuro-basal media (3 ml) 
was added to the dissociated cortical neurons and were then counted using a 
haemocytometer. Subsequently 50,000 cells were plated onto coverslips coated 
with poly-D-lysine (Sigma, P6407) (overnight at room temperature) in a 24 well 
plate. Cultured neurons were left for 48hr before any experiments were 
conducted.  
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Culture media  
 
Table 2.0- Human fibroblast / Mouse embryonic fibroblast medium 
 
Reagent Concentration 
DMEM (Gibco 12491015) - 
L-Glutamine (Gibco 11500626) 1% 
Penicillin/Streptomycin (Gibco 
11528876) 
1% 
Bovine growth serum (HYC001-06B) 10% 
 
Table 2.1- Neuro-basal medium  
 
Reagent Concentration 
Neurobasal media (Gibco 11570556) - 
L-Glutamine (Gibco 11500626) 1% 
Penicillin/Streptomycin (Gibco 
11528876) 
1% 
B27 50x supplement (17504-044) 1x 
 
 
Table 2.2 Triturating solution (50 ml) 
 
Reagent Concentration 
Albumax (Gibco 11020-013) 1% 
Trypsin inhibitor (Sigma T9003) 0.5 mg/ml 
DNAse (Sigma D5025) 0.2 mg/ml 
HBSS +/+ 
 (Thermo scientific SH30268.02) 
- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tables 2.0 - 2.2 - Above tables indicate 
composition of cell culture media and 
solutions. 
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Laboratory consumables  
 
Table 2.3-Tissue culture and lab plastics 
 
Product Company Catalogue number 
Microplate 6 well 
polystyrene 9.5cm2 
growth area 
(VWR) 734-1599 
Microplate 24 well 
polystyrene 1.9cm2 
growth area 
(VWR) 734-1605 
Art filter tips 10l sterile (VWR) 732-2219 
Art filter tips 100l 
sterile 
(VWR) 732-2204 
Art filter tips 200l 
sterile 
(VWR) 732-2207 
Art filter tips 1000l 
sterile 
(VWR) 732-2355 
Pipettes 1ml individually 
wrapped 
(VWR) 612-3707 
Pipettes 2ml individually 
wrapped 
(VWR) 612-3704 
Pipettes 5ml individually 
wrapped 
(VWR) 612-3702 
Pipettes 10ml 
individually wrapped 
(VWR) 612-3700 
Pipettes 25ml 
individually wrapped 
(VWR) 612-3698 
Falcon Tubes 50ml 
sterile 
(VWR) 525-0158 
Universal tubes 30ml (Greiner Bio One) 201171 
Cell scraper small sterile 
18mm 
(VWR) 734-1527 
Tissue culture flask 
25cm2 vented cap 
(Corning) 430639 
Tissue culture flask 
75cm2 vented cap 
(Corning) 430725u 
Tissue culture flask 
175cm2 vented cap 
(Corning) 431080 
Gel tips 1-200 l (Alpha laboratories) LW1100 
Microcentrifuge tube 
polypropelene 1.5 ml 
(Fisher Scientific) 11706467 
 
 
 
 
 
Table 2.3- The above table indicates tissue 
culture and lab plastics used throughout 
experimental procedures.  
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Table 2.4- Tissue culture and lab glassware         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Product Company Catalogue number 
Cover slip Best circular 
13mm diameter 0.08 to 
0.12 mm thick 
Fisher Scientific 12392128 
Chambered cover glass 
Lab-Tek II two well 
sterile 
Fisher Scientific 10654602 
Chambered cover glass 
Lab-Tek II one well 
sterile 
Fisher Scientific 177372 
Glass microscope slides 
76 x 26 mm 
Menzel-Glaser BS7011 
Pasteur Pipettes 230 
mm 
Fisher Brand FB50253 
35 mm dish No.1.5 
0.16-0.19 mm 
Corning p35GC-0-10-C 
Table 2.4- The above table indicates tissue 
culture and lab glassware used throughout 
experimental procedures.  
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Biochemistry and cell assays 
 
Table 2.5- Primary Antibodies 
 
 
 
 
 
Antibody Source 
Western 
blot 
dilution 
Immunofluorescence 
dilution 
Host 
Acetylated 
Tubulin 
Sigma T7451 3:6000 1:400 Mouse 
Actin Sigma A5316 1:5000 - Mouse 
B23 
Life 
technologies 
FC61991 
- 1:1000 Mouse 
Cofilin 
Abcam 
ab11062 
1:10000 - Rabbit 
 
Calnexin 
 
Santa Cruz 
    sc-6465 
1:1000 - Rabbit 
De-
tyrosinated 
tubulin 
Abcam 
ab48389 
1:500 - Mouse 
Dynactin 
(p150/135) 
Santa Cruz 
47711 
1:200 - Rabbit 
Dynein heavy 
chain 
Santa Cruz 
SC-9115 
1:100 - Rabbit 
Dynein 
intermediate 
chain 
Kevin pfister 
ab6304 
1:1000 1:200 Mouse 
Dynein light 
intermediate 
chain 
Kevin pfister 1:1000 - Rabbit 
FUS 
Novus 
NB100-565 
1:1000 1:400 Rabbit 
Giantin 
Santa Cruz 
SC-6465 
- 1:1000 Rabbit 
Golgin 160 
Santa Cruz 
sc-27680 
1:1000 - Goat 
TDP-43 
Proteintech 
10782-2 
- 1:200 Rabbit 
-Tubulin 
(DM1A) 
05-829 1:5000 - Mouse 
Table 2.5- The above table indicates which 
primary antibodies have been employed 
throughout experimental procedures.  
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Table 2.6- Secondary Antibodies 
 
 
 
 
 
 
 
 
 
 
Antibody Source 
Western 
blot 
dilution 
Immunofluorescence 
dilution 
Host 
Anti-rabbit 
IgG HRP 
GE 
Healthcare 
NA934 
1:30,000 - Donkey 
Anti-goat 
IgG HRP 
Santa Cruz 
sc2020 
1:10,000 - Donkey 
Anti-mouse 
AP 
Sigma 
A3562 
1:10,000 - Goat 
Anti-mouse 
HRP 
Dako 
P0260 
1:10,000 - Rabbit 
Anti-rabbit 
Alexa fluor 
546  
Invitrogen 
A11035 
- 1:400 Goat 
Anti-rabbit 
Alexa fluor 
488 
Invitrogen 
A11029 
- 1:400 Goat 
Anti-mouse 
Alexa fluor 
546 
Invitrogen 
A11030 
- 1:400 Goat 
Anti-mouse 
Alexa fluor 
488 
Invitrogen 
A11030 
- 1:400 Goat 
Anti-rabbit 
Alexa fluor 
633  
Invitrogen 
A21072 
- 1:400 Goat 
Table 2.6- The above table indicates which 
secondary antibodies have been employed 
throughout experimental procedures.  
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5.3 Preparation of cell lysates  
 
All following reagents and tools for cell lysate preparation were kept at 4 oC and 
centrifugation steps were conducted at 390 x g unless otherwise stated. Firstly, 
cells (95% confluent) were trypsinised from T175 tissue culture flasks at 37oC for 
5 minutes, centrifuged, and washed once with DPBS -/-. The cells were then 
centrifuged and the DPBS -/- was aspirated before adding an appropriate volume 
of RIPA lysis buffer (25mM Tris HCl pH 7.6, 150mM NaCl, 1% NP-40, 1% sodium 
deoxycholate, 0.1% SDS) to the cells supplemented with phosphatase cocktail 
inhibitor 2&3 (Sigma, P0044) and protease inhibitor (Roche, 11836170001). The 
suspension was then pipetted into a glass dounce homogeniser and the cells 
were then manually homogenised with 20 strokes and left on ice for 20 minutes. 
Cells that were cultured in 6 well plates were not trypsinised, but washed and 
lysed in the plate and manually removed using a cell scraper, transferred into an 
Eppendorf tube before leaving the homogenate on ice for 20 minutes to ensure 
complete lysis of cells.  
 
5.3 Measuring protein concentration of lysates 
 
The protein concentration of cell lysates were measured using a BSA assay as 
per the manufacturers protocol (Thermo scientific, 23227) utilising a standard 
curve using a nanodrop 2000 (Thermo scientific). 
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5.4 SDS-PAGE  
 
Homogenates were either run on 10% laboratory prepared gels or pre-cast 12% 
/4-12% gels (NuPAGE, NP0341/NP0322). Higher percentage gels were used 
when probing for smaller molecular weight proteins and laboratory prepared gels 
were generally employed when protein concentration of the homogenate was 
reduced (more protein can be loaded in laboratory produced gels). Gradient gels 
were used when probing constituents for multiple proteins (Table 2.5). The 
transfer of protein between the gel and PVDF (Amersham, 10600021) membrane 
was conducted at either 100 v for 75 minutes or 20 v for 16 hours.   
 
5.5 Immunoblotting of membranes and quantification 
 
All PVDF membranes were blocked in 5% powdered skimmed milk dissolved in 
PBS containing 0.05% Tween-20 (Sigma, P9416) (PBST) for 30 minutes unless 
specified with agitation on a rocker.  The membranes were then exposed to three 
quick rinses with PBST to ensure all undissolved powder was cleaned from the 
membrane. Primary antibody raised against the target protein was then diluted at 
an optimised dilution in PBST (see Table 2.5) before applying to the membrane 
with agitation for a duration of either one hour or overnight. Subsequently, the 
membrane was washed with PBST twice for a duration of 10 minutes each and 
then twice again for a duration of 5 minutes each.  Secondary antibody with 
immunoreactivity to the host species of the primary antibody was then applied to 
the membrane for one hour. The secondary antibodies applied were diluted in 
PBST (see Table 2.6) and were conjugated with alkaline phosphatase or horse 
radish peroxidase enzymes. The membrane was then exposed to further washing 
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steps as outlined above before applying either CDP-STAR (Sigma, C0712) or 
ECL substrate (Amersham, RPN2232) to the side of the membrane containing 
the protein for a total of 1 minute. Subsequently the excess of the substrate was 
blotted onto tissue before placing between two plastic transparencies (to avoid 
drying out of membranes) in a developing cassette. Developing film 
(Thermofisher, 34089) was then placed in the cassette to ensure a tight sandwich 
between the film and the transparency sheets typically for a duration of 5-60 
seconds before placing in a developer.     
 
5.6 Co-immunoprecipitation 
 
All centrifugation steps in the following protocol were performed at 0.4 x g at a 
temperature of 4 oC for a total of 2 minutes unless otherwise stated. 
 
Protein A sepharose beads (Life Technologies, 101041) were washed with DPBS 
(W/O Ca2+/Mg2+) and centrifuged three times before being conjugated with either 
antibody raised against DYNC1I1 or golgin 160 for 2 hours at 4 oC.  
Simultaneously homogenates obtained from human fibroblasts were exposed to 
pre-washed beads to account for any non-specific interactions between the 
beads and homogenate.  
 
Subsequently, pre cleared homogenates from human fibroblasts were incubated 
with the beads overnight at 4 oC. The beads were then subjected to five washes 
in DPBS each followed by centrifugation (Sigma) before one final wash in double 
distilled H2O at 4 oC. The beads were then centrifuged at 16 x g and exposed to 
1 x SDS sample buffer and boiled 95 oC for 5 minutes to release any protein from 
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the beads. The sample buffer was then removed using a gel loading tip to prevent 
uptake of beads and utilised for SDS-PAGE analysis.  
 
 
5.7 Sucrose density gradient analysis of dynein in DYNC1H1R399G/R399G 
mutants 
 
Linear sucrose gradients were made by the technique of freeze thawing outlined 
by Luthe (Luthe 1983). The gradients were formed by freeze-thawing (three 
times) 4.75 ml of 12.5% sucrose in DPBS -/- supplemented with the protease 
inhibitors and phosphatase inhibitor cocktails 2 & 3 (Roche).  
 
For both DYNC1H1+/+ and DYNC1H1R399G/R399G mutants, four T175 flasks were 
used to grow enough fibroblasts to achieve 10 mg/ml final protein concentration. 
Fibroblasts were washed once in PBS before being trypsinised and spun at 400 
g to a single pellet. Subsequently, cells were lysed in 200 l of RIPA lysis buffer. 
The cells and lysate were transferred to a glass dounce homogeniser before 
applying 20 strokes to lyse any remaining cells in the suspension. The protein 
concentration of the lysate was then measured against a BSA curve normalised 
to RIPA buffer using a nanodrop 2000 (Thermo scientific). The sucrose gradients 
were thawed for 2 hours at 4 oC and carefully a total of 2 mg of protein was then 
loaded on top of the gradients slowly as to not disturb the linear sucrose 
distribution. The gradients were weighed and carefully placed into a swing-bucket 
Sw55 Ti Beckman rotor and spun at 237,000 x g for a total of four hours at 4 oC.  
The gradients were carefully removed from the rotor and fixed in place using a 
clamp stand at eye level before 11 fractions (450 l) were slowly removed with a 
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shortened p1000 filter tip. Collected fractions were kept on ice at 4 oC before 
being transferred to -80 oC for storage before SDS-PAGE analysis.    
 
5.8 Immunocytochemistry of primary cells 
 
 All cells used in immunofluorescent experiments were cultured onto 13 mm glass 
coverslips in 24 well plates which were either coated with collagen type I (BD 
biosciences, 354236) or poly-D-lysine. For collagen coating of coverslips 200 l 
(10 g/ml) was used to cover the coverslips before allowing to air dry in a laminar 
flow tissue culture hood. Similarly, for coating with poly-D-lysine (Sigma, p7280), 
200 l was applied to the coverslips and left at room temperature overnight before 
washing them with 1 ml of double distilled water.  
 
Unless otherwise stated cells were fixed at 4% FA (Thermofisher, 28906) for 5 
minutes at room temperature after washing the cells once with PBS. After fixation 
of the cells, the PFA was aspirated before washing the cells three times in PBS 
before permeabilising the cells with PBS containing 0.1% Triton X-100. Cells 
were then subsequently blocked with 5% BSA (Sigma, A9056) in PBS for 30 
minutes with agitation on a rocker. The blocking solution was then aspirated from 
the wells before applying 200 l of primary antibody diluted into 1% BSA in PBS 
(see Table 2.5 for dilutions). The primary antibody was applied overnight unless 
otherwise stated at 4 oC with agitation on a rocker in a humidified box. 
Subsequently, the primary antibody was aspirated from the wells before washing 
once with 1 ml of PBS with 0.1% tween 20 and 0.02% SDS (PBSTS) for 5 minutes 
with agitation. The PBSTS was then aspirated before applying a fluorescent 
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secondary antibody raised against the host animal the primary antibody was 
produced from at a dilution of 1:400 with agitation. This step and subsequent 
steps were shielded from any light using a foil wrapped box to prevent any 
bleaching of the conjugated fluorophore. Lastly three final washing steps with 1 
ml of PBSTS were performed to remove any unbound secondary antibody. In 
order to mount the coverslips onto glass microscope slides a small volume of 
anti-fade mounting medium containing DAPI was applied to a glass microscope 
slide before carefully removing the coverslip from the (Invitrogen, p36931) 24 well 
plate and placing it on top of the medium (cell-side down). The coverslip was then 
subsequently sealed with quick dry nail varnish before imaging.  
 
5.9 Dynein and Golgi apparatus co-localisation 
 
Human fibroblasts were cultured on glass 13mm coverslips in a 24 well plate at 
a density of 5x104. Cells were washed once in PBS and subsequently fixed in 4% 
PFA for immunoflurorescent staining with antibody against DYNC1I1 and giantin.  
 
The IC and Golgi co-localisation quantification was performed by Dr. Carlos 
Reyes-Aldasoro Constantino in the following way using Matlab: Both channels 
were thresholded with Otsu levels resulting in one red region and several green 
objects. The red channel was processed with closing and dilation of 
morphological operators and used to discard all elements of the green channel 
outside the resulting red region. Several measurements were obtained from the 
segmented results.  
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5.10 Golgi polarisation assay in DYNC1H1R399G mutants 
 
Monolayers of human fibroblasts were cultured on 13 mm glass coverslips before 
introducing a wound across the fibroblast culture from the top to the bottom of the 
coverslip using a sterile 10 l pipette tip. To prevent reattachment of any removed 
cells the cultures were washed three times with MEF medium before being 
allowed to migrate into the wound for 8 hours. Subsequently the monolayers were 
washed once with PBS before fixation with 4% PFA for 5 minutes. 
Immunofluorescent staining was then conducted using a combination of giantin 
and phalloidin in order to determine the location of the Golgi and the direction of 
cell migration through actin visualisation. The quantification of the Golgi 
localisation during migration is outlined below. 
 
5.11 The Azimuthal average quantification of Golgi polarisation 
 
The polarity of the Golgi in migrating fibroblasts was quantified using the ImageJ 
plug-in ‘Azimuthal average’ by plotting normalised fluorescence over each degree 
radian within quadrants of the cell with reference to the direction of migration.  
 
The images were opened in ImageJ and the pictures were split into their 
respective channels. A Gaussian blur filter was then applied to the DAPI image 
depicting the nuclei. Subsequently, a threshold was then set to detect the nuclei 
only in the image. The centre of the nuclei was then obtained by enabling the 
centre of mass option in the measurement settings. This coordinate was recorded 
for each cell analysed. ImageJ was then closed and reopened before opening 
the ‘Azimuthal average’ plugin in ImageJ. The X and Y coordinates were then 
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typed into the values window before setting the inner radius, starting angle, and 
setting bins to 360 to measure each degree of fluorescence. The starting angle 
was determined by measuring the half way point across the leading edge for each 
cell.  
The Azimuthal average was then run and each fluorescence value for each 
degree for each cell was recorded. These values were then averaged across all 
cells measured in each genotype after subtracting a background reading of 
fluorescence from each Image. The final fluorescence values were allocated 
positive values if they were facing the scratch and negative values if they were 
facing away from the scratch (see results).   
 
 
5.12 Endosomal trafficking in DYNC1H1 R399G human fibroblasts   
 
Human fibroblasts were plated onto 13 mm glass coverslips in 24-well plates at 
a density of 5x104 and left to culture overnight. Subsequently the fibroblasts were 
serum starved for 2 hours at 37 oC before being placed on ice at 4 oC in serum- 
free media to prevent any endocytosis for a period of ten minutes. Directly after 
the cells were taken off ice, the cold medium was aspirated and then the cells 
were reintroduced to 37 oC MEF of medium. Immediately 2 g/ml of conjugated 
EGF-555 was added to fibroblasts for ten minutes. The fibroblasts were then 
washed with MEF medium to remove any unbound antibody to the EGF receptor 
before re-introducing the fibroblasts to normal MEF media. Subsequently, the 
cells were then washed once with PBS before fixing the cells in 4% PFA at time 
points 0, 10, 30 and 60 minutes. Coverslips were then mounted and used for 
immunofluorescent imaging.         
109 
 
5.13 Wound healing assay  
 
Wild-type and Arl/+ murine fibroblasts were cultured in a six well plate at a 
confluency of 3X105 cells in each well. The fibroblasts were then treated with 
mitomycin C at a concentration of 10 g/ml for 2 hours to arrest cell proliferation. 
The medium was then subsequently aspirated and washed with MEF media once 
before returning to the incubator for a further 2 hours to allow the fibroblasts to 
recover. A sterile 10 l pipette tip was then used to introduce a monolayer wound 
in each well of cultured fibroblasts before changing the media in each well to 
ensure debris and unattached cells are removed from suspension. The cells were 
then incubated at 37 oC for a duration of 12 hours to monitor cell motility after 
capturing a picture of the cells at time point 0.  
 
In order to accurately capture a picture of cell migration at 12 hours to ensure the 
same position of the wound was imaged, tape was used to mark plate positions 
on a Zeiss Axiovert 25 microscope (Figure 3.1). This ensured that the exact 
location could be imaged at both 0 and 12-hour time points for each genotype. 
The images were captured with a canon G3 camera using an eye-piece adaptor 
(Carl Zeiss, 426126) at three separate positions from each scratch from each well 
at 20x magnification. To ensure the images were calibrated adequately for 
analysis, a picture of a haemocytometer was taken after each set of images to 
ensure that each picture was correctly calibrated (pixels/m).  
 
The acquired images were analysed in ImageJ by deducting the final area at the 
12-hour time point away from the initial area of the wound at the 0-time point, this 
110 
 
value was then divided by 12 to provide a rate with the unit of m2/hr. For 
statistical analysis the data was first tested with a Shapiro-Wilk test to confirm 
normal distribution of data before performing an independent samples t-test.  
 
Figure 3.1 
 
 
 
 
5.14 Single strand break assays with topoisomerase I inhibitor 
camptothecin (CPT) 
 
Cells were counted and plated onto glass coverslips at a density of 5x104 in a 24 
well plate in either fibroblast media or in neurobasal media. After 24 hours, the 
medium was subsequently changed and the cells were exposed to 4 M of CPT 
Figure 3.1- The above image depicts the microscope was marked in 
order to find exact positions of fibroblasts wounds in a 6-well plate. 
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(Sigma, C9911) for a total of 1 hour. When caffeine (Sigma, C0750) was 
employed as in inhibitor in relation to preventing CPT related foci the caffeine was 
used at either 10 m or 20 m and added to the cell culture 1 hour before 
treatment with CPT. After the treatment, cells were washed once in PBS before 
being fixed in 1% PFA, cells were stored at 4 oC until stained for 
immunofluorescent confocal microscopy.  
 
5.15 Transfection and UVA microirradiation assays 
 
In order to detect GFP-FUS, A549 cells were plated onto glass bottom plates 
(MatTek) 2 days before the start of the transfection. Subsequently the 
lipofectamine (GeneJuice) was diluted into optimem at room temperature for 5 
minutes at a ratio of 3:100 l (as per the manufacturer’s protocol). The solution 
was well mixed before adding 1 g of plasmid for a further 30 minutes at room 
temperature.  
 
The transfection solution was then added to the seeded cells to a volume of 2 ml 
of fibroblast media.  The cells were then left for 72 hours at 37 oC before being 
sensitised to 10 mg/ml of Hoescht dye (Sigma, 861405) for 30 minutes. Cells 
which were positive for GFP were then subjected to irradiation with UVA laser at 
351-nm wavelength using a 40x /1.2-W objective mounted on a Zeiss Axiovert. 
Images were taken using a LSM 520 Meta camera. For analysing endogenous 
protein cells were treated as above before being fixed with 4% PFA before 
immunofluorescent staining.  
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5.16 RNA polymerase I and II inhibition 
 
Cortical neurons were cultured as previously described and 24 hours after culture 
were exposed to DRB (Sigma, D1916) at a concentration of 300 M for 1 hour 
and -amanitin (Sigma, A2263) at a concentration of 4 g/ml for 18 hours. They 
are both inhibitors of RNA polymerase II. In order to inhibit RNA polymerase II 
cortical neurons were treated with CX5461 (Selleckchem, 2S684) at a 
concentration of 10 M for 1 hour. Neurons were subsequently washed three 
times in PBS before fixing in 1% PFA before immunofluorescent staining.  
 
5.17 Preparation and cryo-sectioning of murine brains 
 
Adult mice were terminally sedated before exposing the heart and subsequently 
an 18-gauge needle was inserted into the left atrium. An incision was made in the 
right atrium in order for PBS and PFA to drain after it had passed through the 
circulatory system of the mouse. The circulatory systems of adult mice were 
initially washed through with PBS for 5 minutes using a masterflex L/S 77202 at 
a flow rate of 5 ml/min before being perfused with 4% PFA. A last wash –through 
of PBS for 5 minutes was conducted before removing the brain and storing in 
PFA 4% overnight. For P4 mice the brains are substantially smaller and can be 
dissected and placed directly in 4% PFA as in the previous step without the need 
for perfusion. The brains were then transferred into 30% sucrose for 48 hours 
before being frozen in crushed dry ice and stored for sectioning at -80 oC.  
Prior to sectioning the brains were transferred to a Leica cryostat set at -18 oC for 
1 hour in order for the brains to equilibrate to temperature. The brains were then 
secured using a hard setting glue via the posterior of the brain to a stage that 
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then is subsequently secured into a chuck. Sections of the brain were then taken 
at 30m thick and stored in a 24 well plate containing PBS. The sections were 
washed twice in PBS and once in PBS supplemented with 0.2% triton X-100 for 
5 minutes each.  
 
5.18 Cresyl violet staining  
 
The sections were then carefully selected and removed from the 24 well plate 
into a larger 10 cm dish filled with PBS using a fine paint brush to manipulate the 
sections of tissue. Subsequently, the sections were gently moved and secured 
onto glass slides specific for mounting tissue sections (VWR superfrost plus, 631-
0108).   The slides were then left to dry for 16 hours on a drying rack before 
beginning the staining procedure. To stain the tissue sections with cresyl violet 
the glass slides were secured into a slide rack to enable quick transition of slides 
between solutions. Glass dishes were filled with 300 ml of each solution and 
placed in a fume hood. The slides were transferred into histoclear (national 
diagnostics) for 5 minutes; 95% ethanol for 3 minutes; 70% ethanol for 3 minutes; 
H2O for 3 minutes; cresyl violet (Sigma, C5042) stain for 9 minutes (60 oC); H2O 
for 3 minutes; 70% ethanol for 3 minutes; 95% ethanol for 3 minutes; and one 
quick dip in 100% ethanol before returning to a solution of Histo-Clear (National 
Diagnostics, 12358637). Glass rectangular cover-slides were then used to 
protect the mounted sections after application with Histomount (National 
Diagnostics, HS-103).  
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5.19 Propagation and preparation of plasmid DNA  
5.19.1 Transformation of competent DH5- E.coli 
 
Aliquots of competent DH5- E.coli (ThermoFisher, 18265017) were thawed (50 
l) on ice at 4 oC with occasional agitation before 2l of the DYNC1H1-halotag 
plasmid DNA was added and carefully mixed by pipetting and incubated at 4 oC 
for 30 minutes. The mixture was then carefully mixed again before being heat- 
shocked at 42 oC in a water bath for exactly 40 seconds without disturbing the 
mixture. The mixture was then transferred to ice for 2 minutes before SOC 
medium (Invitrogen, 15544034) was added to the mixture (100 l for ampicillin 
selection or 400 l for kanamycin selection, also see Table 2.7). Subsequently 
the mixture was then placed in a shaker for 1 hour at 37 oC before being plated 
onto LB agar plates containing the appropriate antibiotic (at least 100 l of the 
transformed E.coli can be added to the plates) before being carefully distributed 
with a spreader. The plates were then left to dry at room temperature before being 
placed inverted in an incubator at 37 oC overnight. The following morning the 
plates are then checked for colonies.   
 
Table 2.7- Antibiotics used for transformation 
Antibiotic Working concentration 
 (High copy) 
Working concentration 
 (Low copy) 
Ampicillin 50 g/ml 20 g/ml 
Kanamycin 50 g/ml 10 g/ml 
 
 
 
 
 
Table 2.7- Concentrations of antibiotic 
employed during transformation. 
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5.19.2 Midiprep of plasmid DNA  
 
The isolation of plasmid DNA was prepared using the Purelink HiPure Plasmid 
Filter Purification Kit (Invitrogen k2100-04) using the manufacturers instructions. 
A bacterial culture was prepared by initially inoculating a starter culture 
comprising of 5 ml of LB broth with an inoculating loop for 8 hours at 37 oC with 
shaking. Subsequently this culture was then introduced into 100-500ml of LB at 
37 oC for 16 hours at a dilution factor of 1:000 at 37 oC with shaking (200 rpm) 
ensuring that the LB medium had turned cloudy. Either 25 ml (for a high copy 
plasmid) or 75 ml (low copy plasmid) was centrifuged for 30 minutes at 4 oC (3760 
x g). A series of resuspension steps and washing steps were then performed as 
instructed by the manufacturer’s protocol.  Finally, the plasmid DNA was pelleted 
by adding 100% isopropanol (Sigma, 278475), this was carefully removed before 
washing with 70% ethanol with minimal disturbance to the pellet.  The pellet was 
centrifuged again for 10 minutes at 3760 g before carefully removing the ethanol 
and allowing the pellet to air-dry for 10 minutes. Subsequently, the DNA pellet 
was resuspended in an adequate volume of double distilled water (usually 100-
200 l). The obtained concentration was then calculated using a nanodrop 
spectrophotometer before freezing at 80 oC for further downstream applications.   
 
5.19.3 Maxiprep of plasmid DNA  
 
The isolation of plasmid DNA was prepared using the Purelink HiPure Plasmid 
Filter Purification Kit (Invitrogen, k2100-16) using the manufacturers provided 
instructions. A bacterial culture was prepared by initially inoculating a starter 
culture comprising of 5 ml of LB broth with an inoculating loop for 8 hours at 37 
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oC with shaking. Subsequently, this culture was then introduced into 100/500 ml 
of LB at 37 oC for 16 hours at a dilution factor of 1:000 at 37 oC with shaking (200 
rpm) ensuring that the LB medium had turned cloudy. Either 100 ml (for a high 
copy plasmid) or 500 ml (low copy plasmid) was centrifuged for 30 minutes at 4 
oC (3760 x g). A series of resuspension steps and washing steps were then 
performed as instructed by the manufacturer’s protocol.  Finally, the plasmid DNA 
was pelleted by adding 100% isopropanol, this was carefully removed before 
washing with 70% ethanol with minimal disturbance to the pellet.  The pellet was 
centrifuged again for 10 minutes at 3760 x g before carefully removing the ethanol 
and allowing the pellet to air dry for 10 minutes. Subsequently the DNA pellet was 
then resuspended in an adequate volume of double distilled water (usually 100-
400 l). The obtained concentration was then calculated using a nanodrop 
spectrophotometer before freezing at 80 oC for further downstream applications.   
 
 
5.20 Transfection of primary and immortalised cells  
5.20.1 Electroporation of primary human fibroblasts 
 
The electroporation protocol was carried out using a neon transfection system 
(Invitrogen MPK10025) as per the manufacturer’s instructions. Cultured 
fibroblasts were trypsinised from T175 tissue culture flasks and spun at 400 x g 
before being re-suspended in PBS before being re-centrifuged. The cell pellet 
was then re-suspended in 115 l of buffer ‘R’ before being transferred into an 
Eppendorf tube containing 5 g of plasmid DNA. The electroporation module was 
then filled with buffer ‘E’ and changed after every genotype electroporated. The 
buffer ‘R’ plasmid mix was then pipetted up and down to ensure it was mixed and 
carefully inserted into the electroporation module ensuring that there are no 
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bubbles in the tip (bubbles will result in arcing and cell death). The fibroblasts 
were then subsequently electroporated at 1650 mV using a pulse width of 20 ms 
for 1 pulse only. The electroporated fibroblasts were then removed from the 
electroporation module and the electroporated cells were reintroduced into 
recovery media (MEF media lacking antibiotics penicillin or streptomycin). The 
fibroblasts were then plated into a 24 well plate and left to recover for 18 hours 
before being reintroduced to fibroblast media containing antibiotics.  
 
5.20.2 Transfection of cells using lipofection 
 
A549 cells were seeded into 35mm glass bottom dishes at a density of 2 x 105 
and left overnight to culture. To make up the transfection solution 100l of 
Optimem was combined with 4 l of GeneJuice® for 5 minutes at room 
temperature as per the manufacturer’s instructions. Subsequently 1 g of the 
plasmid was then added and carefully pipetted up and down several times before 
being incubated at room temperature for 30 minutes. The mixture was then added 
to a total of 2 ml of warmed medium and added to the cells for 24 hours. The 
medium was then changed before further down-stream applications.  
 
5.21 Image acquisition and analysis 
 
Fixed cell image acquisition was conducted using either a spinning disc Olympus-
3I microscope using a 63x oil objective mounted with an EMCCD Evolve camera 
(confocal), an Olympus BX55 with QI click camera (for morphological brain 
differences in mice) or a Leica TSC SP8 confocal microscope (Leica 
Microsystems) utilising PMT and HyD GsAsp hybrid point detectors (confocal).  
Image analysis was conducted using ImageJ or by Constantino Reyes-Aldosoro 
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using Matlab for quantifying Golgi-DIC co-localisation, Golgi fragmentation in 
p.R399G mutant fibroblasts and peri-nuclear acetylated tubulin.  
 
5.22 Matlab Image analysis  
 
All the images unless otherwise stated were processed automatically with in-
house algorithms developed in Matlab ® (Natick, MA, USA). First, to quantify the 
fragments of Golgi per cell, individual fragments on the red and blue channels 
were identified separately using an intensity-based segmentation based on 
Otsu’s algorithm for optimal thresholds (Otsu 1979). Initially, the green channel 
was segmented to identify a general background and foreground, which 
contained red and green regions by thresholding and a morphological closing 
with a circular structural element of 8-pixel radius. The red channel was 
segmented with an Otsu threshold calculated from the overlap of the foreground 
region with the red channel. The segmentation was applied a labelling and all 
regions with area lower than 10 pixels were discarded. The remaining regions 
were again labelled, counted and their areas and intensities calculated.  
 
Second, to quantify the peri-nuclear acetylated tubulin, a combined intensity and 
distance analysis of the cells was performed similar to the analysis of focal 
adhesions previously described (Reyes-aldasoro et al. 2015). Briefly, the blue 
channel (nucleus) and green channels (whole cell) were segmented through 
intensity thresholding and a series of morphological operators. The distance 
transform from the nucleus of the cell towards the edge of the cell was calculated 
(Kimmel et al. 1996). For each distance from the nucleus, which appeared as an 
irregular concentric region, the mean intensity was calculated. This resulted in an 
intensity profile of the fluorescence as a function of distance from the nucleus 
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from which the average intensity of the profile were calculated. 
5.23 Quantification of western blots 
 
 
All western blot bands quantified used ImageJ densitometry analysis. Breifly, 
lanes were marked using the rectangular selections tool and select ‘first lane’ in 
the ‘analyse’ section of the tool bar.  After selecting multiple lanes ‘plot lanes’ was 
then selected from the ‘analyse’ section of the tool bar. After generation of the 
peaks the background was then subtracted by drawing a straight line under each 
peak. The ‘magic wand’ option is selected and then clicking on each curve 
generated an arbitrary figure for an area under each curve representing the 
protein quantity for each band.  
5.23 Statistical analysis 
 
All data sets obtained from experimental findings were evaluated with tests of 
normality such as the Kolmogorov-Smirnov and the Shapiro Willks. This was 
conducted in SPSS and Q-Q plots were used in order to visualise normally or 
non-normally distributed data. Tests were also used to determine the Skewness 
and Kurtosis of the data obtained to highlight outliers in the data. The correct 
parametric (student T-test or ANOVA) or non-parametric (Mann-Whitney U) 
statistical analysis was then employed to determine significant differences 
between (P<0.005) various sets of data obtained. All graphs plotted from these 
data sets were constructed in GraphPad Prism with the standard error of the 
mean. 
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Chapter 3- Investigating the roles of FUS and TDP-43 in 
DNA damage repair 
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6.0 Introduction  
 
Mutations in both FUS and TDP-43 are known to be pathogenic in familial and 
sporadic ALS. The core reasons for why mutations in these RNA/DNA binding 
proteins result in the disease of motor neurons are not clear as they have diverse 
functions, some of which are shared. 
 
The role of FUS in DNA damage repair has been previously eluded to through 
research conducted by Hicks et al. and Wang et al (Hicks et al. 2000; Wang et 
al. 2008). Firstly, Fus knockout murine fibroblasts were shown to exhibit cases of 
aneuploidy and chromosomal breakage implicating the importance of Fus in 
chromosomal stability (Hicks et al. 2000). Secondly, DNA damage has been 
shown to induce binding of FUS to ncRNAs leading to inhibition of the Cyclin D1 
gene indicating that FUS has an active response to DNA damage (Wang et al. 
2008). However, the exact mechanistic role of FUS when responding to DNA 
damage is unknown and could prove vital in understanding motor neuron 
pathology in ALS. 
 
The way in which TDP-43 responds to instances of DNA damage is even more 
uncertain than the FUS response due to a lack of data. However, importantly 
TDP-43 has been shown to have a close association with transcription. Recent 
literature has suggested that the stalling of transcription at a site of DNA damage 
can initiate a repair mechanism known as transcription-coupled nucleotide 
excision repair (TCR) (Haines et al. 2014). This indicates that transcription and 
lesion repair are perhaps intertwined, but the role (if any) that TDP-43 plays is 
unknown. 
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To investigate these responses to DNA damage I have employed several 
techniques to analyse this in A549 cells, primary human fibroblasts and cortical 
neurons. Cortical neurons were chosen to be studied due to high numbers of 
neurons produced from a single cultured brain.  
 
 I have explored the response to oxidative damage induced by the 
microirradiation of nuclei as well as single strand break induction via 
topoisomerase I inhibition. Furthermore, with a specific focus on FUS, I have 
attempted to explore its mechanisms of recruitment through various cell assays.    
 
6.1 Results 
 
 
6.1.1 Endogenous FUS re-localises to DNA lesions induced by UVA laser-
induced oxidative damage. 
 
There is limited knowledge on the recruitment of FUS to DNA lesions induced by 
oxidative damage. Preliminary investigations in the Hafezparast laboratory with 
collaboration with investigators at the Genome Damage and Stability Centre 
(GDSC) at the University of Sussex began by highlighting the recruitment of GFP 
tagged FUS to UVA-induced DNA damage in A549 cells (Rulten et al. 2013).  
 
In order to establish if the recruitment of FUS to UVA-induced lesions was not an 
artefact of the GFP-tagged protein, untransfected A549 cells were plated onto 
35mm dishes, exposed to Hoechst stain and microirradiated. Subsequently, the 
cells were fixed in 1% PFA 2 minutes later in order to capture the re-localisation 
of FUS and labelled with an anti-FUS antibody for immunofluorescent staining. 
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As seen in Figure 3.2 (panel a) FUS re-localised to the site of microirradiation 
indicated by the dashed inset across the nucleus (also see publication). To 
confirm the specificity of the recruitment of FUS to these sites of damage, A549 
cells were transfected with siRNA against FUS over a 48-hour period before 
microirradiation. The siRNA prevented adequate translation of the FUS protein 
leading to a reduction of re-localised FUS after microirradiation (see Figure 3.2). 
The siRNA efficiency was additionally confirmed by western blot analysis of 
lysates from cells transfected with the siRNA (panel b). In Summary FUS is 
recruited to oxidative damage induced by UVA microirradiation in A549 cells. 
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Figure 3.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2- (a) Endogenous nuclear FUS after microirradiation of 
A459 nuclei and immunofluorescent staining using an anti-FUS 
antibody (b) SDS-PAGE analysis of A549 cell total homogenate 
after 48-hour transfection with siRNA against FUS with -actin 
implemented as a loading control. Image acquisition was 
conducted using a spinning disc Olympus-3I microscope using a 
63x oil objective mounted with an EMCCD Evolve camera. 
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6.1.2 TDP-43-GFP re-localises away from DNA lesions induced by UVA 
laser-induced oxidative damage 
 
TDP-43 shares many functional roles with FUS such as the splicing of pre-mRNA 
and the regulation of transcription. Importantly, both proteins bind to DNA 
elements in order to regulate the production of transcripts. As FUS is clearly 
recruited to UVA-induced DNA damage it is feasible to hypothesise that TDP-43 
may play a similar role and become recruited to DNA strand breaks. In order to 
investigate this A549 cells (3x105) were transfected with TDP-43 tagged with GFP 
in glass bottom 35 mm dishes over a period of 48 hours. The cells were then 
exposed to Hoechst fluorescent stain before being microirradiated for the same 
duration as used when analysing endogenous FUS re-localisation. Nuclear TDP-
43 was then monitored using live cell imaging over a period of 20 seconds (see 
Figure 3.3). After microirradiation of the A549 nuclei the TDP-43-GFP began to 
vacate the area of damage after 2 seconds indicated by the dashed white line 
(panel a).  
 
This experiment was repeated and A549 cells with comparable levels of TDP-43-
GFP transfection were chosen (n=8) in order to quantify this expulsion of TDP-
43. The graph in Figure 3.3 (panel b) indicates that the TDP-43 reduces in the 
area of DNA damage to a level of ~60% over a period of 10 seconds and 
remained at that level thereafter (panel b). This gradual reduction of TDP-43 
localisation to the microirradiated area also rules out the possibility of bleaching 
of the GFP signal as in this case the signal would reduce almost instantly after 
the point of irradiation. This datum indicates that conversely to FUS the TDP-43 
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protein vacates areas of DNA damage evoked by oxidative damage through UVA 
microirradiation. 
 
Figure 3.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3- (a) A549 cells (n=8) transfected with 
TDP-43-GFP after a 48-hour period. Nuclei were 
microirradiated (indicated by the dashed line) and 
imaged for 20 seconds (scale bar 10 m). (b) 
Quantification of the fluorescence of the 
microirradiated region (minus background) over a 
20-second period. Image acquisition was 
conducted using a spinning disc Olympus-3I 
microscope using a 63x oil objective mounted with 
an EMCCD Evolve camera. 
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6.1.3 FUS re-localises to nuclear foci after camptothecin exposure in human 
fibroblasts 
 
The re-localisation of FUS after UVA microirradiation was discovered by our 
collaborating group at the GDSC to be dependent on poly (ADP-ribose) 
polymerase 1 (PARP-1).  Although this provides insight into how FUS responds 
to this type of DNA damage, the use of UVA microirradiation is not comparable 
to actual physiological DNA damage, furthermore, the laser energy could damage 
proteins or protein-DNA/RNA complexes.  
 
To induce a more physiologically relevant type of damage a topoisomerase I 
inhibitor was employed in human fibroblasts.  Topoisomerases are enzymes that 
modulate DNA supercoiling and are important for processes such as 
transcription. These enzymes ‘relax’ supercoiled DNA by introducing DNA breaks 
(single strand or double strand breaks) to allow the passing of another strand 
through the lesion (Uday Bhanu & Kondapi 2010). These enzymes then re-join 
the lesions, however, the use of camptothecin (a potent topoisomerase inhibitor) 
prevents this re-joining of the strands and the damage remains. 
 
To investigate the response of FUS to camptothecin (hereafter CPT) exposure, 
human wild-type fibroblasts were cultured and exposed to either CPT or DMSO 
(control) for a duration of 1 hour. The cells were subsequently fixed and labelled 
with an anti-FUS antibody for immunofluorescence analysis (see Figure 3.4). As 
expected the DMSO control shown in the bottom panel did not result in any re-
localisation of FUS. In contrast, after CPT exposure FUS appeared to re-localise 
to foci in the nucleus (indicated by arrows in the top panel of Figure 3.4). These 
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foci were found to correlate with a co-stain of fibrillarin which is a component of 
nucleoli (see Figure 3.4). In summary, FUS foci associated with the nucleoli form 
as a response to topoisomerase I inhibition after CPT exposure.   
 
 
 
 
Figure 3.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4- Wild-type human fibroblasts treated with 
4 M CPT and DMSO. Cells were fixed and probed 
using antibodies for the nucleoli marker fibrillarin and 
FUS and (imaged at 100x magnification, scale bar 
represents 10 m). Image acquisition was conducted 
using a Zeiss Axiovert equipped with LSM 520 Meta. 
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6.1.4 Camptothecin does not induce TDP-43 nuclear foci formation in 
human fibroblasts 
 
The formation of FUS foci in response to the inhibition of topoisomerase I through 
CPT exposure prompted the possibility that TDP-43 could also undergo nuclear 
re-localisation. As TDP-43 re-localised away from UVA induced DNA damage in 
A549 cells it was hypothesised that CPT could result in a re-organisation of sub-
nuclear TDP-43. 
 
Wild-type human fibroblasts were cultured onto 13mm glass coverslips in a 24 
well plate overnight before a 1-hour exposure to CPT. Cells were fixed as before 
and labelled with an anti-TDP-43 antibody for immunofluorescent analysis. The 
exposure to CPT resulted in no clear re-organisation of sub-nuclear TDP-43 
(Figure 3.5 top panel). Instead the TDP-43 formed ring-like structures that 
appeared in all nuclei treated with CPT. This was not the case in DMSO treated 
cells and no re-localisation of TDP-43 was observed. In summary, TDP-43 did 
not re-localise to foci in wild-type fibroblasts after CPT treatment but instead re-
organised to ring-like structures within the nucleus (see discussion).   
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Figure 3.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5-  Wild-type representative human fibroblast 
nuclei after treatment with 4 M CPT or DMSO (control). 
Cells were fixed and labelled with an antibody against 
TDP-43 for immunofluorescent imaging at 100x 
magnification (scale bar represents 10 m). Image 
acquisition was conducted using a spinning disc 
Olympus-3I microscope using a 63x oil objective 
mounted with an EMCCD Evolve camera. 
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6.1.5 Nuclear re-localisation of FUS after camptothecin treatment in murine 
wild-type and p.D520G mutant cortical neurons 
 
ALS is a disease of neurons in which the synapses between motor neurons and 
the musculature degenerate due to a ‘dying back’ phenomena preventing the 
innervation of muscle and in some cases causing cognitive aberrations (Dadon-
Nachum et al. 2011). The DNA repair process in neurons has to be robust and 
heavily relies on the BER pathway in order to repair oxidative damage-induced 
lesions. Thus in order to analyse the neuronal response of FUS under conditions 
of DNA damage it is imperative to investigate this response in post mitotic 
neurons. 
 
To investigate the FUS response to DNA damage in neurons both wild-type and 
p.D520G cortical neurons were cultured from E18 mice. The neuronal cultures 
were then exposed to CPT treatment or DMSO (control) before being fixed and 
immunostained for FUS.  Analysis of the FUS sub-nuclear re-localisation in wild-
type cortical neurons in response to CPT elicited FUS foci similar to that observed 
in wild-type human fibroblasts (Figure 3.6). In contrast, the DMSO treated control 
neurons rarely presented with FUS foci (Figure 3.6). Both the heterozygous and 
homozygous p.D520G neuronal cultures also presented with FUS foci after 
treatment with CPT and similar to wild-type fibroblasts, rarely presented with FUS 
foci after DMSO exposure.  
 
In order to quantify if any difference in foci number could be detected in p.D520G 
cortical neurons compared to wild-type neurons, cultures were repeated and FUS 
foci were quantified in order to determine any significant differences (see figure 
132 
 
b). The graph depicts a trend of increased mean foci in heterozygous and 
homozygous p.D520G mutants compared to wild-type cells (n = 68, n = 70 and n 
= 85 respectively) although no significant difference could be detected. Similarly 
no significant differences were identified in DMSO treated cells between wild-type 
and p.D520G heterozygous and homozygous (n = 74, n = 104 and n = 98 
respectively) mutant cortical neurons.   
 
Overall these data indicate FUS foci formation in cortical neurons in response to 
topoisomerase I inhibition and no significant alteration in foci formation caused 
by the p.D520G mutation.  
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Figure 3.6 
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6.1.6 TDP-43 forms nuclear foci localised with FUS after camptothecin 
exposure in wild-type murine cortical neurons 
 
To further explore the role of TDP-43 in the DNA damage response, cortical 
neurons were implemented to visualise the response to damage. This was in 
order to test the hypothesis that perhaps even though there was no similar 
response in fibroblasts (as seen with FUS) there could be neuronal specific 
responses of TDP-43 to DNA damage. 
 
Figure 3.6- (a) Wild-type and p.D520G mutant murine 
cortical neuron nuclei treated with either 4 M CPT or 
DMSO (control) 24-hours after culture. Neurons were fixed 
with PFA before being probed with an antibody against FUS 
for immunofluorescent analysis and imaged at 63x 
magnification (scale bar represents 5 m). (b) 
Quantification of the mean number of foci per-nuclei in wild-
type neurons and p.D520G mutants. Image acquisition was 
conducted using a Leica TSC SP8 confocal microscope 
with a 63x objective. 
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To analyse possibility of TDP-43 undergoing sub-nuclear localisation cortical 
neurons were cultured and treated with CPT or DMSO for 1 hour the following 
day and subsequently fixed and labelled with an antibody for TDP-43. Images 
taken at 100x magnification were used to detect any re-localisation of TDP-43. 
Cortical neurons treated with DMSO did not indicate any TDP-43 re-localisation 
in the nucleus as expected (Figure 3.7). Interestingly, wild-type cortical neurons 
treated with CPT indicated small foci that are indicated with white arrows (Figure 
3.7). These foci were less obvious in comparison to the FUS foci previously 
observed in both fibroblasts and cortical neurons. 
 
To further explore the possibility that TDP-43 and FUS were indeed occupying 
similar sub-nuclear areas, further cortical neurons were cultured and stained for 
both FUS (green) and TDP-43 (red) as shown in the bottom panel b of Figure 3.7. 
The co-staining of these interrelated proteins indicated that they both seem to 
occupy the same sub-nuclear region of the nucleus (FUS was previously shown 
to be associated with nucleoli under CPT conditions). In summary this indicates 
that the inhibition of topoisomerase I in cortical neurons is conducive to the 
formation of FUS and TDP-43 co-localised foci in sub-nuclear compartments.  
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Figure 3.7 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7- (a) Wild-type cortical neuron nuclei treated with either 
4 M CPT or DMSO (control) 24-hours after culture. Nuclei were 
labelled with antibody against TDP-43 for immunofluorescent 
analysis and imaged at 63x magnification. TDP-43 foci are 
indicated by white arrows. (b) Wild-type cortical neuron nuclei 
treated with CPT co-labelled for both TDP-43 and FUS at 63x 
magnification (all scale bars represent 5 m). Image acquisition 
was conducted using a spinning disc Olympus-3I microscope 
using a 63x oil objective mounted with an EMCCD Evolve camera. 
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6.1.7 The FUS recruitment to nucleoli associated foci is inhibited by caffeine 
in murine wild-type cortical neurons  
 
In order to further extrapolate the mechanism by which FUS is recruited to 
nucleolar sub-nuclear compartments, it is important to attempt to intersect cellular 
pathways by employing inhibitors for example. The DNA damage response is 
largely mediated by members of the PIKK family of enzymes, which have 
previously been shown to interact with FUS (Gardiner et al. 2008). The use of 
caffeine has been previously shown to inhibit both ATM and ATR kinases 
(Stępnik et al. 2015). To elucidate if these kinases are involved in the recruitment 
of FUS to nucleoli associated foci, cortical neurons were cultured and exposed to 
10 mM and 20 mM concentrations of caffeine before being treated with CPT to 
induce DNA damage (Figure 3.8).  
 
Analysis of nuclear FUS distribution after immunofluorescent staining indicated 
as expected that CPT induced the formation of FUS foci whilst the DMSO control 
did not evoke any response in the nuclei (more than 50 cortical neuron nuclei 
were analysed for every condition) (see Figure 3.8). The foci observed with CPT 
treatment co-localised with B23, a nucleolar associated protein (see discussion). 
In contrast, wild-type cortical neurons treated with 10 mM caffeine exhibited a 
significant (P = 0.0002) reduction in B23 associated FUS foci (see Figure 3.8 
panel b). Furthermore, treatment with 20 mM caffeine significantly (P< 0.001) 
abolished FUS foci in wild-type cortical neurons treated with CPT (Figure 3.8). To 
confirm that the sub-nuclear organisation of FUS was not influenced by caffeine, 
cortical neurons were exposed to caffeine without CPT treatment. These neurons 
indicated normal homogenous nuclear distribution of FUS (see figure panel c).  
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In summary, the treatment of cortical neurons with the PIKK inhibitor caffeine 
resulted in the reduced formation of nucleoli associated FUS foci after 
topoisomerase I inhibition.  
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Figure 3.8 
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Figure 3.8 Cont. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 (a) Wild-type cortical neurons treated with either 
CPT, CPT and caffeine or DMSO (control) 24-hours after 
culture.  Nuclei and nucleoli were labelled with antibody against 
FUS and B23, respectively, for immunofluorescent microscopy. 
(b) Quantification of the mean number of FUS foci per cortical 
neuron nuclei when treated with CPT and CPT with 10 or 20 
mM caffeine pre-treatment. (c) Wild-type cortical neurons 
treated with caffeine alone to demonstrate that caffeine has no 
adverse effect on FUS nuclear localisation (all scale bars 
represent 5 m). Image acquisition was conducted using a 
Leica TSC SP8 confocal microscope with a 63x objective.  
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6.1.8 Nucleoli associated FUS foci are induced by polymerase II inhibition 
but not polymerase I inhibition  
 
Although caffeine is a known inhibitor of the PIKK family of enzymes the off target 
effects of caffeine have to be considered. In order to narrow down the pathway 
of FUS recruitment specific inhibitors were employed by Duncan Moore in the 
GDSC in U2OS cells in order to for a high-through put experimental design before 
attempting any inhibition in neurons. U20S cells were treated with ATM, ATR and 
DNA-PK inhibitors before exposure to CPT. The cells were then fixed for 
immunofluorescent analysis to determine if any of the specific inhibitors 
prevented the recruitment of FUS nucleolar foci.  Surprisingly, these inhibitors 
had no effect on the recruitment of FUS to foci leading to the hypothesis that 
perhaps FUS was not responding to DNA damage per-se, but perhaps to the 
interruption of transcription which occurs whilst DNA lesions are repaired. 
 
In order to investigate this, cortical neurons were cultured from E18 wild-type 
mice and subjected to inhibitors of both RNA polymerases I and II (Figure 3.9). 
The latter is the enzyme responsible for transcribing globally whilst RNA 
polymerase I is responsible for transcribing ribosomal RNA (RNA polymerase III 
transcribes non-coding RNA important for processes such as RNA processing) 
(Canella et al. 2010).  
 
Cortical neurons were fixed for immunofluorescent staining of FUS after DRB 
(300 M for 1 hour) and -amanitin (4 g/ml for 18 hours) exposure, which are 
both inhibitors of RNA polymerase II. Wild-type nuclei from cortical neurons 
presented with foci after both treatments that indicated FUS co-localisation with 
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B23 in all neurons (Figure 3.9). In the case of DRB treatment multiple foci were 
observed that were not always associated with the nucleoli, this could be due to 
the mechanism of inhibition (see discussion and Figure 3.9). In contrast when the 
polymerase I inhibitor CX4561 (10 M for 1 hour) was applied to the wild-type 
cortical neurons no FUS foci were observed after immunofluorescent staining 
(Figure 3.9 panel b). 
 
In summary, inhibition of polymerase II in cortical neurons with -amanitin leads 
to nucleoli associated FUS foci formation. The use of DRB to inhibit polymerase 
II leads to multiple foci formation that are not always associated with nucleoli. 
Lastly, the inhibition of polymerase I does not lead to FUS foci formation.  
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Figure 3.9 
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Figure 3.9 Cont. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9- (a) Wild-type cortical neurons 24-hours after culture 
treated with DNA polymerase II inhibitors -amanitin and DRB for 18 
and 1-hour respectively or DMSO (control) immunostained for FUS 
and B23. (b) Wild-type cortical neurons treated with DMSO or the 
DNA polymerase I inhibitor CX5461 immunostained for FUS (all scale 
bars represent 5 m). Image acquisition was conducted using a Leica 
TSC SP8 confocal microscope with a 63x objective.  
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6.1.9 FUS foci formation is inhibited by dipyridamole in murine wild-type 
cortical neurons 
 
To further elucidate the mechanism of FUS recruitment to nucleoli after CPT 
treatment, other targets of caffeine other than the PIKK enzymes were considered 
potential recruiters of FUS. Caffeine is known to inhibit phosphodiesterases 
(PDEs) that represented a possible chaperone of FUS to CPT induced foci 
(Chavez-Valdez et al. 2016). PDEs in mammals are responsible for the regulation 
of intracellular signalling through degradation of cyclic AMP (cAMP) and cyclic 
GMP (cGMP) (Umar & Hoda 2015).  A paper by Jackson et al. outlines that 
dipyridamole can be implemented in a concentration dependent manner to inhibit 
PDEs. A lower concentration of dipyridamole was observed to have an inhibitory 
effect of PDE 9,10 and 11 whereas high concentrations were shown to inhibit 
PDE 8 (Jackson et al. 2007).  
 
To investigate if FUS was being recruited by any members of the PDE family 
cortical neurons were cultured from wild-type mice and exposed to 10 M and 
300 M dipyridamole for 1 hour before being exposed to CPT treatment (Figure 
4.0). Cortical neuron cultures that were initially exposed to 10 M dipyridamole 
followed by CPT exposure remained to show FUS foci associated with the 
nucleolus (indicated by B23 in Figure 4.0). In contrast, when a higher 
concentration of 300 M dipyridamole was applied to wild-type neurons before 
CPT exposure a significant (P<0.0001) reduction in nuclear FUS foci observed 
(Figure 4.0). 
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In summary, the treatment of wild-type cortical neurons with 300 M dipyridamole 
abolishes the recruitment of FUS to nucleolar associated foci; thus implicating 
PDEs in the recruitment of FUS to nucleoli after inhibition of topoisomerase I 
through CPT treatment (see discussion).  
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Figure 4.0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 4.0- (a) Wild-type cortical neurons pre-treated with 10 M and 
300 M dipyridamole before CPT application. Cortical neuron nuclei 
were then subjected to immunofluorescent staining using antibodies 
against FUS and B23 (scale bar represents 5 m). (b) Quantification 
of the percentage of neurons with FUS nuclear foci when pre-treated 
with 10 M and 300 M dipyridamole (scale bar represents 5 m). 
Image acquisition was conducted using a Leica TSC SP8 confocal 
microscope with a 63x objective.  
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6.10 Chapter 3 Summary 
 
The data presented in this chapter shows that both FUS and TDP-43 respond to 
DNA damage. Firstly, FUS is recruited to damage evoked by oxidative damage 
caused by UVA microirradiation and to foci by topoisomerase I inhibition via CPT. 
However, the p. D520G mutation in murine cortical neurons did not alter the 
response of FUS when treated with CPT. The FUS foci formed are co-localised 
with nucleoli and these foci are replicated when DNA polymerase II inhibitors are 
employed. This recruitment was prevented by caffeine treatment in cortical 
neurons but not individual targeting of the PIKK family members (shown by 
colleagues).  As caffeine also targets PDE’s, dipyridamole was used as a specific 
inhibitor of PDE’s showing that a high concentration of dipyridamole prevents 
FUS foci formation; indicating that PDE’s are likely responsible for the recruitment 
of FUS to nucleoli after CPT treatment. 
 
Secondly, the response of TDP-43 in contrast indicated that oxidative damage 
via UVA microirradiation resulted in the expulsion of TDP-43 from DNA lesions. 
Furthermore, no observable foci could be detected in human fibroblasts (unlike 
FUS) after CPT treatment. However, foci were detected in cortical neurons after 
CPT treatment that co-localised with FUS indicating that perhaps TDP-43 has a 
slightly different role in neurons under conditions of DNA damage. However, time 
restrictions prevented further exploration of the role that TDP-43 plays in the DNA 
damage response. 
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6.11 Chapter 3 discussion 
 
6.11.1 FUS and TDP-43 re-localise after UVA microirradiation in A549 cells  
 
The aim of this study in Chapter 3 was to characterise the response of FUS and 
TDP-43 to DNA lesions. Mutations in both coding genes are pathogenic in ALS 
and could be responsible for crucial DNA repair processes. This is particularly 
imperative for motor neurons as they produce high levels of ROS and are post-
mitotic. To initially examine the response of FUS to oxidative DNA damage A549 
nuclei were micro-irradiated and the re-localisation of FUS was analysed through 
fluorescence microscopy.  
 
After microirradiation of nuclei the endogenous FUS protein localised to the 
damaged region indicating a clear response to the damage. The recruitment of 
FUS was found by colleagues at Sussex University to be inhibited on application 
of a PARP1 inhibitor (KU58948). This PARP1 dependency was further confirmed 
by demonstrating that FUS directly interacted with PARP1 to enable its re-
localisation (Rulten et al. 2013). The microirradiation energy the nuclei were 
exposed to initiated both double and single strand breaks of the DNA double 
helix.  
 
In the instance of SSBs, PARP1 promotes poly(ADP-ribos)ylation of repair 
proteins XRCC1 and polto induce ligase III repair (Ghosh et al. 2016). PARP1 
knockout mice importantly also show delayed repair of SSBs (Schreiber et al. 
2002). Interestingly, Mastrocola et al. demonstrated that PARP1 dependent FUS 
recruitment was initiated through DSB repair and additionally showed that FUS 
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depletion resulted in reduced DSB repair via non-homologous end-joining and 
homologous recombination (Mastrocola et al. 2013). Taken together, it is possible 
that the PARP1 response to both single and double strand breaks promotes the 
recruitment of FUS to DNA damage. 
 
What is the role of FUS at the sites of these DNA lesions? One prospect is that it 
is stabilising pre-mRNA or perhaps processing pre-mRNA at the site of damage 
as FUS is well known for interacting with large numbers of pre-mRNAs. 
Alternatively, it may be the case that FUS is directly involved with the repair of 
DNA lesions as the DNA damage signalling kinase ATM is known to 
phosphorylate FUS perhaps promoting its recruitment (Gardiner et al. 2008). 
Lastly it is possible that FUS is regulating gene expression at the sites of DNA 
damage, as FUS dependent inhibition of the Cyclin D1 gene was observed after 
DNA damage mediated by the binding of FUS to ncRNAs (Wang et al. 2008).  
 
After microirradiation of GFP-TDP-43 transfected A549 nuclei TDP-43 responded 
to the oxidative damage by vacating the microirradiated region of the nucleus. 
This response indicates that in A549 cells the role of TDP-43 may differ from that 
of FUS despite many shared functions between these two proteins (see Chapter 
1). TDP-43 has been identified as a regulator of transcription and depletion of 
TDP-43 results in changes of expression of over 200 proteins in SH-SY5Y cells 
(Štalekar et al. 2015). Transcription-coupled nucleotide excision repair has 
recently been highlighted as a mechanism in which the cessation of transcription 
can initiate repair (Haines et al. 2014). It therefore could be hypothesised that 
TDP-43 is sequestered away from transcriptionally active DNA to facilitate this 
repair mechanism. Although further time and investigation would be needed to 
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confirm the players involved in this active repression of TDP-43 from DNA lesions 
induced by oxidative damage.  
 
6.11.2 FUS, but not TDP-43 form nuclear foci in human fibroblasts after 
topoisomerase I inhibition with CPT 
 
To elicit a more physiologically relevant type of DNA damage, topoisomerase I 
was inhibited with CPT in human fibroblasts in order to produce SSBs and 
consequently monitor re-localisation of FUS and TDP-43. On the application of 
CPT, the FUS protein accumulates into foci in sub-nuclear compartments. When 
co-stained with nucleoli marker fibrillarin, it was clear that the FUS foci were 
forming in associated with the nucleoli within the nucleus.  
 
Upon the global inhibition of topoisomerase I, (and consequently induction of 
single strand breaks) perhaps it would have been expected to visualise many 
FUS foci spread across the whole nucleus. This is because FUS would have been 
recruited to multiple sites of DNA damage, although this was not visually seen. 
However, it is possible that perhaps the low level of damage inflicted by CPT may 
not cause such a dramatic response in comparison to microirradiation of the 
nuclei, and thus be harder to visualise.   
 
Even though this may be the case, a substantial FUS association with the 
nucleolus was observed after CPT exposure. The reason for this could be the 
close association between topoisomerase I and the transcription of ribosomal 
DNA (rDNA). The majority of topoisomerase I is found in the nucleolus as it is 
important for rDNA transcription creating single strand breaks in DNA to relieve 
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torsional forces (Christensen et al. 2004). Due to the association between 
topoisomerase I and rDNA transcription it can be hypothesised that perhaps FUS 
plays a protective role interacting with ribosomal pre-mRNA. As nucleoli are 
transcriptional ‘hot spots’ this could explain the accumulation of FUS in these sub-
nuclear regions.   
 
In contrast, TDP-43 did not appear to form foci in human fibroblast nuclei after 
inhibition of topoisomerase I. This is perhaps in accordance to previous data 
showing its vacation of regions of the nuclei that have been microirradiated (see 
Figure 3.3). However, inhibition of topoisomerase I led to the formation of ring like 
structures observed in the nucleus rather than foci per-se. The TDP-43 staining 
appeared to co-localise with the brighter DAPI staining, these regions are 
associated with heterochromatin. Upon topoisomerase I inhibition the ability of 
heterochromatin to become relaxed into transcriptionally active DNA 
(euchromatin) through SSBs is reduced. The ring-like structures are the outer 
regions of nucleoli as heterochromatin typically surrounds nucleoli (Padeken & 
Heun 2014). This likely explains why more ring like structures were observed in 
human fibroblasts treated with CPT.   
 
However, the association of TDP-43 with heterochromatic regions is harder to 
explain as TDP-43 is well known for the association with transcriptionally active 
regions of DNA. Recent data suggests that TDP-43 has a role in regulating 
chromatin assembly perhaps providing a tentative explanation, though time 
restrictions prevented further investigation of this finding (Amlie-Wolf et al. 2015).  
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6.11.3 FUS and TDP-43 form nuclear foci after CPT treatment in neurons 
 
The incidence of FUS foci in human fibroblasts after the inhibition of 
topoisomerase I prompted investigation into cortical neurons. Cortical neurons 
have an experimental advantage in terms of number of neurons that can be 
isolated from a single murine brain. When wild-type neurons were exposed to 
CPT FUS foci were observed as previously detected in human fibroblasts. This 
indicates that the role that FUS plays during topoisomerase I inhibition is active 
in both mitotic and post mitotic cells, suggesting that ALS mutations in FUS may 
impair this function of FUS. 
 
Importantly, collaborative efforts showed that an ALS R521G FUS mutation 
showed reduced localisation to oxidative damage (Rulten et al. 2013). However, 
the murine D520G mutation did not show a similar impairment in recruitment after 
CPT exposure (Figure 3.6). The D520G mutation is akin to D512G in the human 
sequence and mutations at neighbouring residues such as 513 and 514 are 
thought to be pathogenic in ALS (Lagier-Tourenne et al. 2010). The D520G 
mouse model has no currently identified phenotype or pathology (perhaps 
surprisingly) associated with it, suggesting the amino acid substitution is 
somewhat silent.  
 
Although no nucleoli associated TDP-43 foci were observed in human fibroblasts, 
cortical neurons showed distinct TDP-43 foci in cortical neurons. These foci were 
found to co-localise with FUS and indicates that perhaps TDP-43 may have a 
post-mitotic role after the inhibition of topoisomerase I. 
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In accordance with this observation, electron microscopy data of motor neurons 
have indicated co-localisation of TDP-43 and the nucleolus. Interestingly, a lack 
of TDP-43 in the nucleolus of sporadic ALS patients has been detected, even in 
motor neurons that appeared healthy (Sasaki et al. 2010). This suggests that 
TDP-43 has an important role in nucleoli in post-mitotic cells. However, this does 
not explain why the inhibition of topoisomerase I induces the re-localisation of 
TDP-43 in neurons. It is possible that TDP-43 has a neuroprotective role under 
conditions of DNA damage or cessation of transcription. This is supported 
through evidence from a neuroblastoma cell line indicating a significant reduction 
in cell viability when topoisomerase I was inhibited in parallel with TDP-43 knock 
down (Yu et al. 2012). Overall, this suggests that TDP-43 has a functional role at 
the nucleolus that could be increased under nucleolus stress in neurons, but time 
limitations have prevented further investigation.   
 
6.11.4 The recruitment of FUS to the nucleolus is inhibited by caffeine  
 
To further explore the mechanism of FUS recruitment to the nucleolus initially the 
PIKK family of enzymes were targeted as they are responsible for recruiting 
proteins in the DNA damage response. Caffeine (a known inhibitor of PIKK 
enzymes: ATM, ATR and DNA-PK) was added to cortical neuron cultures 
followed by the addition of CPT. Neurons were then fixed and immuno-labelled 
for FUS. Initially a concentration of 10 mM of caffeine was employed as used by 
Tresini et al in order to inhibit the PIKK enzymes (Tresini et al. 2015). This 
concentration produced a reduction of FUS foci associated with the nucleoli 
(marked by B23) by over 50% although, many nuclei still contained observable 
FUS foci. Colleague Duncan Moore in the GDSC at Sussex University also 
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reported variable effects of the inhibitor caffeine in U2OS cells that could have 
been related to poor solubility in cell culture media. Aside from this, a higher 
concentration of 20 mM was attempted which abolished all FUS foci in cortical 
neurons indicating that 10 mM was not enough to prevent FUS recruitment to 
nucleoli. 
 
This observation led to the hypothesis that one of either ATM, ATR or DNA-PK 
was responsible for recruiting FUS after topoisomerase inhibition by CPT. A high 
throughput screening of specific inhibitors were employed in U2OS by colleagues 
in the GDSC was conducted in order to save time. This was in order to identify 
the specific PIKK member that was responsible for recruiting FUS, although 
surprisingly specific inhibitors of ATM, ATR or DNA-PK did not influence FUS 
recruitment.  
 
6.11.5 RNA polymerase II inhibition produces nucleoli associated FUS foci 
 
This evidence led to the hypothesis that perhaps the PIKK enzymes were not 
responsible for recruiting FUS to the nucleolus and consequently, may not be 
responding to DNA damage, but to the specific cessation of transcription. In order 
to analyse this, cortical neurons were treated with polymerase II inhibitors -
amanitin and DRB before detecting FUS re-localisation with immunofluorescent 
microscopy.  The inhibition of RNA polymerase II evoked the formation of FUS 
foci similarly to that of CPT. Although this was the case DRB inhibition of 
polymerase II led to multiple global FUS foci that were not always associated with 
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the nucleolus.  The inhibition of RNA polymerase I (control) did not evoke a re-
localisation of nuclear FUS.  
 
DRB is known for inhibiting RNA polymerase II by interfering with the elongation  
step of transcription by inhibiting CDK7 and CDK9 which are responsible for 
phosphorylating one of the subunits of RNA polymerase II (Turinetto et al. 2009). 
The action of -amanitin is more direct by interacting with polymerase II and 
preventing its translocation to DNA (Bushnell et al. 2002). These differences in 
the mode of inhibition could explain the difference in FUS foci localisations. FUS 
may be required for an intermediary stage binding to certain molecular weight 
transcripts upon stalling of the elongation step in the case of DRB inhibition in 
comparison to -amanitin inhibition although this is only a hypothesis.   
 
Cortical neurons that were treated with CPT or -amanitin produced FUS foci 
only related to the nucleoli. Both treatments have been found to structurally 
fragment the nucleolus which could potentially evoke a FUS response  (Wachtler 
& Stahl 1993).  A shortage of gene products through inhibition of RNA polymerase 
II could compromise the integrity of the nucleolus (Olson et al. 2000).  
 
Nucleolar structure is dictated by chromatin and it has been proposed that the 
association between FUS and chromatin is dependent on RNA polymerase II 
(McKeown & Shaw 2009; Yang et al. 2014). FUS may be required for the 
production of ribosomal transcripts and it is possible that RNA polymerase II is 
regulating FUS in this manner therefore; when it is inhibited it can no longer 
sequester FUS away from these regions. Interestingly, FUS has been previously 
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found to inhibit transcription by RNA polymerase III clearly indicating an important 
role at the nucleolus (Tan & Manley 2010).  Furthermore, it is possible that FUS 
is involved with the processing of nascent ribosomal RNA transcripts. The global 
inhibition of RNA polymerase II could be evoking a cellular response in which 
ribosome production is increased requiring more FUS to process these 
transcripts. Alternatively, FUS could be binding to these transcripts to prevent any 
further ribosome production in order to conserve cellular energy, further research 
is required to determine this mechanism.  
 
6.11.6 Formation of nucleoli associated FUS foci is inhibited by 
dipyridamole  
 
To further investigate the mechanism of recruitment of FUS to CPT induced foci 
other targets of caffeine had to be considered as specific inhibitors of the main 
members of the PIKK family, did not prevent FUS recruitment. Aside from the 
PIKK family caffeine is known to inhibit PDEs which regulate intracellular 
signalling (Umar & Hoda 2015). Dipyridamole has been previously used in a 
concentration dependent manner in order to selectively inhibit different PDEs. 
Cortical neurons were exposed to 10 M and 300 M dipyridamole for 1 hour 
before being exposed to CPT in an attempt to inhibit FUS recruitment. FUS foci 
were not abolished at the lower concentration of 10 M but could not be detected 
in neuronal nuclei exposed to 300 M dipyridamole before CPT treatment (Figure 
4.0).  Although FUS foci were still observable at 10 M they were often not as 
bright as previously observed FUS foci, making them difficult to image and were 
not always completely co-localised with nucleoli. This could perhaps be due to 
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minor impairment of FUS recruitment caused by effects of the lower concentration 
of dipyridamole. 
 
Jackson et al had shown that lower concentrations of dipyridamole had an 
inhibitory effect of PDE 9, 10 and 11 whereas higher concentrations specifically 
inhibited PDE 8 (Jackson et al. 2007). Therefore, this indicates that the 
recruitment of FUS could be attributed to PDE 8. Despite this being the case off-
target effects cannot be ruled out and a more specific approach using siRNA 
specifically against certain PDEs needs to be employed although this was not 
viable in the time available. 
  
Interestingly, recent evidence has indicated a link between FUS and PDEs, a 
study showing the importance of FUS in cell proliferation indicated that cell 
proliferation was rescued in cells knocked down with FUS when treated with a 
PDE 4 inhibitor (Ward et al. 2014). PDEs have specific substrates and PDE 8 
specifically hydrolyses cAMP, this could represent an indirect mechanism that 
could influence FUS recruitment due to the broad influence of cAMP on 
intracellular signalling. Inhibition of PDEs will increase PKA signalling and lead to 
CREB activation and increased gene expression (see Figure 4.1).  The CREB 
co-activator CREBBP may be down regulated as a consequence resulting in 
reduction of nucleolar chromatin remodelling and therefore reduced FUS 
recruitment (Lee et al. 2014; Cardinaux et al. 2000). However, there are over 100 
proteins that are produced from the PDE genes generated from splice variants 
and alternative translation start sites furthermore; it is possible that more than 
one of these species can influence FUS recruitment to nucleoli (Y. Xu et al. 2011).   
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Figure 4.2 summarises the proposed mechanisms and localisation of both FUS 
and TDP-43 during oxidative DNA damage and topoisomerase I inhibition. 
 
Figure 4.1  
 
 
 
 
Figure 4.1- The above schematic depicts the signalling 
pathway influenced by PDEs. Inhibition of PDEs would lead to 
increased gene expression through CREB activation. This in 
turn could down regulate CREBPB which could decrease 
nucleolar chromatin remodelling and prevent FUS recruitment.  
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Figure 4.2- A summary of proposed responses of both FUS and TDP-43 to microirradiation of 
DNA and the inhibition of topoisomerase I.  
Figure 4.2 
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Chapter 4- The DYNC1H1 R399G mutation in SMA-LED 
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7.0 Introduction 
 
 
Mutations in the DYNC1H1 gene are pathogenic in SMA-LED, a congenital 
condition characterised by motor neuron loss and muscle atrophy of lower limbs. 
The key aberrant molecular mechanisms that underpin this condition are not 
known and the varied association of other signs such as cognitive impairment 
likely reflect the complexity of the disease. 
 
DYNC1H1 is the heavy chain component of cytoplasmic dynein, a protein 
complex which is known for dictating retrograde transport of cargo along 
microtubules. Aside from its connection to microtubules, dynein can be localised 
to many other cellular organelles such as the Golgi apparatus of which its 
associated function is not well understood. 
 
Recent data from Yadav et al. has shown that dynein interacts with a Golgi bound 
protein golgin 160 to tether microtubules to Golgi membranes (Yadav et al. 2012). 
Additionally, mutations in DYNC1H1 have been shown to cause a delay in the 
reformation of the Golgi after induced fragmentation with microtubule 
depolymerising agent nocodazole (Fiorillo et al. 2014; Hafezparast et al. 2003). 
Importantly, Golgi fragmentation has been identified in fibroblasts from SMA-LED 
patients with mutations in BICD2 another Golgin protein. Together, this implicates 
Golgi fragmentation as a potential common mechanism of disease that could 
contribute to the loss of motor neurons in SMA-LED. 
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To address this, I have employed several biochemical techniques to investigate 
 human fibroblasts with a DYNC1H1 mutation p.R399G.  Firstly, this was to 
determine if the mutation causes a disruption of the dynein complex. Secondly, 
to determine if there is disruption of the Golgi apparatus caused by this mutation 
and if so to reveal mechanisms that potentially underlie this pathology.  
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7.1 Results 
7.1.1 Analysis of the dynein complex in p.R399G homozygous fibroblasts 
 
In order to elucidate if the R399G mutation has any adverse effects on the 
formation of the dynein complex, a sucrose density analysis was performed. 
Previous data from the Hafezparast lab has shown that mutations in the dynein 
heavy chain can have adverse effects on the complex formation of dynein. When 
homogenates from the Loa/Loa mouse model were subjected to sucrose density 
gradient analysis it was discovered that the DIC and the DLIC exhibited increased 
binding affinity to the DHC (Deng et al. 2010). This could have detrimental effects 
in terms of further binding of other subunits, adaptor proteins, and importantly 
cargo. 
 
The formation of linear sucrose gradients from 5% to 20% was achieved through 
a method of freeze-thawing. Homogenates from wild-type and homozygous 
fibroblasts were loaded onto these gradients and were subjected to high speed 
centrifugation. A total of 11 fractions were collected from the gradients and were 
analysed through SDS-PAGE. 
 
When analysing the wild-type gradient profile of the DHC it can be seen that the 
DHC occupies fractions 7 through to 11. In comparison the homozygous profile 
was detected through fractions 6-11. To determine if this was a repeatable 
observation this experiment was duplicated and the wild-type gradient was 
probed yet again for the DHC. Figure 4.3 highlights that after the second attempt 
(exp 2) the DHC western blot profile obtained in the wild-type fibroblasts matches 
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the homozygous profile. The repeated attempt importantly correlated with 
previous wild-type DHC profiles of murine origin (Deng et al. 2010). 
Both subunits of dynactin (p150 and p135) were then analysed in terms of their 
distribution throughout the gradients between both genotypes.  Figure 4.3 
highlights that the dynactin subunits can be found in both genotypes between 
fractions 4 and 11 with a very faint signal barely detectable in fraction 3. 
 
Similarly, when probing for the DIC (DYNC1I2) in both wild-type and homozygous 
fractions the protein was detectable in fractions 7 through to 11 in both genotypes 
(Figure 4.3). Interestingly a DIC signal was detectable in fraction 3 for both 
genotypes.  
 
Lastly both DLIC1 and DLIC2 were analysed by western blot to indicate which 
fractions they occupied in the 5-20% gradients (Figure 4.1). Unsurprisingly the 
fractions occupied by the DLIC were reflective of the DIC (from fractions 7-11). In 
addition to this a signal was also detected in fraction 3 similarly to the DIC again 
perhaps eluding to incomplete dynein complexes. In summary, this data indicates 
that the p.R399G mutation does not appear to influence the subunit organisation 
of cytoplasmic dynein. 
 
As the p.R399G mutation resides close to the DIC-DHC binding (see introduction) 
region a co-immunoprecipitation assay was conducted to further confirm that the 
p.R399G mutation was not impeding complex formation. An antibody against the 
DIC subunit of dynein was used to pull down the ~500 kDa DHC subunit in wild-
type, heterozygous and homozygous human fibroblasts. The western blot 
analysis of the co-immunoprecipitation indicated no visual difference between the 
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genotypes in the immunoprecipitation of the DHC when targeting the DIC. This 
further confirms that the p. R399G mutation does not affect the subunit 
composition of the dynein complex.  
 
Figure 4.3 
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Figure 4.3 cont. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3- (a) SDS-PAGE analysis of sucrose density fractionation of 
cellular homogenates from wild-type and p.R399G fibroblasts probed for 
cytoplasmic dynein subunits. Antibodies specific to the DHC, DIC, 
p150/p135, and DLIC subunits of dynein implemented to analyse the 
complex integrity of dynein. Sucrose gradient 5-20%. (b) Sucrose 
density gradient indicating gradient separation of Golgi (Giantin), 
cytoplasmic (HDAC6), and endoplasmic reticulum fractions (calnexin). 
(c) Co-immunoprecipitation of the DHC subunit using an antibody 
against DIC subunit of dynein in wildtype and p.R399G mutant 
fibroblasts conducted in two experiments (n= 2).  
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7.1.2 The p.R399G mutation causes Golgi fragmentation in human 
fibroblasts 
 
Dynein has an important role in Golgi homeostasis, previously mutations have 
elicited delayed Golgi reformation after nocodazole treatment. To establish if the 
p.R399G mutation effects Golgi integrity, initially live cell imaging of the Golgi was 
conducted using a Cell Light BacMam 2.0 viral labelling system (labels Golgi 
resident enzyme N-acetylgalactosaminyltransferase 2). When visualised for the 
first time the Golgi appeared to have a fragmented phenotype in the heterozygous 
and homozygous mutants with less frequently observed interconnection between 
cisternae (Figure 4.4 panel a). This phenotype was further investigated during 
live cell imaging by taking Z-stack images of the entire Golgi structure indicating 
that the mutation was resulting in fragmentation in the X, Y and the Z plane 
(Figure 4.4 panel b). 
 
To understand the extent of this phenotype and for high –throughput 
quantification purposes, mutant fibroblasts were cultured and fixed to coverslips 
in a 24-well plate for immunofluorescent imaging. The cells were then labelled 
with the cis/medial marker giantin to visualise the Golgi. Low magnification 
images (20x, n = 6 from 2 experiments) were taken in order to visualise many 
cells in a large field of view in order to improve the accuracy of any Golgi 
phenotypes the mutation could be causing (Figure 4.4 panel c). An algorithm was 
then employed to accurately calculate the extent of the fragmentation in the 
mutants. High throughput quantification revealed that both heterozygous and 
homozygous fibroblasts had significantly fragmented Golgi with increasing 
zygosity compared to wild-type cells (P = 0.0061 and P <0.0001, respectively) 
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(Figure 4.4 panel d). This data shows that the p. R399G DYNC1H1 mutation 
compromises the structural integrity of the Golgi. 
 
Figure 4.4 
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Figure Cont. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
d 
Figure 4.4- (a) Live cell imaging of the Golgi complex in fibroblasts 
at 63x magnification using the BacMam 2.0 cell light Golgi reagent. 
(b) 3D rendering of the Golgi complex from live cell imaging in the Y 
and Z axis to visualise Golgi fragmentation in both dimensions. 
Imaged with a spinning disc Olympus-3I microscope using a 63x oil 
objective mounted with an EMCCD Evolve camera (c) High through-
put quantification images of the Golgi apparatus (20x) from wild-type 
and p.R399G mutant fibroblasts. (d) Quantification of Golgi 
fragmentation from images in (c).  
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7.1.3 DYNC1H1-Halotag transfection restores a compact Golgi morphology 
in p. R399G homozygous fibroblasts 
 
To elucidate if the R399G mutation in the dynein heavy chain was the direct 
cause of the Golgi fragmentation, homozygous fibroblasts were transfected with 
the wild-type DYNC1H1-halotag construct. Fibroblasts were electroporated and 
left to recover for 48 hours before being fixed and then immunostained with 
giantin in order to assess Golgi integrity.  
 
Analysis of the wild-type human fibroblasts that when transfected with the Halotag 
construct displayed an unusual Golgi phenotype in comparison to the mutant 
fibroblasts (Figure 4.5); Overexpression of the wild-type dynein heavy chain in 
wild-type fibroblasts resulted in severe fragmentation of the Golgi in all cases 
where electroporation of the Halotag construct had been successful. Golgi mini-
stacks were observed in the peri-nuclear region of the fibroblasts with multiple 
smaller Golgi objects distributed in the cellular periphery.  
 
In surprising contrast, the +/R399G and the R399G/R399G mutant fibroblasts 
displayed intact Golgi cisternae in comparison. The +/R399G fibroblasts indicated 
some partial fragmentation whereas the homozygous genotype displayed 
remarkable condensation and compaction of the Golgi cisternae (Figure 4.5). 
This clearly highlights that the R399G mutation in the dynein heavy chain seems 
to be directly responsible for the fragmentation of the Golgi cisternae in human 
fibroblasts. 
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Figure 4.5 
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 Figure 4.5- Wild-type and p.R399G mutant fibroblasts transfected with a wild-type 
DYNC1H1-Halotag construct. Giantin labelled Golgi is represented in the red channel; the 
Halotag plasmid is illustrated in the green channel and the cell nuclei are represented with 
DAPI in the blue channel. Wild-type cells efficiently transfected with the DYNC1H1 plasmid 
present with a severely fragmented Golgi phenotype. Heterozygous mutants appeared 
with a partially fragmented phenotype after transfection with the Halotag plasmid. Lastly 
the homozygous fibroblasts that had been transfected with the Halotag plasmid all 
illustrated Golgi’s with intact, compact morphologies. Image acquisition was conducted 
using a spinning disc Olympus-3I microscope using a 63x oil objective mounted with an 
EMCCD Evolve camera. 
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7.1.4 Investigating Golgi orientation and morphology in p.R399G mutants 
in migrating fibroblasts 
 
The Golgi apparatus has a pivotal role in the migration and arborisation of 
neurons, both of which are fundamental during development. In particular, these 
processes are reliant on the ability of the Golgi to re-orientate in a unipolar fashion 
towards the growth cone, site of arborisation, or leading edge (Yadav et al. 2009; 
Horton et al. 2005; Hanus & Ehlers 2008). 
 
To elucidate if the fragmentation of the Golgi apparatus in human fibroblasts with 
the R399G mutation resulted in disruption of Golgi polarisation a wound healing 
assay was performed. This process involved growing cells in a monolayer on a 
coverslip and then introducing a monolayer wound and leaving the cells for 6 
hours. After which, fibroblasts would begin to migrate and could be fixed and 
immuno-stained for F-actin (phalloidin) and the Golgi (giantin antibody). Cells 
imaged were chosen by the classical shape of a migrating fibroblast exhibiting a 
wide leading edge and a thinner trailing edge using -actin as a guide (Figure 4.6 
panel a).  
 
To determine distribution of the Golgi apparatus across all genotypes during 
migration the azimuthal average of all migrating cells were analysed across 15 
cells of each genotype (see materials and methods). The distribution of the 
fluorescence of the Golgi was then averaged and plotted as an average 
distribution of Golgi during migration over 360 degrees (Figure 4.6 panels b and 
c). In wild-type fibroblasts the distribution of the Golgi apparatus was as expected, 
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polarised towards the direction of migration with an elongated cisternae 
appearance outstretched towards the leading edge of the cell. 
 
Surprisingly, when the Golgi from the R399G mutant fibroblasts were analysed 
both the heterozygous and homozygous genotypes also had re-orientated in a 
polarised manner towards the leading edge. However, the R399G mutants 
displayed a condensation phenotype which increased in severity with increasing 
zygosity (Figure 4.6 panels a and b). There was a significant increase in Golgi 
condensation in the homozygous mutants compared to wild-type fibroblasts (P = 
0.016). Although an increase in Golgi condensation was observed in the 
heterozygous fibroblasts, no significant difference was found in comparison to 
wild-type cells. 
In summary these data show that the p.R399G mutation is correlated with the 
loss of the elongated, expanded cisternae observed in wild-type migrating 
fibroblasts. 
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Figure 4.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6- (a) p.R399G mutant fibroblasts during migration six hours 
post monolayer wound exhibit a condensed Golgi phenotype in 
comparison to wild-type cells. The direction of cell migration was 
determined using F-actin stain phalloidin (cell edges seen in blue). The 
Golgi was visualised using an antibody against giantin (shown in red). 
(b) Quantification of the distribution of the Golgi apparatus during 
migration post scratch (n=15) using the Azimuthal average plugin in 
ImageJ. (c) Representative schematic of the quantification of Golgi 
distribution during cell migration; the fluorescence from the Golgi was 
measured across 360 degrees (see methods). Image acquisition was 
conducted using a spinning disc Olympus-3I microscope using a 63x oil 
objective mounted with an EMCCD Evolve camera. 
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7.1.5 The p.R399G mutation results in an increased interaction between 
dynein and Golgin 160 recapitulated with nocodazole treatment in wild-type 
fibroblasts  
 
Recent evidence from Yadav et al. (2012) has shown that the DIC subunit of the 
dynein complex directly interacts with golgin160 complex. The knock-down of 
golgin 160 results in Golgi fragmentation and may lend to the hypothesis that 
perturbed interaction between the DIC and golgin 160 is affected in p.R399G 
mutant fibroblasts. This was investigated through co-immunoprecipitation of 
golgin 160 using an antibody against the DIC subunit.  
 
Golgin 160 associated with the DIC subunit of dynein was assessed with SDS-
PAGE (Figure 4.5 panel a). The ‘IP’ section of the panel indicates the amount of 
golgin160 pulled down with the corresponding amount of the DIC subunit of 
dynein directly below. As the blot indicates the first Golgin160 band observed 
above the 98 kDa ladder marker appears stronger with incidence of the p.R399G 
mutation. This band is likely the 155 kDa isoform of golgin 160.  
 
Similarly, in panel b the co-immunoprecipitation has been performed using 
antibody against golgin 160 to assess the amount of associated DIC (Figure 4.7 
panel b). As in the previous co-immunoprecipitation, it can be observed that the 
quantity of the DIC protein that has been co-immunoprecipitated with golgin 160 
increases with incidence of the R399G mutation. The input panels for both co-
immunoprecipitations reflect quantity of protein present in cell homogenates prior 
to the assays. In summary the p.R399G mutation causes an increased interaction 
between the DIC subunit of dynein and golgin 160. 
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To assess if this was a cause or consequence of the fragmentation, a similar co-
immunoprecipitation was performed using homogenate from cells treated with 
nocodazole for different periods of time. Nocodazole causes microtubule 
depolymerisation and consequently causes fragmentation of the Golgi. 
 
The DIC IP panel (Figure 4.7 panel c) shows DIC associated golgin 160 after the 
co-immunoprecipitation using an antibody against the DIC subunit of the dynein. 
In wild-type fibroblasts the quantity of DIC- associated golgin 160 increases after 
increased exposure to nocodazole up to 4 hours. The increased intensity of this 
golgin 160 isoform was not observed in p.R399G mutants after increasing 
exposure to nocodazole. Importantly, it must be noted that the band that appears 
above the proposed 155 kDa isoform is assumed to be the 167 kDa isoform and 
is extremely variable in appearance during SDS-PAGE analysis (see discussion).  
To conclude the increased association between golgin 160 and dynein appears 
as a consequence of Golgi fragmentation indicated by the increased association 
of golgin 160 and dynein in wild-type cells after nocodazole treatment.  
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Figure 4.7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7- (a) SDS-PAGE analysis of a co-immunoprecipitation of 
golgin 160 using an antibody against the DIC in wild-type and in 
p.R399G mutant fibroblasts. (b) Co-immunoprecipitation of the DIC 
using an antibody against golgin 160. (c) Input loading of total 
cellular homogenates harvested post fibroblast treatment of 
nocodazole for 0.5, 2, and 4 hours (top panel). The bottom panel 
illustrates a co-immunoprecipitation of golgin 160 using an anti-DIC 
antibody from fibroblasts treated with nocodazole (as above).  
D 
D 
D 
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7.1.6 The p.R399G mutation in human fibroblasts results in a depletion of 
acetylated tubulin at Lysine 40 
 
The increased association between golgin 160 and DIC with concurrent Golgi 
fragmentation is paradoxical as Yadav et al showed that siRNA against golgin 
160 causes Golgi fragmentation (Yadav et al. 2012). This leaves open the 
possibility that altered microtubule stability or associated modifications may 
underlie the fragmentation. As stated in the introduction, microtubule 
modifications such as acetylation are important for both the association of dynein 
with microtubules as well as Golgi cohesion. 
 
To investigate if the Golgi fragmentation in the p.R399G fibroblasts was due to 
depleted acetylated tubulin, western blot analysis was used to compare total 
acetylated tubulin between wild-type and homozygous mutants (Figure 4.8 panel 
a). A clear depletion of acetylated tubulin was detected in the homozygous 
mutants (*P<0.05) compared to wild-type fibroblasts (Figure 4.8 panel b). 
Simultaneously, fellow lab member Fabio Simoes analysed the levels of 
detyrosinated tubulin (detyrosinated microtubules are proposed to have 
increased stability) elucidating that no statistical difference was detected between 
wild-type and mutant fibroblasts (Figure 4.8).  
 
To further confirm and establish this phenotype both wild-type and p.R339G 
heterozygous and homozygous fibroblasts were labelled with anti-acetylated 
tubulin antibody for immunofluorescent imaging. The majority of acetylated 
tubulin is found in the peri-nuclear region of cells and high resolution microscopy 
was employed to accurately resolve the microtubules in a 40 m radius around 
181 
 
the nucleus (Figure 4.8 c). Quantification of the mean intensity of acetylated 
tubulin was conducted through Matlab by Constantino Reyes Aldosoro and 
indicated that both heterozygous and homozygous fibroblasts elicited depleted 
acetylated tubulin in this region compared with wild-type cells (P = 0.0141 and P 
= 0.0001 respectively). In summary the DHC p.R399G mutation causes a specific 
reduction of lysine 40 acetylation of tubulin in human fibroblasts.  
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Figure 4.8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a 
Acetylated tubulin 
Cofilin 
Detyrosinated tubulin 
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Figure 4.8 Cont. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8- (a) SDS-PAGE western blot of acetylated tubulin and 
detyrosinated tubulin in wild-type and p.R399G homozygous 
fibroblasts. Both cofilin and -actin are presented as loading 
controls respective to their adjacent bands. (b) Quantification of 
acetylated tubulin and detyrosinated tubulin in wild-type and 
homozygous fibroblasts. (c) Immunofluorescent high resolution 63x 
images of peri-nuclear acetylated tubulin (shown in green) in fixed 
wild-type and p.R399G mutant fibroblasts (asterisks highlight 
zoomed in regions). (d) Quantification of peri-nuclear (40m) 
acetylated tubulin in wild-type and mutant fibroblasts. Image 
acquisition was conducted using a Leica TSC SP8 confocal 
microscope with a 63x objective.  
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7.1.7 Elucidating the rate of -tubulin deacetylation at Lysine 40 in p.R399G 
homozygous fibroblasts 
 
HDAC6 is the primary deacetylase enzyme in cells that can remove the acetyl 
group present on tubulin at the Lysine 40 residue. As a depletion of acetylated 
tubulin has been detected in p.R399G mutants it is important to measure the rate 
of deacetylation. This was achieved by treating cells with tubacin, a potent 
HDAC6 inhibitor in order to increase the amount of acetylated tubulin. The drug 
was then washed away from the cells in order to measure the rate of 
deacetylation. The subsequent homogenates obtained from these cells were then 
subjected to SDS-PAGE analysis (Figure 4.9 panel a).  
 
The western blot indicates that at the 2-hour time point in homozygous mutant 
fibroblasts after tubacin wash-out there was a substantial decrease in acetylated 
tubulin in comparison to the wild-type cells. This is not due to changes in total 
tubulin as no differences in the control blot could be detected and levels of 
acetylated tubulin are comparable at the 0-time point for both wild-type and 
mutant fibroblasts (Figure 4.9 panel a). The quantification of three separate 
experiments did not yield a significant difference between the genotypes although 
a clear trend of increased deacetylation can be seen in the homozygous mutant 
fibroblasts (Figure 4.9 panel b).   
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Figure 4.9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9- (a) SDS-PAGE analysis of total cell homogenates 
harvested from wild-type and mutant p.R399G fibroblasts after 
post 20 M tubacin washout. The response to the tubacin 
washout was monitored using an antibody against acetylated 
tubulin at 0,0.5, 1,2 and 3-hour time points. (b) Quantification of 
acetylated tubulin normalised to either actin or cofilin, total -
tubulin was also probed for to demonstrate no change in protein 
levels. 
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7.1.8 Dynein depletion on the Golgi apparatus in p.R399G fibroblasts is not 
rescued by increasing acetylated tubulin 
 
 
Dynein preferentially interacts with microtubules that are acetylated at Lysine 40 
and furthermore, the population of microtubules that are associated with the Golgi 
are rich with post-translational modifications. Therefore, it could be hypothesised 
that the recruitment of dynein to Golgi membranes is possibly promoted by 
microtubule acetylation. 
 
To test this hypothesis p.R399G fibroblasts were cultured on glass coverslips and 
labelled with antibodies against the DIC as well as giantin to visualise the Golgi. 
High resolution images of the Golgi in wild-type and p. R399G homozygous 
mutants were taken to assess the extent of DIC associated with the Golgi 
membranes. In this analysis, the total intensity of the DIC signal present on the 
Golgi was divided by the area of the Golgi apparatus in both genotypes (Figure 
5.0 panel a). Visually, a striking reduction of DIC signal associated with the Golgi 
apparatus was apparent in the p.R399G homozygous fibroblasts compared to the 
wild-type cells. Quantification of the reduction indicated a significant difference 
between wild-type (N = 21) and homozygous (N = 20) fibroblasts (P <0.05 see 
Figure 5.0 panel b) from three experiments. To establish if this depletion of dynein 
from the Golgi membranes could be improved by increasing acetylated tubulin 
via inhibition of HDAC6, fibroblasts were treated with tubacin (Figure 5.0 panel 
a).  Upon visualisation of dynein in these treated cells no obvious improvement 
of dynein associated with the Golgi was detected. The reduction of dynein at the 
Golgi in p.R399G human fibroblasts in comparison to wild-type cells was 
statistically maintained (P = 0.0052). 
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In summary, the p.R399G mutation results in a striking depletion of dynein 
associated with the Golgi apparatus. However, this depletion seems independent 
of the reduced acetylation at Lysine 40 of -tubulin.  
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Figure 5.0 
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Figure 5.0 Cont. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.0- (a) Immunofluorescent images taken at 63x magnification (1.2 
factor zoom) of wild-type and homozygous p.R399G fixed fibroblasts 
stained with antibodies against the DIC (green) and giantin Golgi marker 
(red). Wild- type fibroblasts show visual association between the DIC and 
giantin signals whereas the homozygous mutants do not. Tubacin treated 
homozygous mutants do not show recovery of DIC –Golgi localisation. (b) 
Quantification of the DIC total intensity associated with the Golgi divided by 
Golgi area in wild-type and homozygous mutants (see materials and 
methods). Image acquisition was conducted using a Leica TSC SP8 
confocal microscope with a 63x objective.  
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7.1.9 Increasing acetylated tubulin in p.R399G homozygous mutants 
rescues Golgi fragmentation  
 
 
Simultaneously whilst investigating the association between dynein and the Golgi 
apparatus (see above) the extent of Golgi fragmentation was also examined. This 
was to determine if increasing acetylation through tubacin had any impact on 
Golgi fragmentation in the p.R399G mutant fibroblasts and three independent 
experiments were subsequently conducted (Wild type N=30, p.R399G 
homozygous N=33, wild type tubacin N=33, p.R399G homozygous tubacin 
N=32). 
 
As expected in DMSO treated cells a clear increase in Golgi fragmentation in the 
p.R399G mutants remained both visually and quantitatively compared to wild-
type fibroblasts (***P<0.001, Figure 5.1 panels a and b). When treated with 
tubacin, wild-type human fibroblasts did not show any significant change in mean 
Golgi fragments. In contrast when p.R399G homozygous fibroblasts were treated 
with tubacin the fragmentation of the Golgi apparatus significantly decreased to 
wild-type levels (**** P<0.0001). 
 
These results indicate that the HDAC6 inhibitor tubacin can rescue Golgi 
fragmentation inflicted by the p.R399G mutation although the lack of dynein 
present on the Golgi apparatus cannot be rescued through this mechanism.  
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Figure 5.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1- (a) Immunofluorescent images of fixed wild-type and 
p.R399G mutant fibroblasts stained with giantin (Golgi) treated with either 
DMSO or 20 M tubacin. (b) Quantification of Golgi fragments from wild-
type or homozygous p.R399G fibroblasts after treatment with tubacin or 
DMSO (control). Image acquisition was conducted using a Leica TSC 
SP8 confocal microscope with a 63x objective.  
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7.1.10 Increasing acetylated tubulin at Lysine 40 results in a down-
regulation of golgin 160 
 
As golgin 160 is part of a tether that couples microtubules to the Golgi membrane 
through dynein it was hypothesised that changes in acetylation may affect golgin 
160 expression. Yadav et al. had previously shown that the siRNA knock-down 
of golgin 160 had no impact on microtubule acetylation however, the response of 
golgin 160 to changes in -tubulin have not been reported.  
 
Both wild-type and p.R399G fibroblasts were cultured in a 6-well plate and treated 
with tubacin before harvesting the homogenates for SDS-PAGE analysis. Both 
wild-type and mutant fibroblasts illustrated a dramatic increase in acetylated 
tubulin as expected (Figure 5.2 panel a). In contrast, the amount of golgin 160 
detected in both genotypes fell dramatically after tubacin treatment. 
Quantification of wild-type fibroblasts from separate experiments experiments (N 
= 3) indicated a significant decrease (*P<0.05) of golgin 160 after exposure to 
tuabcin (Figure 5.2 panel b). This result indicates that the level of golgin 160 is 
responsive and downstream to changes in acetylated tubulin at Lysine 40.   
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Figure 5.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2- (a) SDS-PAGE analysis of total cell homogenates 
from wild-type and homozygous p.R399G mutants using 
antibodies against acetylated tubulin and golgin 160 with and 
without tubacin treatment of cells. The loading control 
employed in this blot was -actin. (b) Quantification of golgin 
160 in wild-type fibroblasts after treatment with 20 M tubacin 
or DMSO (control).  
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7.1.11 The maturation of endosomes is impaired in p. R399G mutant 
fibroblasts  
 
Dynein is important for the retrograde motility of endosomes within the endocytic 
pathway. Dynein contributes to the short-range mobilisation of endosomes but 
importantly, is responsible for driving the long-range transport of endosomes in 
which dynactin is highly essential and integral for neuronal function (Flores-
Rodriguez et al. 2011). Furthermore, mutations in the tail or motor domains of the 
DHC have been found to perturb early endosome trafficking (Xiang et al. 2015; 
Garrett et al. 2014). It is critical therefore to establish if the p.R399G mutation 
could be causing endosomal pathology in human fibroblasts as it provides insight 
into dynein motility in these mutants. 
 
Initially, as the number of endosomes produced during endocytosis is likely 
affected by cell size, the area of wild-type and heterozygous and homozygous 
mutants were measured (N = 15, respectively). Statistical analysis indicated no 
difference in cell size between the different genotypes (Figure 5.3 panel b). 
 
Next, to determine if the p.R399G mutation was detrimental to endocytosis; 
fibroblasts were exposed to EGF-Alexa Fluor ® 555 after serum starvation and 
fixed at 0, 10, 30, and 60 minute time points. The number of endosomes from 
each cell (N >10 for each genotype at every time point) were then counted using 
the particle analysis tool on ImageJ (see Figure 5.3 panel a, c,).  
 
Statistical analysis indicated that there were no differences in number of 
endosomes between genotypes at any time point (Figure 5.3 panel c). Despite 
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this a trend can be observed of increased number of endosomes in p.R399G 
homozygous cells at the 0 and 10 minute time points compared to wild-type and 
heterozygous fibroblasts.  
 
As endosomes mature through the early to late stages of the endocytic pathway 
they become larger in size. To elucidate if the p.R399G mutation was indeed 
effecting this process the area of all detected endosomes were quantified (Figure 
5.3 panel d). Statistical analysis indicated significant differences between all three 
genotypes at both 0 and 10-minute time points (***P<0.001). Noticeably 
endosomes from the heterozygous fibroblasts were much larger than both the 
wild-type and homozygous cells (Figure 5.3 panels a and d). No differences in 
endosome size were noted at the 30-minute time point. However, at the 60-
minute time point, endosome sizes in the heterozygous and homozygous 
fibroblasts were statistically smaller than wild-type cells (***P<0.001 and 
***P<0.001 respectively). 
 
In summary, these results indicate that the p.R399G mutation in the DHC does 
not affect the ability of cells to endocytose the EGF receptor. Despite this the 
mutation alters the size of endosomes observed suggesting that maturation is 
impaired. The increase in endosome size in the heterozygous fibroblasts at 
earlier time points could suggest an affect caused by mixed dynein populations 
of wild-type and mutant DYNC1H1.  
 
 
 
 
 
196 
 
Figure 5.3 
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Figure 5.3 Cont. 
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Figure 5.3- (a) Images of wild-type and p.R399G mutant fibroblasts 
indicating endosomes (black punctate signals) detected by thresholding in 
ImageJ with cell-edge traced and the nuclei (blue) super-imposed at time 
point 0 after addition of EGF-Alexa Fluor ® 555. (b) Quantification of cell 
area in wild-type and mutant fibroblasts showing no significant differences 
between genotypes. (c) Quantification of mean number of particles 
(endosomes) per cell in each genotype after serum starvation and addition 
of EGF-Alexa Fluor ® 555 at 0, 10, 30, and 60-minute time points (no 
significant differences were found). (d) Quantification of endosome sizes 
for each genotype measured at each time point to measure endosome 
maturation significant differences are indicated by *** (P<0.0001). Image 
acquisition was conducted using a spinning disc Olympus-3I microscope 
using a 63x oil objective mounted with an EMCCD Evolve camera. 
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7.12 Chapter 4 summary  
 
The data from this chapter has shown that the p.R399G mutation does not affect 
the subunit assembly of the dynein complex suggesting that disruption of the 
complex is not the underlying pathogenic mechanism caused by this mutation. 
Additionally, this chapter has indicated for the first time that dynein mutations in 
human cells can cause inherent fragmentation of the Golgi apparatus which also 
effects Golgi morphology during migration. Additionally, this fragmentation is 
coupled with an increased interaction between golgin 160 and dynein and a 
decrease in acetylated -tubulin at Lysine 40. This indicates for the first time that 
mutations in DYNC1H1 can influence the acetylation of microtubules at Lysine 
40. Importantly, the Golgi fragmentation can be rescued with HDAC6 inhibition, 
but a lack of association between dynein and the Golgi was not rescued 
suggesting a segregation of mechanisms. Lastly, endocytosis was not affected 
by the p.R399G mutation although a significant delay in endosome enlargement 
was observed indicating the mutation is affecting maturation of endosomes.  
 
7.13 Chapter 4 Discussion  
 
7.13.1The p.R399G mutation does not affect the dynein complex 
 
Previous evidence from the Hafezparast lab has shown that mutations in the DHC 
subunit of dynein can impair dynein complex formation. Specifically, the Loa 
mutation was found to cause an increase in binding in the DIC and the DLIC 
subunits of dynein. To determine if the p.R399G mutation influences subunit 
binding of the dynein complex a sucrose density gradient was performed with 
subsequent SDS-PAGE analysis of wild-type and homozygous fibroblasts. It is 
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worthy to note that much optimisation was needed to accurately perform this type 
of analysis due to the sensitivity of the technique. Analysis of the Western blots 
indicated a possible dissociation of DYNC1H1 from the complex as indicated by 
a signal in fraction 6. However, duplication of this experiment identified this signal 
also in wild-type fibroblasts. This led to the conclusion that the difference from the 
first experiment was likely due to a Western blot discrepancy with the DYNC1H1 
protein due to its large size (>500kDa) and not a disruption caused by the 
p.R399G mutation.  
 
Interestingly, a signal from the DYNC1I2 was repeatedly observed in both 
genotypes in fraction 3 indicating a possible dissociation away from the complex. 
This was coupled with matching signals in fraction 3 from DYNC1LI1/2 in both 
genotypes. The DIC and DLIC complex with the DHC in the dynein complex but 
have not been found to be functionally active outside of the dynein complex thus 
far.  However, the dynein light chains such as LC8 has multiple binding partners 
that are dynein independent (Asthana et al. 2012). Therefore, the DIC and DLIC 
observed in fraction 3 could represent partially dissociated dynein through the 
homogenisation process.  
 
In order to confirm that the p.R399G mutation was not disrupting any subunit 
interaction, an IP was performed between DIC and DYNC1H1 as the mutation 
lies closest to the DIC binding region. Investigation of the subsequent blot, 
however, indicated no differences in the binding affinity between DYNC1H1 and 
the DIC and furthermore, indicated no DYNC1H1 homodimerisation defect.  
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7.13.2 The p.R399G mutation causes Golgi fragmentation and perturbed 
morphology during migration in human fibroblasts 
 
Dynein has a key role in Golgi homeostasis and previous data from the 
Hafezparast lab has shown that Arl and Loa mutations in the DHC can inflict 
impaired Golgi recovery after nocodazole treatment. To study the structure of the 
Golgi, both live cell imaging and fixed cell imaging techniques were employed. 
Results from these investigations showed that the p.R399G mutation caused 
fragmentation of the Golgi apparatus. This is further confirmed by the 
electroporation of the mutant fibroblasts with a wild-type dynein construct which 
rescued the fragmentation of the Golgi apparatus.  
 
It has been shown that DHC human mutations can result in impaired Golgi 
recovery after nocodazole treatment (Fiorillo et al. 2014). But my data for the first 
time show that inherent fragmentation is present in patient cell harbouring the p. 
R399G mutation. 
 
The reasons for why this fragmentation is observed is less clear however, it is 
likely due to an interruption of a dynein specific interaction or perhaps an impact 
upon microtubule dynamics or stability which prompted further investigation. 
 
To further explore this phenotype, the Golgi of migrating fibroblasts harbouring 
the p.R399G mutation were studied and compared to wild-type migrating cells. 
The ability of cells to migrate and neurons to undertake arborisation is partly 
dependent on the Golgi, thus, it was hypothesised that this dysregulation could 
underlie SMA-LED. Dynein is crucial for Golgi re-orientation, these results from 
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this experiment however, did not indicate an impairment of the Golgi to orientate 
towards the direction of migration in p.R399G mutants (Yadav et al. 2012). 
Rather, a condensation phenotype is observed in the mutants in comparison to 
the wild-type fibroblasts.  
 
This could perhaps indicate that the mechanism of Golgi re-orientation is not 
affected by this mutation, but instead segregated sections of Golgi membrane 
collapse into a peri-nuclear region. My data could suggest another function of 
dynein that maintains the Golgi in an expanded morphology perhaps to ensure 
adequate secretion and delivery of proteins to their target sites.  
 
7.13.3 The p.R399G mutation results in an increased interaction between 
golgin 160 and dynein. 
 
These morphological results prompted investigation into the interaction between 
dynein and a protein known as golgin 160 which represents the only known 
binding partner of dynein at the Golgi membrane. Golgin 160 resides in the 
membrane of the Golgi apparatus and consequently, dynein acts as the tether 
between microtubules and the Golgi (Yadav et al. 2012). Immunoprecipitation of 
golgin 160 with its binding partner DIC, however, indicated that the p.R399G 
mutation resulted in an increased interaction with golgin 160. This was a 
surprising result as Yadav et al. demonstrated that knock-down of golgin 160 
causes extensive Golgi fragmentation (Yadav et al. 2012). Additionally, the 
authors had previously shown that siRNA against golgin 160 resulted in an 
inability for the Golgi to orientate during migration (Yadav et al. 2009). 
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As results show that re-orientation is not impaired by the mutation and that an 
increase in golgin 160 binding is observed in mutants, this strongly suggests that 
the interaction between dynein and golgin160 is unaffected. Rather, this indicates 
a compensatory response to ameliorate the Golgi fragmentation. This is 
supported by the fact that when the Golgi was artificially fragmented using 
nocodazole in wild-type cells, the quantity of golgin 160 pulled down with dynein 
increased. There was little or no response to this artificial fragmentation in 
mutants suggesting that this compensatory mechanism may already be active. 
Despite this, increased affinity between golgin 160 and dynein due to the 
p.R399G mutation cannot be completely ruled out. 
 
7.13.4 The p.R399G mutation causes depletion of acetylation at Lys40  
 
The data indicating that the interaction between dynein and golgin 160 was 
increased prompted the hypothesis that another faulty mechanism may be the 
cause of the observed Golgi fragmentation. Microtubules have long known to be 
important in the structural maintenance of the Golgi apparatus. Additionally, these 
Golgi associated microtubules are rich in post translational modifications (PTMs) 
such as acetylation at Lys40 are thought to contribute to Golgi coherence (Rios 
2014; Thyberg & Moskalewski 1993).  
 
Initially, p.R399G homozygous mutant fibroblasts were analysed by SDS-PAGE 
in order to quantify the amount of acetylated tubulin at Lys40 (acetylated tubulin 
hereafter) in comparison to wild-type cells. This indicated a significant reduction 
of acetylated tubulin in homozygous mutants. This difference was not observed 
when detyrosinated tubulin (another Golgi PTM) was analysed suggesting that 
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the p.R399G mutation was specifically affecting acetylated tubulin. This was 
further confirmed with high resolution immunofluorescent images of peri-nuclear 
acetylated tubulin indicating a significant reduction in the p.R399G mutants.  
 
The question as to why a mutation in dynein is affecting PTMs of microtubules is 
not clear. Currently there is conflicting evidence as to the stabilising implications 
of PTMs upon microtubules. The acetylation of microtubules occurs when they 
are stable, the p.R399G mutation could be effecting the stability of microtubules 
as dynein travels along them. However, reduced stability would have also led to 
a decrease in detyrosinated tubulin which was not observed. 
 
This therefore indicates a specific mechanism that dynein influences for the 
acetylation of microtubules, this might not be surprising as dynein preferentially 
interacts with acetylated microtubules. A potential mechanism could be through 
a protein known as GEF-H1, a nucleotide exchange factor associated with 
microtubules. It is known to increase microtubule stability and acetylation but 
importantly interacts with dynein through Tctex-1 (Yoshimura & Miki 2011; Meiri 
et al. 2014). This is currently under investigation by the Hafezparast lab as it could 
be the link between dynein and acetylation of microtubules. Interestingly, further 
data from this lab has shown that fibroblasts from the Loa mouse model also 
show depletion of acetylated tubulin.  
 
 
 
205 
 
7.13.5 Evaluating the rate of -tubulin deacetylation in p.R399G 
homozygous fibroblasts 
 
The lack of acetylated tubulin at Lysine 40 in p.R399G mutants prompted the 
hypothesis that the deacetylation rate in p.R399G mutant fibroblasts may be 
different to that of wild-type cells. To test this a HDAC6 inhibitor tubacin was 
employed to maximise the acetylation of the microtubules, tubacin was then 
washed out and the amount of acetylation at Lysine 40 was monitored over a 3-
hour period. 
 
The quantification of the rate of deacetylation in homozygous mutants indicates 
a trend of increased deacetylation in comparison to wild-type cells. Although this 
was not measured to be a significant result, comparing total -tubulin between 
the two genotypes clearly indicates that it is not simply a general reduction in total 
-tubulin. There are multiple reasons for why an increased deacetylation rate is 
observed in the homozygous mutants.  
 
Firstly, as aforementioned, this could be related to microtubule stability but this is 
unlikely. Secondly, the active availability of HDAC6 in p.R399G homozygous 
mutants could be impaired. HDAC6 interacts with dynein as an adaptor for cargo 
that has been tagged with ubiquitin for clearance of misfolded or aggregating 
proteins (Kawaguchi et al. 2003). If the p.R399G mutation somehow causes 
increased aberrant binding of HDAC6 to dynein it may promote deacetylation of 
microtubules due to more available HDAC6. Despite this the impact of HDAC6 
and dynein interaction upon the rate of deacetylation is currently unknown. 
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Lastly, an increase in actual HDAC6 activity could be possible, Rho-associated 
coiled-coil kinase (ROCK) activity increases the activity of HDAC6 through 
TPPP1 phosphorylation (Schofield et al. 2012). ROCK is a target of Rho which 
can be activated by GEF-H1 release from microtubules (an aforementioned 
binding partner of dynein) (Takesono et al. 2010). In summary, this means that a 
binding deficiency between dynein and GEF-H1 caused by the p.R399G mutation 
could underlie the observed acetylated tubulin phenotype. The intricacies of this 
pathway would have to be carefully considered in future research.   
 
7.13.6 Homozygous p.R399G mutant fibroblasts show dynein depletion on 
the Golgi apparatus which cannot be rescued through increasing 
acetylated tubulin 
 
It is possible that the acetylation of microtubules could be important in recruiting 
dynein to the Golgi. This is due to the fact that dynein preferentially binds 
acetylated microtubules and the Golgi has a large proportion of acetylated 
microtubules associated with it. To analyse this the DIC co-localised with the 
Golgi was evaluated in homozygous p.R399G mutants and wild-type fibroblasts. 
A reduction in associated DIC with the Golgi was detected in the mutants 
compared to the wild-type cells however, this was not rescued with tubacin 
treatment.  
 
These results show that a reduced acetylated tubulin phenotype and a reduced 
DIC-Golgi association phenotype exist due to the p.R399G mutation, but they are 
likely unrelated. Although a link between Golgi-dynein localisation and the 
acetylation status of microtubules cannot be ruled out. The increase in acetylation 
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through HDAC6 inhibition did not promote the association of dynein with the 
Golgi. This suggests that the recruitment of dynein to Golgi membranes is 
impaired. Interestingly, it has been shown that cells lacking Golgin 160 cause 
dynein associated with the Golgi to be depleted more than 90% (Yadav et al. 
2012). In the case of the p.R399G mutants there is an increase in Golgin 160 and 
dynein interaction but less dynein associated with the Golgi. This could perhaps 
suggest that dynein could be interacting with Golgin 160 away from Golgi 
membranes but remains to be determined. Poor immunofluorescent staining with 
the Golgin 160 antibody prevented any analysis of Golgin 160 localisation in 
p.R399G mutant fibroblasts.  
 
7.13.7 Increasing microtubule acetylation through HDAC6 inhibition in 
p.R399G homozygous mutants rescues Golgi fragmentation  
 
Even though increasing microtubule acetylation did not influence the association 
between dynein and the Golgi, it was important to determine if the Golgi 
fragmentation phenotype could be rescued. Wild-type and homozygous mutants 
were treated with tubacin to determine if HDAC6 inhibition could rescue Golgi 
fragmentation. The results showed that the fragmentation in the p.R399G 
homozygous mutants significantly reduced when treated with tubacin. This 
indicates that increasing acetylation at Lysine 40 of microtubules in mutants may 
rescue the phenotype through a mechanism that maybe unrelated to lack of 
dynein on the Golgi membranes that may actually cause the fragmentation. 
Conversely the tubacin treatment maybe bypassing an aberrant mechanism of 
acetylation related to the localisation of dynein to the Golgi. This data further 
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indicates that the lack of co-localisation between dynein and the Golgi may not 
be solely imperative to Golgi cohesion.   
 
 
Interestingly, recent evidence gathered in the Hafezparast lab has shown that 
another human dynein mutation p.D338N results in depletion of acetylated 
tubulin. Despite this there is no lack of co-localisation of dynein with the Golgi but 
no inherent Golgi fragmentation suggesting that both deficiencies are required for 
Golgi fragmentation. This is summarised in a diagram depicted in Figure 5.4. 
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 Figure 5.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4- The above diagram depicts the impact of human dynein mutations upon the 
acetylation status of microtubules as well the co-localisation of dynein to the Golgi. The 
summation of the MT acetylation and dynein recruitment to the Golgi dictate the structural 
integrity of the Golgi in human fibroblasts. 
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Increasing acetylation at Lysine 40 results in a down-regulation of golgin 
160 
 
The concomitant reduction in acetylated microtubules coupled with an increased 
interaction between dynein and golgin 160 in p.R399G mutant fibroblasts 
prompted the idea that these phenotypes may be interrelated. To test this 
hypothesis both wild-type and homozygous mutant p.R399G fibroblasts were 
treated with HDAC6 inhibitor tubacin, before analysing golgin 160 through SDS-
PAGE analysis (Figure 5.0).  
 
Data obtained from this experiment indicated that the golgin 160 seems to be 
down regulated when the acetylation at Lysine 40 is increased in both wild-type 
and mutant cells.  Previous (unpublished) data from Yadav et al. has shown that 
golgin 160 knockdown did not affect acetylated tubulin (Yadav et al. 2009). 
Together, this suggests that golgin 160 is regulated down-stream of acetylated 
tubulin. Furthermore, it is possible that the decrease in acetylated tubulin in the 
p.R399G mutants is causative of the increased interaction between golgin 160 
and dynein previously shown. This proposes a potential regulation of golgin 160 
through PTMs of microtubules although time restrictions have prevented further 
investigation.  
 
The maturation of endosomes is impaired in p.R399G mutant fibroblasts  
 
Dynein is integral for the retrograde motility of endosomes during the endocytic 
pathway. Other mutations in the DHC such as in the Loa mouse model have 
indicated deficiencies in endocytic trafficking (Garrett et al. 2014).  Wild-type and 
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p.R399G mutant fibroblasts were serum-starved before exposure to EGF-Alexa 
Fluor ® 555 and fixed at several time points in order to monitor endocytosis 
(Figure 5.1).  
 
The number of endosomes did not significantly differ between genotypes at any 
of the time points (0, 10, 30 and 60 minutes). This indicated that the process of 
endocytosis was not affected by the p.R399G mutation.  This was a distinct 
possibility as dynein has been implicated in the tubular internalisation of vesicles 
(Day et al. 2015). Upon analysing the size of the endosomes in order to measure 
endosome maturation the p.R399G mutation caused a delay in endosome 
maturation in the homozygous fibroblasts (particularly at the 10 minute time 
point). Previous data from Garrett et al. showed that the Loa homozygous 
fibroblasts also show a reduction in size of EGF containing vesicles at the ten-
minute time point (Garrett et al. 2014).  
 
This indicates a dynein dependent step of endosome maturation that is affected 
by mutations in the DHC. Interestingly, the endosomes observed in the 
heterozygous mutants at the 0 and 10-minute time points seem to be much larger 
than the other genotypes. These larger endosomes could actually represent 
small clusters of endosomes in which the clusters are periodically brought 
together for maturation but the DHC mutation causes disruption of the endosomal 
fusion. This may be due to mixed populations of dynein imparting counteractive 
effects on endosomal maturation in the heterozygous fibroblasts but this requires 
further investigation.  
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Chapter 5- Analysing the impact of the Arl mutation on 
cell migration and brain morphology 
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8.0 Introduction 
 
The Arl mouse model was generated through ENU mutagenesis and exhibits an 
autosomal dominant p.Trp1206Arg mutation in the tail domain of Dync1h1. This 
model effectively recapitulates the slow motor neuron degenerative progression 
of SMA-LED, therefore representing a valuable model for understanding aspects 
of disease progression in SMA-LED.  
 
A common condition compounding SMA-LED in patients is MCD in which the 
aberrant organisation of neurons in the cortex can result in cognitive deficits.  Not 
all patients with DYNC1H1 mutations present with MCD and it is currently 
unknown why this disparity exists. Previous data from the Hafezparast lab at 
Sussex University have shown that the Loa mutation (another tail domain 
mutation) causes a deficit in fibroblast migration. Importantly, the Loa mutation 
has been found to impair cortical lamination in mice although it is unclear if this 
has any relationship to aberrant cell migration (Ori-McKenney & Vallee 2011). 
 
Currently, there is no information outlining the effects of the Arl mutation on both 
cell migration and its impact on cortical organisation of the brain. As both the Loa 
and Arl mutations have been found to impair Golgi recovery after fragmentation 
with nocodazole, it was hypothesized that they share common insufficiencies of 
cellular function. This could potentially also translate to shared abnormalities in 
the organisation of the cortex. 
 
To investigate this, I have employed a fibroblast migration assay to investigate 
the impact of the Arl mutation on the speed of cell migration. Secondly I have 
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used perfusion and cryosectioning techniques in order to study gross anatomical 
differences in the brain between wild-type and Arl/+ adult mice. Lastly, the impact 
of the Arl mutation on cortical organisation was studied in p4 littermates. 
 
8.1 Results 
 
8.1.1 The Arl/+ mutation results in delayed cell migration in mouse 
embryonic fibroblasts. 
 
Previous data from the Hafezparast lab has implicated mutations in Dync1h1 in 
causing a defect in cell migration. Mouse embryonic fibroblasts cultured from the 
homozygous Loa mouse model indicated significant impairment in fibroblast 
migration. The p.Trp1206Arg Arl mutation is over 500 amino acids further towards 
the C-terminal in comparison to the Loa mutation. Although this is the case, both 
mutations still reside in the tail domain of the DHC and raises the hypothesis that 
mutations in the tail domain impair cell migration. 
 
To investigate if the Arl mutation can result in perturbed cell migration, both wild- 
type and heterozygous fibroblasts were cultured in 6 well plates at the same 
density of 3 x 105. After 24 hours, monolayers of fibroblasts were observed at the 
same density for both genotypes. Cells were treated with 10 g of mitomycin C 
to prevent cell division before introducing a monolayer wound across all wells 
using a 10 l pipette tip. Pictures were taken at the time of introducing the wound 
and 12 hours later in order to derive comparisons (see Figure 5.5).  Visually after 
12 hours, Arl/+ fibroblasts had not closed the wound as quickly in comparison to 
the wild-type fibroblasts used as a control (Figure 5.5). In order to quantify this 
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difference, images were taken from three wound healing experiments for wild-
type and Arl/+ fibroblasts furthermore, for each wound three images were taken 
in three separate positions (n = 9). The rate of gap closure was quantified in each 
case and a significant (P<0.05) delay in fibroblast migration was calculated in the 
case of the Arl/+ fibroblasts in comparison to the wild-type cells (Figure 5.5).  
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Figure 5.5 
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8.1.2 The organisation of cortical layers is impaired in Arl/+ adult mice  
 
In accordance with the impaired Loa/Loa fibroblast migration data obtained by Dr 
Muruj Barri others have reported neuronal migration defects in the same 
genotype. Vallee et al. shows neuronal migration and cortical lamination deficits 
in the homozygous Loa mouse in comparison to wild-type mice (Ori-McKenney 
& Vallee 2011).  
 
Similarly, as both the Loa and Arl mutations seem to result in a delay in fibroblast 
migration after a wound healing assay it was hypothesised that gross structural 
brain aberrations may be detected in Arl/+ mice. In order to test this hypothesis 
two adult Arl/+ (169 and 251 days old) and wild-type mice (115 and 122 days old) 
were perfused with 1% PFA to structurally preserve the brain. Subsequently, the 
Figure 5.5- (a) Images (20x) of fibroblasts monolayer wound for 
both Arl/+ and wild-type cells indicating 0 and 12 hours post 
wound imaged on Zeiss Axiovert 25 (scale bar 100 m). (b) 
Quantification of the rate of fibroblast migration for both wild- 
type and Arl/+ fibroblasts.  
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brains were cryopreserved, sectioned and then stained with cresyl violet in order 
to visualise the cell bodies of neurons in the coronal slices (see materials and 
methods).  
 
Cortical slices were imaged at 4x and a murine brain atlas (Allen brain atlas 
available from: http://developingmouse.brain-map.org) was used in order to 
correctly match anatomical positions of every slice in both genotypes for definitive 
accuracy.   
 
Cortical layers were determined through cross referencing images from Vallee et 
al (Ori-McKenney & Vallee 2011). Analysis of the coronal section of wild-type 
mice indicated a clear banding pattern of neurons in sections from both anterior 
and posterior regions of the brain (Figure 5.6). In comparison the Arl/+ mice 
exhibited a disorganised appearance of neurons in both layers II/III (white arrow) 
and prominently in layer IV (orange arrow). This abnormal neuronal phenotype 
was observed in both anterior and posterior regions of the brain (see Figure 5.6). 
In summary, this indicates that the Arl mutation perturbs neuronal organisation in 
the murine brain.  
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Figure 5.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6-  Images (4x) of coronal brain sections in anterior 
and posterior positions taken from both wild-type and Arl/+ 
mice stained with cresyl violet. Cortical layers are indicated 
on the left hand side of the figure as well as the corpus 
callosum (cc).  White and orange arrows indicate observed 
structural differences. Cartoon brain images by Richard 
Osgood (scale bar represents 500 m). Image acquisition 
was conducted using an Olympus BX55 with QI click 
camera. 
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8.1.3 The Arl/+ mutation causes a collapse of the third ventricle and 
condensation of the dentate gyrus.  
 
After analysis of the disparity between Arl/+ and wild-type cortical neuron banding 
patterns observed in matched brain sections, other brain regions were examined 
for gross anatomical differences. Examination of the ventral regions of the brain 
in the Arl/+ mice, a striking observation regarding the third ventricle was 
highlighted. In all wild-type brain sections, the third ventricle appears to have an 
expanded phenotype with a clearly defined edge and a larger area polarised 
towards the dorsal region of the ventricle (Figure 5.7 panel a). Contrastingly, the 
third ventricle observed in Arl/+ brain sections exhibit a remarkable collapsed 
appearance with no polarity in area observed (Figure 5.7 panel a).  In order to 
measure this difference, the area of the third ventricle was quantified in both Arl 
and wild-type genotypes with ImageJ (n = 4 respectively). The third ventricle size 
in Arl mice was measured to be significantly reduced in comparison to the third 
ventricles from the wild-type mice (Figure 5.7 panel b).  
 
The examination of the dorsal area of the brain was prompted by the discovery 
by Vallee et al. that the size of the dentate gyrus was diminished in the Loa/Loa 
brain (Ori-McKenney & Vallee 2011). Upon observation of the dentate gyrus in 
the Arl/+ mice a clear condensed phenotype can be observed eliciting a 
distinctive shape. In comparison all sections from wild-type mice indicated a much 
narrower and protracted appearance in (Figure 5.7 panel c). In order to quantify 
any differences, the length of the dentate gyrus was measured from the most 
distal tips of the region in both genotypes (n = 4 in both cases). Although a clear 
trend of a reduced size of dentate gyrus can be seen in the Arl/+ genotype in 
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comparison to the wild-type brain, no statistical difference was found (Figure 5.7 
panel d).  
 
In summary the Arl mutation causes collapse of the third ventricle of the brain 
and an alteration of the shape of the dentate gyrus but without statistically 
affecting its length.  
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Figure 5.7 
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Figure 5.7 cont. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 5.7- (a) Images (4x) of the third ventricle wild-type and 
Arl/+ matched coronal sections stained with cresyl violet. (b) 
Quantification of the area of the third ventricle in wild-type and 
Arl/+ mice. (c) Images (4x) of the dentate gyrus stained with 
cresyl violet in wild-type and Arl/+ matched coronal brain 
sections. Cartoon brain indicates position of coronal sections, 
dotted line represents measured region (d) Quantification of 
the length of the dentate gyrus in both wild-type and Arl/+ 
brain sections (scale bars represent 500 m). Image 
acquisition was conducted using an Olympus BX55 with QI 
click camera. 
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8.1.4 The corpus callosum and dentate fascia brain regions are condensed 
in Arl/+ mice 
 
 
The corpus callosum and dentate fascia (CC and DF) are situated dorsally above 
the dentate gyrus and functionally represent the fibre tract that connects both 
hemispheres of the brain (Paul et al. 2014). Visual analysis of this area of the 
brain in the Arl/+ coronal sections indicated that the size of this tract in the Arl/+ 
mice was much smaller in comparison to the wild-type brain sections (see Figure 
5.8).  In order to quantify the size of this brain region the CC & DF region was 
measured using ImageJ in 14 separate brain sections (Figure 5.7 panel a) for 
each genotype (sections derived from 2 different mice for each genotype). 
Quantification of this distance indicated a significant decrease (P<0.001) in the 
size of the CC & DF region in Arl/+ mice in comparison to wild-type mice (Figure 
5.8 panel b).  
 
The neighbouring brain region termed the retrosplenial area (indicated by the 
orange asterisk) additionally indicated a visually discernible phenotype in the 
Arl/+ brain sections in comparison to wild-type. This region in Arl/+ mice has a 
very granular and disorganised appearance, whereas in the wild-type brain 
regions, the retrosplenial area represents a distinct, defined band of cell bodies 
(Figure 5.8 panel a). 
 
In summary, the Arl mutation results in condensation of the CC and DF brain 
region as well as a disordered and granular appearance of the retrosplenial area 
in comparison to wild-type mice.  
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Figure 5.8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8- (a) Images (4x) of the corpus callosum (CC) 
and dentate fascia (DF) as well as the retrosplenial area 
(indicated by an orange asterisk) stained with cresyl violet 
in wild-type and Arl/+ coronal brain sections (scale bar 
represents 250 m). (b) Quantification of the combined 
length of the corpus callosum and the dentate fascia in 
wild-type and Arl/+ brain sections. Image acquisition was 
conducted using an Olympus BX55 with QI click camera. 
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8.1.5 Cortical organisation is disrupted in p4 Arl/+ mice in comparison with 
littermates  
 
Previous investigation into structural organisation of the cortical layers in Arl/+ 
mice were conducted in adult mice that were not age-matched. This presents the 
possibility that loss of neurons in the cortex (even though this may be unlikely in 
mice ~200 days old) in older mice could portray a similar phenotype to that of 
disorganisation of the cortical layers.  
 
In order to investigate differences in younger litter mates p4 mice were culled 
before removal of the brain. Due to the small size of the brains in comparison to 
adult mice, the brains were placed directly into 1% PFA for fixation. The brains 
were then imaged (Figure 5.9) and both wild-type and Arl/+brains were weighed 
(0.19 g and 0.2 g, respectively). The brains were cryopreserved before 
cryosectioning and cresyl violet staining.  
 
Upon Imaging the Arl/+ sections indicated a clear phenotype of regular regions 
of missing neuronal cell bodies in layer II/III indicated by the white arrow (see 
Figure 5.9). In comparison brain atlas matched sections in wild-type mice did not 
show this phenotype. Additionally, Arl/+ mice indicated a clear band of neurons 
at layer V (indicated by the orange arrow). This banding pattern was not apparent 
in any of the sections observed in wild-type mice, but instead a more granular 
phenotype is observed with a denser population of cell bodies seen just above 
the orange arrow (Figure 5.9). Interestingly observation of the corpus callosum 
tract (labelled cc) clearly shows that this tract is much larger in the wild-type mice 
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in comparison to the Arl/+ mice. This runs in accordance with the previous 
quantification of this region in adult mice. 
 
In summary, the Arl mutation clearly affects cortical organisation in p4 Arl/+ mice 
in comparison to their wild-type littermates and furthermore a reduced size in the 
corpus callosum is also observed in the Arl heterozygous mice.  
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Figure 5.9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9- (a) Images (4x) of matched coronal brain sections from 
p4 wild-type and Arl/+ littermates stained with cresyl violet. Cortical 
layers are indicated on the left of the figure, the corpus callosum is 
represented by cc. White and Orange arrows indicate gross 
differences in the banding pattern of neurons between genotypes 
(scale bar represents 500 m). (b) Pictures of both wild-type and 
Arl/+ brains prior to cryopreservation and sections. Image 
acquisition was conducted using an Olympus BX55 with QI click 
camera. 
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8.6 Chapter 5 summary  
 
The data presented in this chapter indicates that mutations in Dync1h1 have a 
negative effect on the speed of cell migration, shown by a deficit in rate of wound 
closure in heterozygous Arl fibroblasts. Furthermore, cortical organisation or 
lamination appears to be effected by the Arl mutation from observations in Arl/+ 
adult mice.  This is further supported by data from p4 littermates further indicating 
that a distinct disorganisation of layers II/III was apparent at this stage of brain 
development. Finally, other gross anatomical differences were observed in Arl/+ 
adult mice. This included the dramatic collapse of the third ventricle, alteration of 
the dentate gyrus morphology, condensation of the CC and DF (which could also 
be observed in p4 mice) and disorganisation of the retrospenial area. Overall, this 
clearly indicates that the Arl mutation results in striking anatomical differences in 
the brain, but importantly highlights disrupted cortical lamination which shows 
deficits in brain development caused by this mutation.  
 
8.7 Chapter 5 discussion 
 
8.7.1 The Arl mutation causes delayed cell migration in mouse embryonic 
fibroblasts 
 
Previous data from Dr Muruj Barri in the Hafezparast lab has shown that the Loa 
homozygous mouse model elicits a deficit in cell migration. This initiated the 
investigation into the Arl mutation to examine if this mutation resulted in aberrant 
cell migration. This was conducted by culturing Arl heterozygous fibroblasts and 
subjecting them to a monolayer wound before measuring the rate of migration 
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over a 12-hour time period.  The results obtained indicated that there was a 
significant decrease in the rate of cell migration in the heterozygous fibroblasts in 
comparison to the wild-type cells. Coupled with the observed deficit in cell 
migration shown by the Loa homozygous fibroblasts, this indicates that mutations 
in the DHC tail domain of dynein can result in disrupted cellular migration. 
 
There are several reasons as to why mutations in dynein could interfere with the 
process of cellular migration. Firstly, as shown in chapter 4 mutations in dynein 
can disrupt the Golgi complex. Both Arl (unpublished) and Loa mutations result 
in delayed recovery of the Golgi after nocodazole treatment (Hafezparast et al. 
2003). The Golgi is important for delivering new proteins to leading edge of cells, 
disruption of which could have a negative impact upon cell migration (Bergmann 
et al. 1983). Secondly, similarly to the Golgi, the MTOC reorientation is dependent 
on dynein which is imperative to polarize microtubules towards the direction of 
migration (Palazzo et al. 2001). Additionally, migrating fibroblasts have 
microtubules which are rich in PTMs and regarded as stable, inhibition of dynein 
reduces acetylated tubulin levels indicating that dynein activity alone has an 
influence on the stability of microtubules (Sainath & Gallo 2014; Palazzo et al. 
2003). Interestingly, a very recently discovered mutation in NEK1 has been 
shown to be associated with fALS risk. NEK1 is thought to be important for 
microtubule stability and axonal polarity perhaps leading to similar aberrant 
functions that DYNC1H1 mutations may cause in SMA-LED (Kenna et al. 2016).  
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8.7.2 The organisation of cortical layers is impaired in Arl/+ mice 
 
The aberrant fibroblast migration observed in the Arl/+ fibroblasts further 
provoked the idea that perhaps neuronal organisation in the cortical layers of the 
murine brain could be affected. To explore this hypothesis initially two Arl adult 
mice were perfused in order to look at morphological brain differences. Upon 
investigation, clear disorganisation and reduced neuronal banding was observed 
in cortical layers II/III. This then prompted further investigation of p4 Arl/+ mice 
for comparison against a wild-type litter mate. Similarly, obvious disorganisation 
of cortical layers II/III were observed as well as in cortical layer V. This represents 
evidence that the Arl/+ mutation is having a dramatic effect upon cortical 
lamination in these mice. It must be noted that these investigations were very 
time consuming due to the infamous difficulty in breeding of the Arl/+ mice.  
 
This data then correlates with evidence from Ori-Mckenney showing that Loa 
homozygous mice indicated neuronal migration defects seen in cortical layers II 
and III (Ori-McKenney & Vallee 2011).  Furthermore, this type of cortical 
lamination is characteristic of disrupted organisation observed in heterozygous 
Lis1 mice (Hirotsune et al. 1998). LIS1 promotes microtubule bound states of 
dynein towards the tips of microtubules, importantly it interacts with another 
dynein adaptor Nudel/Nude, mutations in which cause abnormally developed 
brains (Han et al. 2001; Bradshaw et al. 2013). Furthermore, LIS1 is known to 
attenuate the force production of dynein (McKenney et al. 2010). 
 
This could affect the role that dynein has in apical motility of the nucleus in G2 of 
migrating neuronal progenitors (Dantas et al. 2016). Interestingly, Nudel and Lis1 
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null murine fibroblasts have also been shown to have microtubule organisation 
defects (Sasaki et al. 2005). Aside from migration deficits, this could result in 
defective neuronal arborisation or axonal pathfinding. Taken together these 
migratory processes could clearly be disrupted by aberrant dynein. 
 
It is not yet determined if the Arl mutation could cause disruption between the 
complex and interaction with adaptors or if the Arl mutation causes a general 
impairment of dynein force production or perhaps causes microtubule 
destabilisation. Either way thus far both Loa and Arl mutations produce similar 
cortical lamination phenotypes due to Dync1h1 tail domain mutations.  
 
8.7.3 The Arl/+ mutation causes a collapse of the third ventricle and 
condensation of the dentate gyrus  
 
Investigation into other differences in morphology in the Arl/+ mice led to the 
observation of the collapse of the third ventricle in comparison to wild-type mice. 
This was a strikingly significant observation detected in the Arl/+ mice which 
again could be related to LIS1. Mutations in PAFAH1B1, the gene encoding LIS1 
have been shown to cause aberrant ependymal lining of the third ventricle 
(Assadi et al. 2003). Additionally, Pafah1b1 +/- mice have been seen to exhibit 
large morphological differences (similar to that of the Arl/+ mice) of the third 
ventricle suggested to be due to a reduction in ependymal cells (Assadi et al. 
2003). Ependymal cells are a type of epithelial cell that comprise the lining of the 
ventricles. They represent the barrier between the brain and cerebral spinal fluid 
(Kishimoto & Sawamoto 2012). This type of polarised cell is very dependent on 
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microtubule integrity and it is very likely that Dync1h1 and Lis1 mutations result 
in similar microtubule defects potentially causing this phenotype. 
 
Similarly, the Arl/+ mice indicated morphological condensation of the dentate 
gyrus although this was not found to be significantly different. Importantly, in the 
Loa homozygous mouse a compaction of the dentate gyrus was also observed, 
this supports the evidence for Dync1h1 mutations resulting in defects in dentate 
gyrus morphology. These morphological differences in the Loa homozygous 
mouse were attributed to the distribution of granule cells which again could be an 
outcome of impaired cell migration (Ori-McKenney & Vallee 2011).  
 
8.7.4 The corpus callosum and the dentate fascia brain regions are 
condensed in Arl/+ mice 
 
Further analysis of brain abnormalities in the Arl/+ mice highlighted a reduced 
size in the corpus callosum and the dentate fascia in comparison to the wild-type 
equivalent region of the brain (Figure 5.5). Interestingly, MRI data from a patient 
with a p.Tyr970Cys DYNC1H1 mutation indicated thinning of the corpus callosum 
brain region (Scoto et al. 2015). Considering the large size of the DHC the p. 
Trp1206Arg Arl mutation exists close by in a similar region of the tail domain of 
dynein. The similarity in reduced size of the corpus callosum between the 
aforementioned patient and the Arl/+ mouse further highlights the important value 
of this SMA-LED mouse model. Furthermore, patients with DYCN1H1 mutations 
in the homodimerisation domain have been reported to exhibit irregular corpus 
callosum morphology; suggesting that this could represent a general 
morphological consequence of DYNC1H1 mutations (Jamuar et al. 2014). There 
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is limited information on the impact of DYNC1H1 mutations upon the morphology 
of the dentate fascia. However, the proximal nature of the corpus callosum and 
the dentate fascia suggests that perhaps migration defects in dynein mutants 
influences the morphologies of both sub-structures. 
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Chapter 6- Conclusion and general discussion 
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9.0 Conclusion  
 
The data presented in this thesis has firstly advanced our knowledge of 
proteins FUS and TDP-43 and potential pathogenic mechanisms in adult onset 
ALS. Secondly, this thesis has explored the cellular impact of dynein heavy chain 
mutations related to the childhood onset condition SMA-LED by analysing  
patient p.R399G fibroblasts and the Arl/+ mouse model. 
 
My data has shown that both FUS and TDP-43 respond to oxidative DNA damage 
as well as indicating a FUS specific nucleoli recruitment after topoisomerase I 
inhibition in mitotic cells. Importantly, I have also shown that both proteins are 
recruited to the nucleoli in cortical neurons after topoisomerase I inhibition. 
Focussing on FUS recruitment led to the finding that RNA polymerase II inhibition 
resulted in nucleoli FUS foci in neurons, indicating that the cessation of 
transcription initiates this recruitment. Both caffeine and high concentrations of 
dipyridamole inhibited FUS recruitment suggesting that PDEs may be 
responsible for this FUS response. 
 
Furthermore, for the first time, my data has shown inherent Golgi fragmentation 
in fibroblasts from a SMA-LED patient with a p.R399G DYNC1H1 mutation. This 
led to the discovery of increased interaction between dynein and golgin 160, 
irregular Golgi morphology during migration and decreased acetylated -tubulin 
at Lysine 40 in p.R399G mutants. Further investigations indicated aberrant Golgi-
dynein localisation and increasing microtubule acetylation did not rescue this 
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phenotype but crucially rescued Golgi fragmentation. This suggests that HDAC6 
inhibitors may have a future role to play in SMA-LED treatment. 
 
Lastly in correlation with this data I have for the first time shown that the murine 
Dync1h1 Arl/+ mutation results in impaired rate of migration in fibroblasts. This 
led to the discovery of gross disorganisation of cortical lamination in these mice. 
Additionally, reduced size of the third ventricle as well as compaction of the 
corpus callosum and the dentate fascia was detected in Arl/+ mice. These 
findings broaden the phenotypes associated with the Arl mutation and highlights 
the importance of this model in future research of SMA-LED. 
 
9.1 General discussion 
 
Motor neuron disease is a collective-term for a group of neurological conditions 
in which motor neurons degenerate leading to loss of muscle innervation which 
can be fatal. Both ALS and SMA-LED are contrasting diseases despite the 
parallel connection of neurodegeneration of motor neurons. ALS is a disease in 
which multiple mechanisms of disease pathogenesis have been put forward in 
the field over many years suggesting that perhaps there may be further 
subdivisions of this disease in the future. The complexity of potential disease 
mechanisms also arises from mutations in proteins in which have many diverse 
complex functions. Both FUS and TDP-43 fall into this category and have been 
extensively researched in the context of ALS for many years without a single 
disease mechanism arising as a definitive leading contributor to ALS 
pathogenesis. This raises the possibility that mutations in both FUS and TDP-43 
could result in a syndrome of collective aberrant processes that are specific to 
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motor neurons leading to their degeneration. A leading theory in motor neuron 
degeneration is the protein aggregation hypothesis in which mutant or misfolded 
protein such as FUS aggregates in the cytoplasm leading to terminal cellular 
disruption. This type of pathology is shared across different neurodegenerative 
disorders such as Parkinson’s disease, Alzheimer’s disease and prion diseases. 
This theory suits the progression of these diseases of older age as the delicate 
preservation of protein folding mechanisms are perturbed over time leading to 
accumulation of unfolded protein. This coupled with a reduced efficacy of the 
proteasome degradation system provides an attractive potential overall leading 
mechanism of age related neuron deterioration.  
 
In the context of this thesis, investigation into both FUS and TDP-43 has been 
focussed on understanding the role they play the DNA damage response. 
Although not a leading theory in the pathogenesis of ALS the importance of 
understanding differences in DNA damage repair between mitotic and non-mitotic 
cells could clarify the importance of genome stability in motor neurons. In 
symmetry with the age related accumulation of the mis-folded protein theory, 
accumulation of DNA lesions in motor neurons over time could equally be the root 
cause of motor neuron death in ALS. Other neurological disorders support this 
theory such as Cockayne syndrome in which the genetic stability is thought to be 
impaired through mutations in a NER associated protein. Additionally, 
Parkinson’s disease and Huntington’s disease have also been linked with 
defective DNA repair  processes such as BER and NER (Jeppesen et al. 2011).  
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Importantly in sALS, evidence of aberrant mitochondrial DNA repair has been 
reported which could be another parallel mechanism in which defective 
mitochondria contribute to the degenerative process. Furthermore, a rare infantile 
ALS can be caused by a mutation in the ALS2 protein which is suggested to 
protective under conditions of oxidative damage (Jeppesen et al. 2011). It is 
possible that other proteins in ALS have direct roles to play in the management 
of oxidative damage in motor neurons including at the DNA repair level. It is highly 
likely that the FUS protein is critical in DNA repair management in motor neurons 
and further investigations will unravel its holistic importance in this respect.  
 
In contrast, SMA-LED is a neurodegenerative disorder which exhibits mutations 
in proteins such as DYNC1H1 and BICD2 which are associated with the dynein 
retrograde motor. The challenge in investigating defective dynein functionality 
arises when the full extent of the roles it plays are not well understood. Dynein is 
well known for its role in axonal transport and shares structural similarity with 
other similar motors such as myosin. However, dynein is found in very many 
different cellular compartments and is not only always associated with 
microtubules. In this thesis, dynein is found to be closely associated with the Golgi 
apparatus, but why this close association exists and how it is regulated is 
currently unknown. A regulation between acetylated microtubules, Golgi 
membranes, golgin 160 and dynein likely only forms a small snapshot of how 
many proteins regulate the Golgi apparatus. The bigger question is which 
element of dynein dysfunction is the most important/causative in SMA-LED? One 
would assume that aberrant retrograde transport is the main candidate. However, 
if retrograde transport was this severely impaired by DYNC1H1 mutations it could 
be expected perhaps in other cell types. The retrograde functionality of dynein 
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may not be the most crucial factor during axonal growth and pathfinding but its 
role at the Golgi apparatus for example could be much more critical for early 
neuronal development. 
 
SMA-LED is a congenital condition which suggests that defective wiring of 
neurons during development could be a likely root cause. This would potentially 
explain cases in which some patients with DYNC1H1 mutations also show 
cognitive impairment. This is supported by data in this thesis in which the Arl 
mouse model clearly shows a disruption in cortical organisation. Potentially, this 
indicates that even though motor neurons in SMA-LED predominantly 
deteriorate, other types of neurons and perhaps supporting cells may also be 
effected in some cases. The variety of symptoms experienced by SMA-LED 
patients with DYNC1H1 mutations indicates that perhaps small modulations in 
the dynein complex can have diverse and contrasting repercussions. This is not 
surprising for a complex with a high number of functioning components with many 
potential functional roles.      
 
The future challenge of determining the underlying cause of both ALS and SMA-
LED   will to some extent be governed by the ever growing knowledge about 
neuroscience and cell biology in general. Additionally, understanding common 
genetic aberrations between patients through sequencing has been a powerful 
tool to this date and is likely to continue to yield further informative data.   
Increasing our current understanding through these mechanisms is somewhat 
limited by current technology but recent advances in gene editing platforms have 
created further tools that also could serve as a therapeutic starting point in the 
near future. The use of pharmaceutical drugs such as riluzole in the case of ALS 
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has only had limited benefit for patients. The advancement of therapeutic 
strategies will undoubtedly improve the lives of patients suffering with 
neurodegenerative disorders. 
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